{
  "meta": {
    "title": "Peptide Research Atlas · Public edition",
    "built": "2026-10-15",
    "scope": "All 36 imported compounds, with distinct nonpersonal protocol variants and explicit evidence gaps. Includes clinical, preclinical, theoretical, creator and forum material. Some saved-review entries have no primary citation; that limitation is retained. Personal history and raw documents are excluded. Coverage includes the saved reviews and the audited October 15 GH article, not every protocol on the internet.",
    "publicationStatus": "Public research edition"
  },
  "sources": {
    "adipotide-protocol-jarvis-macaque-source": {
      "id": "adipotide-protocol-jarvis-macaque-source",
      "title": "Adipotide in obese rhesus macaques",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3666164/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, fixed-dose study.",
      "reviewState": "not_yet_reviewed"
    },
    "aicar-protocol-jarvis-red-cabg-source": {
      "id": "aicar-protocol-jarvis-red-cabg-source",
      "title": "Acadesine in RED-CABG",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/1216478",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Methods.",
      "reviewState": "not_yet_reviewed"
    },
    "ampk": {
      "id": "ampk",
      "title": "O304 TELLUS · JCI Insight 2018",
      "url": "https://insight.jci.org/articles/view/99114",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "amq2018": {
      "id": "amq2018",
      "title": "Neelakantan et al. · NNMT inhibitors and diet-induced obesity in mice · PMID 29155147",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29155147/",
      "kind": "Preclinical primary research",
      "verified": true,
      "note": "PubMed abstract and figure captions checked 1 November 2026; full methods and precise in-vivo salt-equivalent dosing require further verification.",
      "reviewState": "not_yet_reviewed"
    },
    "amqpk": {
      "id": "amqpk",
      "title": "Awosemo et al. · 5-amino-1MQ rat oral pharmacokinetics · PMID 34304009",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34304009/",
      "kind": "Preclinical PK primary research",
      "verified": true,
      "note": "PubMed abstract checked 1 November 2026; IV and oral rat PK only; full methods and exact administered mass not audited.",
      "reviewState": "not_yet_reviewed"
    },
    "aodfda": {
      "id": "aodfda",
      "title": "FDA PCAC AOD-9604 review · December 2024",
      "url": "https://www.fda.gov/media/183584/download",
      "kind": "Regulatory evidence review",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "ara290-diabetes-2015": {
      "id": "ara290-diabetes-2015",
      "title": "Brines et al. · ARA 290 in type 2 diabetes · Molecular Medicine 2015",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/",
      "kind": "Human primary research",
      "verified": true,
      "note": "Full text reviewed 24 October 2026. DOI 10.2119/molmed.2014.00215; PMID 25387363. Checked design, outcomes, formulation, route-specific PK and adverse events. PK values are reported here from prior normal-volunteer analyses, not newly measured in this diabetes trial.",
      "reviewState": "not_yet_reviewed"
    },
    "ara290-macular-2020": {
      "id": "ara290-macular-2020",
      "title": "Lois et al. · Cibinetide in diabetic macular edema · J Clin Med 2020",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7408632/",
      "kind": "Human primary research",
      "verified": true,
      "note": "Full text reviewed 24 October 2026. DOI 10.3390/jcm9072225; PMID 32674280. Checked open-label design, nine enrolled/eight completers, 12-week SC exposure, average eye outcomes, adverse events and antibody testing.",
      "reviewState": "not_yet_reviewed"
    },
    "ara290-sarcoidosis-2017": {
      "id": "ara290-sarcoidosis-2017",
      "title": "Culver et al. · Cibinetide corneal nerve fiber trial · IOVS 2017",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28475703/",
      "kind": "Human primary research abstract",
      "verified": true,
      "note": "PubMed abstract reviewed 24 October 2026; full text not independently reviewed. DOI 10.1167/iovs.16-21291; PMID 28475703. Scope: phase 2b design, corneal nerve fiber endpoint and dose comparison; no broad clinical efficacy or safety conclusion.",
      "reviewState": "not_yet_reviewed"
    },
    "bpc": {
      "id": "bpc",
      "title": "Rat Achilles study · PMID 14554208",
      "url": "https://pubmed.ncbi.nlm.nih.gov/14554208/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "cagrilintide-pk": {
      "id": "cagrilintide-pk",
      "title": "Nielsen et al. Human cagrilintide PK in renal and hepatic impairment",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42228334/",
      "kind": "Human primary research",
      "verified": true,
      "note": "Published online 1 June 2026; DOI 10.1007/s40262-026-01654-0; NCT04209049 and NCT05564104. Primary paper abstract checked 16 October 2026; full text not accessible in this review.",
      "reviewState": "not_yet_reviewed"
    },
    "cjc-dac": {
      "id": "cjc-dac",
      "title": "Teichman et al. · long-acting CJC-1295 · PMID 16352683",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/",
      "kind": "Primary research",
      "verified": true,
      "note": "Selected primary findings checked 15 October 2026 for the GH article audit; no full systematic review. Preserve molecule, population, route and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "cjc-dac-protocol-jarvis-single-dose-source": {
      "id": "cjc-dac-protocol-jarvis-single-dose-source",
      "title": "CJC-1295 with DAC single-dose trial",
      "url": "https://academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.pdf",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary paper, Study 1.",
      "reviewState": "not_yet_reviewed"
    },
    "cjc-pulses": {
      "id": "cjc-pulses",
      "title": "Ionescu and Frohman 2006 PMID 17018654",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/",
      "kind": "Primary human research",
      "verified": true,
      "note": "Selected abstract findings checked 15 October 2026; preserve exact molecule, route, population and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "dihexa-protocol-jarvis-aged-rat-source": {
      "id": "dihexa-protocol-jarvis-aged-rat-source",
      "title": "Dihexa in aged rats",
      "url": "https://jpet.aspetjournals.org/content/jpet/344/1/141.full.pdf",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Fig. 5.",
      "reviewState": "not_yet_reviewed"
    },
    "dsip-protocol-jarvis-crossover-source": {
      "id": "dsip-protocol-jarvis-crossover-source",
      "title": "DSIP in a human sleep crossover study",
      "url": "https://pubmed.ncbi.nlm.nih.gov/6895513/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract, PMID 6895513.",
      "reviewState": "not_yet_reviewed"
    },
    "eloralintide-protocol-jarvis-phase2-source": {
      "id": "eloralintide-protocol-jarvis-phase2-source",
      "title": "Eloralintide phase 2 obesity trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41207310/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract, NCT06230523.",
      "reviewState": "not_yet_reviewed"
    },
    "fda-risk": {
      "id": "fda-risk",
      "title": "FDA · bulk substances with potential safety risks",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
      "kind": "Regulatory safety review",
      "verified": true,
      "note": "Re-read 22 October 2026; FDA page content current as of 22 April 2026. Lists certain bulk drug substances for compounding that may present significant safety risks. This check covers that page, not causality for any individual product.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-dennis": {
      "id": "flgr-dennis",
      "title": "Dennis et al. 2002 · Albumin binding and protein PK · PMID 12119302",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12119302/",
      "kind": "Primary preclinical research",
      "verified": true,
      "note": "Indexed abstract and publisher excerpts checked 3 November 2026. SA21 binding and antibody-fragment platform precedent, not FLGR-242 PK.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-farber-interview": {
      "id": "flgr-farber-interview",
      "title": "Michael Farber interview · Peptide of the Week, October 2026",
      "url": "https://www.spreaker.com/episode/the-man-who-invented-klotho-flgr-242-michael-farber-pt-1-peptide-of-the-week-podcast--75853071",
      "kind": "Promotional interview description",
      "verified": false,
      "note": "Episode description reviewed 3 November 2026. Interview audio and transcript were not audited. Product claims are unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-farber-patent": {
      "id": "flgr-farber-patent",
      "title": "Farber · Enhanced peptide constructs for albumin binding · US12377158B1",
      "url": "https://patents.google.com/patent/US12377158B1/en",
      "kind": "Patent disclosure",
      "verified": true,
      "note": "Relevant specification passages checked 3 November 2026. Verification covers what the patent says and does not validate its PK claims or establish commercial product identity.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-hill": {
      "id": "flgr-hill",
      "title": "Hill et al. 2002 · Myostatin-binding proteins · PMID 12194980",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12194980/",
      "kind": "Primary mechanistic research",
      "verified": true,
      "note": "PubMed abstract checked 3 November 2026 for serum binding and FLRG reporter assay. FLRG refers to FSTL3.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-mendias": {
      "id": "flgr-mendias",
      "title": "Mendias et al. 2008 · Tendons in myostatin-deficient mice · PMID 18162552",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18162552/",
      "kind": "Primary preclinical research",
      "verified": true,
      "note": "Indexed abstract and full-text excerpts checked 3 November 2026. Constitutive knockout mouse model.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-nakatani": {
      "id": "flgr-nakatani",
      "title": "Nakatani et al. 2008 · Transgenic FS I-I in mdx mice · DOI 10.1096/fj.07-8673com",
      "url": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.07-8673com",
      "kind": "Primary preclinical research",
      "verified": true,
      "note": "Publisher abstract checked 3 November 2026 for ligand-binding constants and transgenic mouse outcomes.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-precursor": {
      "id": "flgr-precursor",
      "title": "Esch et al. 1987 · Follistatin precursors · PMID 3153465",
      "url": "https://pubmed.ncbi.nlm.nih.gov/3153465/",
      "kind": "Primary molecular research",
      "verified": true,
      "note": "PubMed abstract checked 3 November 2026 for the precursor lengths and the mature 315-residue sequence.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-registry-audit": {
      "id": "flgr-registry-audit",
      "title": "Atlas trial-registry snapshot · FLGR-242",
      "url": "https://clinicaltrials.gov/search?term=FLGR-242",
      "kind": "Registry search locator",
      "verified": false,
      "note": "Atlas main snapshot listed zero studies for the hyphenated spelling. Indexed searches for both spellings found no matching primary study. Direct registry result retrieval was unavailable on 3 November 2026.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-rooks": {
      "id": "flgr-rooks",
      "title": "Rooks et al. 2020 · Bimagrumab in sarcopenia · PMID 33074327",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33074327/",
      "kind": "Primary human randomized trial",
      "verified": true,
      "note": "Abstract and selected full-text excerpts checked 3 November 2026 for lean mass and physical performance. Trial used bimagrumab.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-saitoh": {
      "id": "flgr-saitoh",
      "title": "Saitoh et al. 2020 · DF-3 · PMID 31874826",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31874826/",
      "kind": "Primary preclinical research",
      "verified": true,
      "note": "PubMed abstract checked 3 November 2026 for peptide length, reporter assay, mouse route and muscle mass outcome.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-schuelke": {
      "id": "flgr-schuelke",
      "title": "Schuelke et al. 2004 · MSTN mutation and hypertrophy · PMID 15215484",
      "url": "https://pubmed.ncbi.nlm.nih.gov/15215484/",
      "kind": "Primary human genetics",
      "verified": true,
      "note": "Indexed record and publisher excerpts checked 3 November 2026. Single human genetic case with no administered construct.",
      "reviewState": "not_yet_reviewed"
    },
    "flgr-thompson": {
      "id": "flgr-thompson",
      "title": "Cash et al. 2009 · Myostatin–follistatin 288 structure · PMID 19644449",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19644449/",
      "kind": "Primary structural research",
      "verified": true,
      "note": "PubMed abstract and selected figure captions checked 3 November 2026. The structures involve FST288, not the marketed construct.",
      "reviewState": "not_yet_reviewed"
    },
    "forz": {
      "id": "forz",
      "title": "FORZINITY prescribing information",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75",
      "kind": "Human label",
      "verified": true,
      "note": "Indication, regimen, accelerated-approval limitation and SC PK checked 15 October 2026.",
      "reviewState": "not_yet_reviewed"
    },
    "gh-report-20261015": {
      "id": "gh-report-20261015",
      "title": "Joe Mars GH peptide guide 15 October 2026",
      "url": "https://www.thepeptidereport.com/growth-hormone-peptides-the-complete-guide-to-sermorelin-cjc-1295-ipamorelin-and-tesamorelin/",
      "kind": "Affiliate editorial and community protocols",
      "verified": false,
      "note": "Owner supplied article text on 15 October 2026 after direct access failed. Affiliate disclosure retained. Selected underlying primary studies checked separately; schedules are unverified community practice.",
      "reviewState": "not_yet_reviewed"
    },
    "gh-sleep-takahashi-1968": {
      "id": "gh-sleep-takahashi-1968",
      "title": "Takahashi et al. · Growth hormone secretion during sleep · JCI 1968",
      "url": "https://www.jci.org/articles/view/105893",
      "kind": "Human physiology study abstract",
      "verified": true,
      "note": "Publisher abstract reviewed 25 October 2026; DOI 10.1172/JCI105893; PMID 5675428. Eight young adults, 38 nights, blood sampling and sleep recordings. General sleep/GH physiology, not tesamorelin treatment or comparative timing efficacy.",
      "reviewState": "not_yet_reviewed"
    },
    "ghk": {
      "id": "ghk",
      "title": "Rat wound-chamber study · PMID 8227353",
      "url": "https://www.jci.org/articles/view/116842",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "guide": {
      "id": "guide",
      "title": "Peptide Protocol Field Guide · version 7",
      "url": null,
      "kind": "Saved review summary; not a primary study",
      "verified": false,
      "note": "Only nonpersonal extracted statements are included. The saved review was reread on 15 October 2026; original study, creator or forum links were not reopened for this extraction. A missing primary citation remains a source limitation. Raw private documents are not served.",
      "reviewState": "not_yet_reviewed"
    },
    "hex-cycle": {
      "id": "hex-cycle",
      "title": "Rahim et al 1998 hexarelin PMID 9589671",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9589671/",
      "kind": "Primary human research",
      "verified": true,
      "note": "Selected abstract findings checked 15 October 2026; preserve exact molecule, route, population and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "hgh-protocol-jarvis-genotropin-adult-source": {
      "id": "hgh-protocol-jarvis-genotropin-adult-source",
      "title": "Genotropin adult GH deficiency label",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765&version=36",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, section 2.2.",
      "reviewState": "not_yet_reviewed"
    },
    "ipa-pk": {
      "id": "ipa-pk",
      "title": "Gobburu et al 1999 PMID 10496658",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/",
      "kind": "Primary human research",
      "verified": true,
      "note": "Selected abstract findings checked 15 October 2026; preserve exact molecule, route, population and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-27499402": {
      "id": "jarvis-lead-src-27499402",
      "title": "Intravenous glutathione for skin lightening: Inadequate safety data.",
      "url": "https://www.samj.org.za/index.php/samj/article/download/10878/7534",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (cc-by-nc) on 2026-10-31; the owner approved the verification. PMID 27499402.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-29733881": {
      "id": "jarvis-lead-src-29733881",
      "title": "Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8916541/",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 29733881. Journal notice: retraction PMID 40312093.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-33178027": {
      "id": "jarvis-lead-src-33178027",
      "title": "From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.",
      "url": "https://europepmc.org/articles/PMC7593869",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 33178027. Journal notice: retraction PMID 40312093.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-34512549": {
      "id": "jarvis-lead-src-34512549",
      "title": "LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity.",
      "url": "https://europepmc.org/articles/PMC8428150",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 34512549.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-38866494": {
      "id": "jarvis-lead-src-38866494",
      "title": "The role of KNDy neurons in human reproductive health.",
      "url": "https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ24-0006/_pdf",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (cc-by-nc-nd) on 2026-10-31; the owner approved the verification. PMID 38866494.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-41897500": {
      "id": "jarvis-lead-src-41897500",
      "title": "A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial.",
      "url": "https://europepmc.org/articles/PMC13023597",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 41897500.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-42952740": {
      "id": "jarvis-lead-src-42952740",
      "title": "Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator.",
      "url": "https://europepmc.org/articles/PMC13713458",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 42952740.",
      "reviewState": "not_yet_reviewed"
    },
    "jarvis-lead-src-42953880": {
      "id": "jarvis-lead-src-42953880",
      "title": "VIP-Mediated Syndromes: Contrasting Presentations and Multidisciplinary Management of Two Rare Neuroendocrine Tumors.",
      "url": "https://europepmc.org/articles/PMC13716408",
      "kind": "Primary source read by Jarvis, verification approved by the owner",
      "verified": true,
      "note": "Jarvis read the full text (PMC open access) on 2026-10-31; the owner approved the verification. PMID 42953880.",
      "reviewState": "not_yet_reviewed"
    },
    "jx-asx-aod-2007": {
      "id": "jx-asx-aod-2007",
      "title": "Metabolic Pharmaceuticals Ltd. ASX announcement: Metabolic's obesity drug, Phase 2B clinical trial results (AOD9604, OPTIONS study)",
      "url": "https://data-api.marketindex.com.au/api/v1/announcements/XASX:PNV:XX270709/pdf",
      "kind": "Primary research",
      "verified": true,
      "note": "Published 2007-02-21 (ASX announcement; third-party archive host). Retrieved 2026-10-22. Full text read: OPTIONS 536 enrolled, oral 0.25/0.5/1 mg/day vs placebo with diet and exercise, primary endpoint not met, program terminated; Appendix 1 describes the earlier phase 2b (best dose 1 mg, p=0.1).",
      "reviewState": "not_yet_reviewed"
    },
    "klotho-protocol-jarvis-rhesus-source": {
      "id": "klotho-protocol-jarvis-rhesus-source",
      "title": "Soluble rhesus α-klotho in aged macaques",
      "url": "https://www.nature.com/articles/s43587-023-00441-x.pdf",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Fig. 2.",
      "reviewState": "not_yet_reviewed"
    },
    "klow1": {
      "id": "klow1",
      "title": "PeptaBase KLOW proposal",
      "url": "https://www.peptabase.com/peptides/klow",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "klow2": {
      "id": "klow2",
      "title": "PeptideFox KLOW proposal",
      "url": "https://peptidefox.com/tools/klow-dosage-calculator",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "klow3": {
      "id": "klow3",
      "title": "Research Stacks KLOW proposal",
      "url": "https://researchstacks.com/klow-stack/",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "klow4": {
      "id": "klow4",
      "title": "Reddit · PeptideForum KLOW thread",
      "url": "https://www.reddit.com/r/PeptideForum/comments/1mrdvkv/dosage_on_klow/",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "klow5": {
      "id": "klow5",
      "title": "Reddit · PeptideGuide KLOW thread",
      "url": "https://www.reddit.com/r/PeptideGuide/comments/1lv5pap/klow_dosage_inquiry_80mg_8ml_of_bac_too_much/",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "klow6": {
      "id": "klow6",
      "title": "Reddit · PeptidePathways KLOW experience",
      "url": "https://www.reddit.com/r/PeptidePathways/comments/1qp05yu/i_started_klow_ghk_cubpc_157tb_500kpv_peptide/",
      "kind": "Online proposal / anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "kpv": {
      "id": "kpv",
      "title": "Mouse colitis study · PMID 18061177",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "l-carnitine-protocol-jarvis-carnitor-dialysis-source": {
      "id": "l-carnitine-protocol-jarvis-carnitor-dialysis-source",
      "title": "CARNITOR dialysis-associated deficiency label",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, Dosage and Administration.",
      "reviewState": "not_yet_reviewed"
    },
    "linked-03285429f913": {
      "id": "linked-03285429f913",
      "title": "Linked research or regulatory reference (not independently reverified by publication)",
      "url": "https://www.instagram.com/p/DecLxVTOcC3/",
      "kind": "Reference requiring claim-specific verification",
      "verified": false,
      "note": "Linked by the Jarvis finding; publication does not verify the claim.",
      "reviewState": "not_yet_reviewed"
    },
    "linked-12d60d041733": {
      "id": "linked-12d60d041733",
      "title": "Linked research or regulatory reference (not independently reverified by publication)",
      "url": "https://www.instagram.com/p/DekqVU3BvRl/",
      "kind": "Reference requiring claim-specific verification",
      "verified": false,
      "note": "Linked by the Jarvis finding; publication does not verify the claim.",
      "reviewState": "not_yet_reviewed"
    },
    "linked-de5ea69b02ec": {
      "id": "linked-de5ea69b02ec",
      "title": "Linked research or regulatory reference (not independently reverified by approval)",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75",
      "kind": "Reference requiring claim-specific verification",
      "verified": false,
      "note": "Linked by curator; inclusion does not verify the social claim.",
      "reviewState": "not_yet_reviewed"
    },
    "ll37-protocol-jarvis-venous-ulcer-source": {
      "id": "ll37-protocol-jarvis-venous-ulcer-source",
      "title": "LL-37 topical venous leg ulcer phase IIb trial",
      "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000536-10/results",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Trial registry, arms and endpoints.",
      "reviewState": "not_yet_reviewed"
    },
    "m2015": {
      "id": "m2015",
      "title": "Lee et al. · Cell Metabolism 2015 · PMID 25738459",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25738459/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "m2021": {
      "id": "m2021",
      "title": "Reynolds et al. · Nature Communications 2021",
      "url": "https://www.nature.com/articles/s41467-020-20790-0",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "masld": {
      "id": "masld",
      "title": "Retatrutide MASLD substudy · Nature Medicine 2024",
      "url": "https://www.nature.com/articles/s41591-024-03018-2",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "mazdutide-protocol-jarvis-glory1-source": {
      "id": "mazdutide-protocol-jarvis-glory1-source",
      "title": "Mazdutide GLORY-1 trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40421736/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract, PMID 40421736.",
      "reviewState": "not_yet_reviewed"
    },
    "melanotan-i-protocol-jarvis-scenesse-source": {
      "id": "melanotan-i-protocol-jarvis-scenesse-source",
      "title": "Afamelanotide SCENESSE implant label",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48&version=11",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, Dosage and Administration.",
      "reviewState": "not_yet_reviewed"
    },
    "melanotan-ii-protocol-jarvis-phase1-source": {
      "id": "melanotan-ii-protocol-jarvis-phase1-source",
      "title": "Melanotan II pilot phase I study",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8637402/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract, PMID 8637402.",
      "reviewState": "not_yet_reviewed"
    },
    "mjones": {
      "id": "mjones",
      "title": "MOTS-c frequency video · transcript-derived summary",
      "url": "https://youtubesummary.com/summary/Iik5YjAEn1c",
      "kind": "Secondary transcript index",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "mm": {
      "id": "mm",
      "title": "MMPOWER-3 · Neurology 2023 · PMID 37268435",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37268435/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "mots-nash-bcl2": {
      "id": "mots-nash-bcl2",
      "title": "MOTS-c and BCL-2 in experimental NASH · PMID 38206815",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38206815/",
      "kind": "Preclinical primary research",
      "verified": false,
      "note": "Experimental NASH models; does not demonstrate human MASLD efficacy.",
      "reviewState": "not_yet_reviewed"
    },
    "mots-review": {
      "id": "mots-review",
      "title": "Dr. Jones MOTS-c Protocol Deep Dive",
      "url": null,
      "kind": "Saved review summary; not a primary study",
      "verified": false,
      "note": "Only nonpersonal extracted statements are included. The saved review was reread on 15 October 2026; original study, creator or forum links were not reopened for this extraction. A missing primary citation remains a source limitation. Raw private documents are not served.",
      "reviewState": "not_yet_reviewed"
    },
    "mseq": {
      "id": "mseq",
      "title": "Dr. Jones · repair, optimize, fuel sequence",
      "url": "https://www.youtube.com/watch?v=fg-jSQwg6wY",
      "kind": "Creator report",
      "verified": false,
      "note": "Citation preserved from the MOTS-c review; original video not reopened in this protocol extraction.",
      "reviewState": "not_yet_reviewed"
    },
    "oxytocin-protocol-jarvis-labor-source": {
      "id": "oxytocin-protocol-jarvis-labor-source",
      "title": "Oxytocin label for induction or stimulation of labor",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fe8365-86e3-414e-84dc-c98e097a2f36",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, Dosage and Administration.",
      "reviewState": "not_yet_reviewed"
    },
    "p21-protocol-jarvis-maternal-chow-source": {
      "id": "p21-protocol-jarvis-maternal-chow-source",
      "title": "P021 maternal chow experiment",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7450938/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Treatment of animals with P021.",
      "reviewState": "not_yet_reviewed"
    },
    "pe-22-28-protocol-jarvis-mouse-ip-source": {
      "id": "pe-22-28-protocol-jarvis-mouse-ip-source",
      "title": "PE 22-28 mouse corticosterone experiment",
      "url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00643/full",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Fig. 5.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-39724554": {
      "id": "pmid-39724554",
      "title": "The First Triple Agonist for Antiobesity: Retatrutide.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39724554/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 39724554 reviewed / verified at 2026-10-17T12:44:35.822Z. Note: Reviewed article. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42135195": {
      "id": "pmid-42135195",
      "title": "Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42135195/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42135195 reviewed / verified at 2026-10-17T12:47:22.621Z. Note: Reviewed and relevant. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42219269": {
      "id": "pmid-42219269",
      "title": "Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42219269/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42219269 reviewed / verified at 2026-10-18T01:26:49.270Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42250575": {
      "id": "pmid-42250575",
      "title": "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42250575 reviewed / verified at 2026-10-20T03:58:20.004Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42385950": {
      "id": "pmid-42385950",
      "title": "Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42385950/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42385950 reviewed / verified at 2026-10-20T03:58:35.071Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42444567": {
      "id": "pmid-42444567",
      "title": "Medical treatments for obesity: what does the future have in store?",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42444567/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42444567 reviewed / verified at 2026-10-18T07:01:42.362Z. Note: Pubmed article reviewed.. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42603384": {
      "id": "pmid-42603384",
      "title": "Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42603384/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42603384 reviewed / verified at 2026-10-20T03:58:47.536Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42608321": {
      "id": "pmid-42608321",
      "title": "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42608321/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42608321 reviewed / verified at 2026-10-20T03:58:59.092Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42630988": {
      "id": "pmid-42630988",
      "title": "Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42630988/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42630988 reviewed / verified at 2026-10-20T03:59:32.696Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42673585": {
      "id": "pmid-42673585",
      "title": "Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42673585/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42673585 reviewed / verified at 2026-10-21T07:11:32.217Z. Note: Pubmed study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42734711": {
      "id": "pmid-42734711",
      "title": "Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42734711/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42734711 reviewed / verified at 2026-10-21T07:11:43.911Z. Note: Pubmed study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42744908": {
      "id": "pmid-42744908",
      "title": "Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42744908/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42744908 reviewed / verified at 2026-10-21T07:12:03.821Z. Note: Pubmed study with strong evidence. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42751099": {
      "id": "pmid-42751099",
      "title": "Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42751099/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42751099 reviewed / verified at 2026-10-21T07:12:36.734Z. Note: Pubmed study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42768195": {
      "id": "pmid-42768195",
      "title": "Future GLP-1 receptor co-agonists and their cardiac effects.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42768195/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42768195 reviewed / verified at 2026-10-21T07:12:52.265Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42783450": {
      "id": "pmid-42783450",
      "title": "The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42783450/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42783450 reviewed / verified at 2026-10-21T07:13:15.899Z. Note: Side effect possibilities. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42808923": {
      "id": "pmid-42808923",
      "title": "Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42808923/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42808923 reviewed / verified at 2026-10-21T07:13:34.205Z. Note: Pubmed study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42811393": {
      "id": "pmid-42811393",
      "title": "Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42811393/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42811393 reviewed / verified at 2026-10-21T07:17:01.298Z. Note: Safety study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42823062": {
      "id": "pmid-42823062",
      "title": "Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42823062/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42823062 reviewed / verified at 2026-10-21T07:16:34.683Z. Note: Study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42843917": {
      "id": "pmid-42843917",
      "title": "Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42843917/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42843917 reviewed / verified at 2026-10-21T07:16:20.236Z. Note: Side effects. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42849462": {
      "id": "pmid-42849462",
      "title": "Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42849462/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42849462 reviewed / verified at 2026-10-21T07:16:05.971Z. Note: Study. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42849689": {
      "id": "pmid-42849689",
      "title": "GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42849689/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42849689 reviewed / verified at 2026-10-21T07:15:53.310Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42871568": {
      "id": "pmid-42871568",
      "title": "The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42871568/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42871568 reviewed / verified at 2026-10-21T07:14:14.262Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42873315": {
      "id": "pmid-42873315",
      "title": "GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42873315/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42873315 reviewed / verified at 2026-10-21T07:15:29.785Z. Note: Side effects. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42883986": {
      "id": "pmid-42883986",
      "title": "GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42883986/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42883986 reviewed / verified at 2026-10-21T07:14:55.745Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42889249": {
      "id": "pmid-42889249",
      "title": "Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42889249/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42889249 reviewed / verified at 2026-10-21T07:15:09.879Z. Note: Info. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42904878": {
      "id": "pmid-42904878",
      "title": "Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42904878/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42904878 reviewed / verified at 2026-10-23T08:20:25.747Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42907720": {
      "id": "pmid-42907720",
      "title": "Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42907720/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42907720 reviewed / verified at 2026-10-23T08:20:40.574Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42942810": {
      "id": "pmid-42942810",
      "title": "Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42942810/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42942810 reviewed / verified at 2026-10-27T18:45:14.990Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42942813": {
      "id": "pmid-42942813",
      "title": "Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42942813/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42942813 reviewed / verified at 2026-10-27T18:45:30.957Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42947668": {
      "id": "pmid-42947668",
      "title": "From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42947668/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42947668 reviewed / verified at 2026-10-28T15:50:03.293Z. Note: Pubmed. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pmid-42978208": {
      "id": "pmid-42978208",
      "title": "Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42978208/",
      "kind": "Literature source accepted by owner review",
      "verified": false,
      "note": "Owner marked PMID 42978208 reviewed / verified at 2026-11-08T03:42:51.620Z. Note: Use of GLP for PCOS. The source remains not yet independently re-audited, and the evidence class was not promoted.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-aml-2020": {
      "id": "pnc27-aml-2020",
      "title": "Wang et al. · Targeting Cell Membrane HDM2 in AML · Leukemia 2020 · PMID 31337857",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7951797/",
      "kind": "Preclinical primary research full text",
      "verified": true,
      "note": "Reviewed 2 November 2026. Full main text, methods and figure captions reviewed; supplemental files not independently opened. Online 23 July 2019, January 2020 issue. DOI 10.1038/s41375-019-0522-9. Human-derived cells in mice are preclinical.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-cervical-2025": {
      "id": "pnc27-cervical-2025",
      "title": "Krzesaj et al. · Cervical cancer cell comparison · 2025 · PMID 40750238",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40750238/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; HTB-35/SiHa versus PCS-480; IC50 12.4 micromolar. Full text not reviewed.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-doj-bishop": {
      "id": "pnc27-doj-bishop",
      "title": "US Department of Justice · US v Bishop · PNC-27 distribution case",
      "url": "https://www.justice.gov/usao-ndal/us-v-bishop",
      "kind": "Official regulatory/enforcement history",
      "verified": true,
      "note": "Reviewed 2 November 2026. Official account reviewed; historical unapproved products and nonsterile manufacturing. Does not establish intrinsic peptide toxicity or a current exhaustive regulatory audit.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-gi-case-2017": {
      "id": "pnc27-gi-case-2017",
      "title": "Aguon et al. · Experimental PNC-27 and massive GI hemorrhage · AJG 2017 conference case report",
      "url": "https://doi.org/10.14309/00000434-201710001-01880",
      "kind": "Human adverse-event case report",
      "verified": true,
      "note": "Reviewed 2 November 2026. Conference case-report abstract reviewed; one heavily pretreated patient, no causal attribution established.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-k562-2014": {
      "id": "pnc27-k562-2014",
      "title": "Davitt et al. · p53-null K562 cells · 2014 · PMID 25117093",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25117093/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; human cell line and murine leukocyte controls, not patients treated.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-leukemia-2020": {
      "id": "pnc27-leukemia-2020",
      "title": "Thadi et al. · Leukemia-cell necrosis within four hours · 2020 · PMID 32878773",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32878773/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; U937, OCI-AML3 and HL-60. DOI 10.21873/anticanres.14488. Culture timing is not clinical onset.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-mito-2024": {
      "id": "pnc27-mito-2024",
      "title": "Krzesaj et al. · Mitochondrial disruption · 2024 · PMID 38802154",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38802154/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; dye retention and immuno-electron microscopy in MIA-PaCa-2 cancer cells. Full text not reviewed.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-oncolyze": {
      "id": "pnc27-oncolyze",
      "title": "Oncolyze · OM-301 development identity",
      "url": "https://www.oncolyze.com/science/",
      "kind": "Sponsor development statement",
      "verified": true,
      "note": "Reviewed 2 November 2026. Sponsor page reviewed; explicitly identifies OM-301 as previously PNC-27. Sponsor claims are not independent efficacy verification.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-ovarian-2015": {
      "id": "pnc27-ovarian-2015",
      "title": "Sarafraz-Yazdi et al. · Patient-derived ovarian cancer cultures · 2015 · PMID 26663795",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26663795/",
      "kind": "Preclinical ex vivo primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; two primary cultures, not a clinical treatment trial.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-paclitaxel-2017": {
      "id": "pnc27-paclitaxel-2017",
      "title": "Alagkiozidis et al. · Paclitaxel and PNC-27 synergy · 2017 · PMID 28667027",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28667027/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; ID8 cell experiments and intraperitoneal ovarian cancer mouse model. PNC-27 administration route/dose not established by abstract.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-pancreas-2008": {
      "id": "pnc27-pancreas-2008",
      "title": "Sookraj et al. · Pancreatic cancer membrane-pore formation · JACS 2008 conference abstract",
      "url": "https://www.sciencedirect.com/science/article/pii/S1072751508008351",
      "kind": "Preclinical conference abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Publisher abstract/section snippets reviewed, not a full-length study. DOI 10.1016/j.jamcollsurg.2008.06.247. Exact PNC-27 identity checked; do not substitute PNC-28 studies.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-pnas-2010": {
      "id": "pnc27-pnas-2010",
      "title": "Sarafraz-Yazdi et al. · Membrane HDM2 targeting · PNAS 2010 · PMID 20080680",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20080680/",
      "kind": "Preclinical primary research abstract",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract reviewed; engineered membrane-localization experiment checked. DOI 10.1073/pnas.0909364107. Full text not independently reviewed.",
      "reviewState": "not_yet_reviewed"
    },
    "pnc27-pores-2022": {
      "id": "pnc27-pores-2022",
      "title": "Sarafraz-Yazdi et al. · PNC-27/HDM2 pore model · Biomedicines 2022 · PMID 35625682",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35625682/",
      "kind": "Preclinical primary research abstract and figure captions",
      "verified": true,
      "note": "Reviewed 2 November 2026. Abstract, figure captions and conflict statement reviewed. DOI 10.3390/biomedicines10050945. Authors disclose inventorship on related patents; not independent replication.",
      "reviewState": "not_yet_reviewed"
    },
    "r2": {
      "id": "r2",
      "title": "TRIUMPH-2 · Lancet 2026 · DOI 10.1016/S0140-6736(26)01861-1",
      "url": "https://doi.org/10.1016/S0140-6736(26)01861-1",
      "kind": "Primary research",
      "verified": false,
      "note": "Publication identity confirmed in search; numerical results retained as imported, not re-audited from full text.",
      "reviewState": "not_yet_reviewed"
    },
    "r3": {
      "id": "r3",
      "title": "TRIUMPH-1 · NEJM 2026 · DOI 10.1056/NEJMoa2604169",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/",
      "kind": "Primary research",
      "verified": true,
      "note": "Abstract retrieved 15 October 2026; 12 mg weight outcome checked. Full article/supplement not audited for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "retatrutide-osa-42904878": {
      "id": "retatrutide-osa-42904878",
      "title": "Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (NEJM 2026)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42904878/",
      "kind": "Human trial publication abstract",
      "verified": false,
      "note": "DOI 10.1056/NEJMoa2611477; full OSA text, supplementary safety tables, protocol and statistical analysis plan not independently verified.",
      "reviewState": "not_yet_reviewed"
    },
    "rphase2": {
      "id": "rphase2",
      "title": "Jastreboff et al. · NEJM 2023 retatrutide obesity phase 2 · PMID 37366315",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/",
      "kind": "Human primary research",
      "verified": true,
      "note": "Published 26 June 2023; DOI 10.1056/NEJMoa2301972; NCT04881760. Abstract results, once-weekly SC randomization arms and safety conclusions independently checked; supplemental adverse-event detail needs distinct source citation.",
      "reviewState": "not_yet_reviewed"
    },
    "rphase2supp": {
      "id": "rphase2supp",
      "title": "Jastreboff et al. · NEJM 2023 Phase 2 supplementary appendix · Table S14",
      "url": "https://gwern.net/doc/longevity/glp/retatrutide/2023-jastreboff-supplement.pdf",
      "kind": "Study supplementary material",
      "verified": false,
      "note": "Same third-party mirror. The previous semaglutide path redirects here. Tables S6, S8, S12 and S13 were read 22 October 2026. Still not the journal-hosted appendix.",
      "reviewState": "not_yet_reviewed"
    },
    "semaglutide-protocol-jarvis-ozempic-source": {
      "id": "semaglutide-protocol-jarvis-ozempic-source",
      "title": "Ozempic prescribing information",
      "url": "https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, Dosage and Administration.",
      "reviewState": "not_yet_reviewed"
    },
    "seqvideo": {
      "id": "seqvideo",
      "title": "Dr. Jones · Fat-loss sequencing video",
      "url": "https://www.youtube.com/watch?v=UNoMjEryd-E",
      "kind": "Creator report",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "serm-1997": {
      "id": "serm-1997",
      "title": "Khorram et al 1997 modified GHRH analogue PMID 9141536",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9141536/",
      "kind": "Primary human research",
      "verified": true,
      "note": "Selected abstract findings checked 15 October 2026; preserve exact molecule, route, population and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "serm-men": {
      "id": "serm-men",
      "title": "Vittone et al 1997 GHRH 1 29 PMID 9005976",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9005976/",
      "kind": "Primary human research",
      "verified": true,
      "note": "Selected abstract findings checked 15 October 2026; preserve exact molecule, route, population and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "slu": {
      "id": "slu",
      "title": "SLU-PP-332 exercise response · PMID 36988910",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36988910/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "slu915": {
      "id": "slu915",
      "title": "SLU-PP-915 paper · PMID 41421047",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41421047/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "social-03285429f913": {
      "id": "social-03285429f913",
      "title": "Owner-published Jarvis finding",
      "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-0f6550f59c98": {
      "id": "social-0f6550f59c98",
      "title": "Owner-published Jarvis finding",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-12d60d041733": {
      "id": "social-12d60d041733",
      "title": "Owner-published Jarvis finding",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-33956f741338": {
      "id": "social-33956f741338",
      "title": "Owner-published Jarvis finding",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42253238/",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-480244d77b66": {
      "id": "social-480244d77b66",
      "title": "Owner-published Jarvis finding",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42814954/",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-4929293bb614": {
      "id": "social-4929293bb614",
      "title": "Owner-approved instagram discussion",
      "url": "https://www.instagram.com/p/DeCezzJgdw5/",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "social-4ca2e571666c": {
      "id": "social-4ca2e571666c",
      "title": "Owner-approved tiktok discussion",
      "url": "https://www.tiktok.com/@thepepedit/video/7673643223369141526",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "social-6415cae3ca10": {
      "id": "social-6415cae3ca10",
      "title": "Owner-published Jarvis finding",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42820639/",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-cd11ee7bb303": {
      "id": "social-cd11ee7bb303",
      "title": "Owner-published Jarvis finding",
      "url": "https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4591528",
      "kind": "Owner-published research lead",
      "verified": false,
      "note": "Owner published this finding from the Jarvis queue. Publication does not raise its evidence class.",
      "reviewState": "not_yet_reviewed"
    },
    "social-d45b7522b007": {
      "id": "social-d45b7522b007",
      "title": "Owner-approved instagram discussion",
      "url": "https://www.instagram.com/p/DefSB8ehNgr/",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "social-de5ea69b02ec": {
      "id": "social-de5ea69b02ec",
      "title": "Owner-approved tiktok discussion",
      "url": "https://www.tiktok.com/@alexoptimize/video/7658790636400774420",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "social-e063d16d706c": {
      "id": "social-e063d16d706c",
      "title": "Owner-approved instagram discussion",
      "url": "https://www.instagram.com/p/DeiVbJ_R-01/",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "social-ed4663ec85a6": {
      "id": "social-ed4663ec85a6",
      "title": "Owner-approved facebook discussion",
      "url": "https://www.facebook.com/reel/1141288005253823/",
      "kind": "Social media research lead",
      "verified": false,
      "note": "Owner approved inclusion; claim itself remains unverified.",
      "reviewState": "not_yet_reviewed"
    },
    "ssvideo": {
      "id": "ssvideo",
      "title": "SS-31 Before vs After MOTS-c",
      "url": "https://www.youtube.com/watch?v=7C70pWMi46Y",
      "kind": "Creator anecdote",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "stackvideo": {
      "id": "stackvideo",
      "title": "Dr. Jones · Tesamorelin + Retatrutide",
      "url": "https://www.youtube.com/watch?v=tRIoqrw-6_A",
      "kind": "Creator report",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "survodutide-protocol-jarvis-phase2-source": {
      "id": "survodutide-protocol-jarvis-phase2-source",
      "title": "Survodutide phase 2 obesity trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39821928/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Trial subgroup publication, NCT04667377.",
      "reviewState": "not_yet_reviewed"
    },
    "sv": {
      "id": "sv",
      "title": "EGRIFTA SV prescribing information",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224",
      "kind": "Human label",
      "verified": true,
      "note": "Dose, indication and formulation-specific half-life checked 15 October 2026.",
      "reviewState": "not_yet_reviewed"
    },
    "synergy-mash": {
      "id": "synergy-mash",
      "title": "Loomba et al. · Tirzepatide SYNERGY-NASH · NEJM 2024 · PMID 38856224",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38856224/",
      "kind": "Human primary research",
      "verified": false,
      "note": "Primary trial cited by owner-supplied video; study outcomes reconciled in private Jarvis audit 2026-10-29. No automatic evidence-tier promotion.",
      "reviewState": "not_yet_reviewed"
    },
    "tb4": {
      "id": "tb4",
      "title": "Full-length thymosin beta-4 phase I · PMID 20536472",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20536472/",
      "kind": "Primary research",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "tbrain": {
      "id": "tbrain",
      "title": "Baker et al. · 2012 · PMID 22869065",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22869065/",
      "kind": "Primary research",
      "verified": true,
      "note": "Selected primary findings checked 15 October 2026 for the GH article audit; no full systematic review. Preserve molecule, population, route and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "tesa-label-review-20261025": {
      "id": "tesa-label-review-20261025",
      "title": "DailyMed EGRIFTA WR prescribing information · selected safety and administration sections",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75",
      "kind": "Human regulatory label",
      "verified": true,
      "note": "Sections 1, 2, 4, 5 and 14 reopened 25 October 2026. Scope: indication, non-substitutable formulations, daily administration, IGF-1 monitoring, fluid retention, glucose risk and withdrawal outcomes. Safety/trial values derive from original EGRIFTA studies; not research-vial validation.",
      "reviewState": "not_yet_reviewed"
    },
    "tesa-muscle-2019": {
      "id": "tesa-muscle-2019",
      "title": "Adrian et al. · Tesamorelin muscle CT exploratory secondary analysis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/",
      "kind": "Human exploratory secondary analysis",
      "verified": true,
      "note": "Full text reviewed 25 October 2026. DOI 10.14283/jfa.2018.45; PMID 31237318. CT imaging at baseline and 26 weeks: 193 tesamorelin VAT responders and 148 placebo participants. Responder selection and absent functional endpoints limit causal/general clinical interpretation.",
      "reviewState": "not_yet_reviewed"
    },
    "tesa-video-casey-20260920": {
      "id": "tesa-video-casey-20260920",
      "title": "Casey / Living Youthful · Tesamorelin Dosing Guide + The Best Peptides to Stack",
      "url": "https://www.youtube.com/watch?v=2QpW4Y-DvfY",
      "kind": "Creator video; transcript reviewed",
      "verified": false,
      "note": "User-supplied timestamped transcript and independently retrieved transcript reviewed 25 October 2026. YouTube metadata gives 20 September 2026 Pacific / 21 September UTC. Creator observations and affiliate disclosure are not controlled clinical evidence. No visual-frame analysis claimed.",
      "reviewState": "not_yet_reviewed"
    },
    "tesa-withdrawal-2010": {
      "id": "tesa-withdrawal-2010",
      "title": "Falutz et al. · 2010 randomized tesamorelin trial with withdrawal extension",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20101189/",
      "kind": "Human randomized trial abstract",
      "verified": true,
      "note": "Abstract reviewed 25 October 2026; full article not independently reviewed. DOI 10.1097/QAI.0b013e3181cbdaff; PMID 20101189; NCT00435136 and NCT00608023. 404 adults with HIV and central fat accumulation; original 2 mg SC daily formulation; 6-month primary phase and 6-month extension.",
      "reviewState": "not_yet_reviewed"
    },
    "tirzepatide-protocol-jarvis-zepbound-source": {
      "id": "tirzepatide-protocol-jarvis-zepbound-source",
      "title": "Zepbound prescribing information",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b",
      "kind": "Prescribing information",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: DailyMed, Dosage and Administration.",
      "reviewState": "not_yet_reviewed"
    },
    "tliver": {
      "id": "tliver",
      "title": "Stanley et al. · Lancet HIV 2019 · PMID 31611038",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31611038/",
      "kind": "Primary research",
      "verified": true,
      "note": "Selected primary findings checked 15 October 2026 for the GH article audit; no full systematic review. Preserve molecule, population, route and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "tp508-protocol-jarvis-chrysalin-source": {
      "id": "tp508-protocol-jarvis-chrysalin-source",
      "title": "TP-508 in diabetic foot ulcers",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17244316/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract, PMID 17244316.",
      "reviewState": "not_yet_reviewed"
    },
    "tvideo": {
      "id": "tvideo",
      "title": "Hunter Williams · Tesamorelin Masterclass",
      "url": "https://www.youtube.com/watch?v=V_Yd07NqXYM",
      "kind": "Creator report",
      "verified": false,
      "note": "Citation imported from the field guide; not independently reopened for this build.",
      "reviewState": "not_yet_reviewed"
    },
    "tvis": {
      "id": "tvis",
      "title": "Falutz et al. · NEJM 2007",
      "url": "https://doi.org/10.1056/NEJMoa072375",
      "kind": "Primary research",
      "verified": true,
      "note": "Selected primary findings checked 15 October 2026 for the GH article audit; no full systematic review. Preserve molecule, population, route and outcome limitations.",
      "reviewState": "not_yet_reviewed"
    },
    "urolithin-protocol-jarvis-middle-aged-source": {
      "id": "urolithin-protocol-jarvis-middle-aged-source",
      "title": "Urolithin A in middle-aged adults",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35584623/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary abstract and Fig. 1, PMID 35584623.",
      "reviewState": "not_yet_reviewed"
    },
    "urolithin-protocol-jarvis-older-adults-source": {
      "id": "urolithin-protocol-jarvis-older-adults-source",
      "title": "Urolithin A in older adults",
      "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788244",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Methods.",
      "reviewState": "not_yet_reviewed"
    },
    "vip-protocol-jarvis-inhaled-pph-source": {
      "id": "vip-protocol-jarvis-inhaled-pph-source",
      "title": "Inhaled VIP in primary pulmonary hypertension",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC154449/",
      "kind": "Primary study or trial registry",
      "verified": true,
      "note": "Checked 3 November 2026. Retrieval scope: Primary article, Methods and Results.",
      "reviewState": "not_yet_reviewed"
    },
    "wr": {
      "id": "wr",
      "title": "EGRIFTA WR prescribing information",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75",
      "kind": "Human label",
      "verified": true,
      "note": "Dose and formulation-specific PK checked 15 October 2026; not a review of every label section.",
      "reviewState": "not_yet_reviewed"
    }
  },
  "compounds": [
    {
      "id": "tirzepatide",
      "name": "Tirzepatide",
      "pathway": "Metabolic / appetite",
      "target": "GLP-1 and GIP receptor agonism",
      "aliases": "LY3298176",
      "kind": "Peptide",
      "records": [
        {
          "id": "tirzepatide-1",
          "tier": "H",
          "title": "SYNERGY-NASH biopsy-confirmed MASH resolution at 52 weeks",
          "summary": "MASH resolution without worsening fibrosis was observed in 44%, 56%, and 62% in the three tirzepatide groups versus 10% with placebo.",
          "context": "Phase 2 randomized study in adults with biopsy-confirmed MASH and F2/F3 fibrosis; endpoint at 52 weeks.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Resolution of MASH without worsening fibrosis is not identical to fibrosis regression; disease-specific regulatory indications must be independently checked.",
          "strength": "Human randomized trial; primary source bibliographic identifier preserved; detail from prior private audit",
          "refs": [
            "synergy-mash"
          ]
        },
        {
          "id": "tirzepatide-protocol-jarvis-zepbound",
          "tier": "H",
          "title": "Zepbound prescribing information",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Patients meeting the respective labeled indications",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2.5 mg initiation; 5, 10 or 15 mg weight-management maintenance; 10 or 15 mg OSA maintenance; Route: Subcutaneous; Frequency: Once weekly; Species: Human; Population: Patients meeting the respective labeled indications",
          "ptype": "label",
          "limit": "Initiation lasts four weeks. Escalation is in 2.5 mg increments after at least four weeks at the current dose. Maximum 15 mg weekly.",
          "strength": "DailyMed, Dosage and Administration",
          "refs": [
            "tirzepatide-protocol-jarvis-zepbound-source"
          ],
          "protocolDetails": {
            "amount": "2.5 mg initiation; 5, 10 or 15 mg weight-management maintenance; 10 or 15 mg OSA maintenance",
            "route": "Subcutaneous",
            "frequency": "Once weekly",
            "duration": null,
            "species": "Human",
            "population": "Patients meeting the respective labeled indications"
          },
          "sourceLocator": {
            "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b",
            "section": "DailyMed, Dosage and Administration"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "retatrutide",
      "name": "Retatrutide",
      "pathway": "Metabolic / appetite",
      "target": "GLP-1, GIP and glucagon receptor agonism",
      "aliases": "RETA LY3437943",
      "kind": "Peptide",
      "gap": "SC trials exist; an absolute human SC bioavailability percentage is not established in this import. Oral and IM PK are not established here.",
      "records": [
        {
          "id": "retatrutide-1",
          "tier": "H",
          "title": "Phase 3 obesity evidence",
          "summary": "TRIUMPH-1 reported mean weight loss of 25.0% at 12 mg versus 3.9% with placebo at 80 weeks.",
          "context": "2,339 adults with obesity; phase 3 randomized trial.",
          "route": "SC",
          "pk": "studied",
          "pktext": "Human SC administration; absolute percentage not established here.",
          "protocol": null,
          "ptype": null,
          "limit": "Trial methods are research context. No split-weekly regimen or peptide combination was validated by this trial.",
          "strength": "Randomized trial; abstract checked",
          "refs": [
            "r3",
            "guide"
          ]
        },
        {
          "id": "retatrutide-2",
          "tier": "H",
          "title": "Phase 2 liver / visceral fat findings",
          "summary": "A small MASLD substudy supports liver- and visceral-fat reductions with retatrutide alone.",
          "context": "Human phase 2a substudy; 98 participants.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "These outcomes do not demonstrate extra benefit from adding tesamorelin.",
          "strength": "Randomized trial; imported",
          "refs": [
            "masld",
            "guide"
          ]
        },
        {
          "id": "retatrutide-3",
          "tier": "H",
          "title": "Phase 2 obesity efficacy at 24 and 48 weeks",
          "summary": "In 338 randomized adults, least-squares mean weight reduction at week 24 was 7.2% (1 mg), 12.9% (combined 4 mg), 17.3% (combined 8 mg), and 17.5% (12 mg), versus 1.6% placebo; at week 48: 8.7%, 17.1%, 22.8%, and 24.2%, versus 2.1% placebo.",
          "context": "Jastreboff et al., NEJM 2023; NCT04881760. Primary endpoint week 24; week 48 was secondary. BMI >=30 or 27 to <30 with weight-related condition.",
          "route": "SC",
          "pk": "studied",
          "pktext": "Once-weekly SC trial; absolute human SC bioavailability not reported in this efficacy publication.",
          "protocol": null,
          "ptype": null,
          "limit": "Group estimates are not individual predictions. Excluded populations and longer-term maintenance or clinical outcomes are not established by this 48-week Phase 2 trial.",
          "strength": "Peer-reviewed randomized double-blind placebo-controlled human Phase 2 trial; abstract independently checked",
          "refs": [
            "rphase2"
          ]
        },
        {
          "id": "retatrutide-4",
          "tier": "H",
          "title": "Phase 2 weekly SC trial arms and titration",
          "summary": "Six retatrutide randomized groups: 1 mg; 4 mg starting 2 mg; 4 mg starting 4 mg; 8 mg starting 2 mg; 8 mg starting 4 mg; and 12 mg starting 2 mg, plus placebo. Treatment continued 48 weeks.",
          "context": "Jastreboff et al., NEJM 2023, NCT04881760. Study arms and initial doses from methods, not personal titration instructions.",
          "route": "SC",
          "pk": "studied",
          "pktext": "Subcutaneous once weekly; oral, IM, split-weekly and combination routes/regimens were not evaluated.",
          "protocol": null,
          "ptype": null,
          "limit": "Research regimens are not recommended individualized protocols. This abstract does not specify each escalation step or validate a nontrial formulation.",
          "strength": "Direct trial design, Phase 2",
          "refs": [
            "rphase2"
          ]
        },
        {
          "id": "retatrutide-5",
          "tier": "H",
          "title": "Phase 2 safety and sensory adverse events",
          "summary": "Gastrointestinal adverse events were most common, dose related and generally mild to moderate; lower initial dose partially mitigated them. Dose-related heart-rate increases peaked at 24 weeks and declined afterward. Supplemental Table S14 reports hyperesthesia-related events including sensitive skin, allodynia and skin-burning symptoms.",
          "context": "Safety monitoring in 48-week Phase 2 obesity trial; supplementary adverse-event tabulation is source-distinct from trial abstract.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Adverse-event reports show association, not a diagnosis or proof of causation for an individual. Rare and long-term risks remain incompletely characterized.",
          "strength": "Randomized human trial plus supplementary AE table; appendix provenance noted",
          "refs": [
            "rphase2",
            "rphase2supp"
          ]
        },
        {
          "id": "retatrutide-6",
          "tier": "U",
          "title": "Phase 2 evidence boundaries and research limitations",
          "summary": "This trial does not establish long-term cardiovascular event reduction, safety of nontrial products, oral bioavailability, twice-weekly superiority, or benefit/safety of combining retatrutide with tirzepatide or other peptide therapies.",
          "context": "338-person Phase 2 placebo-controlled trial funded by Eli Lilly; no active semaglutide or tirzepatide comparator.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Absence of data is not proof of no benefit or harm. Avoid inferring personalized dosing and long-term outcomes from interim weight measures.",
          "strength": "Explicit trial-design limitations",
          "refs": [
            "rphase2"
          ]
        },
        {
          "id": "retatrutide-7",
          "tier": "T",
          "title": "Combination rationale is a hypothesis",
          "summary": "Different receptor pathways do not prove synergy, muscle preservation, safety or optimal sequencing with tesamorelin.",
          "context": "Mechanistic extrapolation from separate-drug results.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No controlled combination study was identified in the imported review.",
          "strength": "Imported synthesis",
          "refs": [
            "stackvideo",
            "guide"
          ]
        },
        {
          "id": "retatrutide-8",
          "tier": "H",
          "title": "Phase 2a MASLD MRI-PDFF liver-fat endpoint",
          "summary": "Relative reductions in liver fat at 24 weeks averaged 81.4% (8 mg) and 82.4% (12 mg); at 48 weeks, the 12 mg group averaged 86.0%.",
          "context": "NCT04881760 MASLD substudy; 98 adults; MRI-based liver-fat endpoint rather than histologic fibrosis reversal.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Small imaging substudy with reduced follow-up sample; cannot infer individual outcomes or fibrosis reversal, and liver-fat improvement does not isolate the glucagon-receptor mechanism.",
          "strength": "Human phase 2a MRI-PDFF evidence; study citation included in existing Atlas",
          "refs": [
            "masld"
          ]
        },
        {
          "id": "retatrutide-protocol-phase3-4",
          "tier": "H",
          "title": "TRIUMPH target 4 mg weekly",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 4 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "ptype": "studied",
          "limit": "Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.",
          "strength": "Study regimen · imported source",
          "refs": [
            "r3",
            "r2",
            "guide"
          ],
          "protocolDetails": {
            "amount": "4 mg target; start 2 mg",
            "frequency": "Once weekly",
            "duration": "80 weeks",
            "timing": "Escalation every four weeks through applicable steps: 2 → 4 mg",
            "route": "SC",
            "species": "Human",
            "population": "TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              2,
              17
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "retatrutide-protocol-phase3-9",
          "tier": "H",
          "title": "TRIUMPH target 9 mg weekly",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 9 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "ptype": "studied",
          "limit": "Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.",
          "strength": "Study regimen · imported source",
          "refs": [
            "r3",
            "r2",
            "guide"
          ],
          "protocolDetails": {
            "amount": "9 mg target; start 2 mg",
            "frequency": "Once weekly",
            "duration": "80 weeks",
            "timing": "Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 mg",
            "route": "SC",
            "species": "Human",
            "population": "TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              2,
              17
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "retatrutide-protocol-phase3-12",
          "tier": "H",
          "title": "TRIUMPH target 12 mg weekly",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 12 mg target; start 2 mg; Frequency: Once weekly; Duration: 80 weeks; Timing: Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 → 12 mg; Route: SC; Species: Human; Population: TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes",
          "ptype": "studied",
          "limit": "Protocol details are preserved from the prior source review; supplements were not reopened. No split-weekly schedule was tested here.",
          "strength": "Study regimen · imported source",
          "refs": [
            "r3",
            "r2",
            "guide"
          ],
          "protocolDetails": {
            "amount": "12 mg target; start 2 mg",
            "frequency": "Once weekly",
            "duration": "80 weeks",
            "timing": "Escalation every four weeks through applicable steps: 2 → 4 → 6 → 9 → 12 mg",
            "route": "SC",
            "species": "Human",
            "population": "TRIUMPH-1: adults with obesity without diabetes; TRIUMPH-2: adults with obesity and type 2 diabetes"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              2,
              17
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "retatrutide-protocol-phase2",
          "tier": "H",
          "title": "Phase 2 dose-arm range",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Phase 2 obesity trial",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1–12 mg study arms; Frequency: Once weekly; Duration: 48 weeks; Route: SC; Species: Human; Population: Phase 2 obesity trial",
          "ptype": "studied",
          "limit": "The field guide provides a range, not a full arm-by-arm escalation table. Do not reconstruct missing steps.",
          "strength": "Study regimen · imported source",
          "refs": [
            "rphase2",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1–12 mg study arms",
            "frequency": "Once weekly",
            "duration": "48 weeks",
            "route": "SC",
            "species": "Human",
            "population": "Phase 2 obesity trial"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              13,
              14
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "retatrutide-protocol-optimizer",
          "tier": "A",
          "title": "Speaker’s low-dose optimizer suggestion",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Speaker describes “healthy optimizers”",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1–2 mg; Route: Not documented; Population: Speaker describes “healthy optimizers”",
          "ptype": "anecdotal",
          "limit": "Frequency, route and cycle were not documented in this passage. Not a validated longevity regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "stackvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1–2 mg",
            "route": "Not documented",
            "population": "Speaker describes “healthy optimizers”"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              14
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "retatrutide-protocol-sequence",
          "tier": "A",
          "title": "Retatrutide before adding tesamorelin",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: Wait two to four weeks or longer before adding tesamorelin; Route: Not documented; Sequence: Introduce retatrutide first; add tesamorelin after the reported adjustment interval",
          "ptype": "anecdotal",
          "limit": "Sequential introduction may aid attribution but does not establish combination benefit, safety or an optimal interval.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "stackvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "Wait two to four weeks or longer before adding tesamorelin",
            "route": "Not documented",
            "sequence": "Introduce retatrutide first; add tesamorelin after the reported adjustment interval"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              14
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "approved-d45b7522b007",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "FDA classification and Lilly appeal determine market exclusivity and compounding",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Legal and regulatory claims require independent docket and decision verification",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-d45b7522b007"
          ]
        },
        {
          "id": "approved-ed4663ec85a6",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "Retatrutide acts on GLP-1, GIP and glucagon receptors",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Mechanism broadly supported; comparative efficacy not established by receptor count alone",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-ed4663ec85a6"
          ]
        },
        {
          "id": "approved-03285429f913",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "Nonapproved reta vials are not FDA-regulated study drug",
          "context": "Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "FDA confirms retatrutide cannot be used in compounding and remains unapproved",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-03285429f913",
            "linked-03285429f913"
          ]
        },
        {
          "id": "approved-0f6550f59c98",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "80-week weight reduction and glycaemic outcomes; dysesthesia, hypotension and gastrointestinal adverse events require safety review",
          "context": "Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Trial-specific population; no generalization to non-study formulations; primary publication should be read in full before claims approval",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-0f6550f59c98"
          ]
        },
        {
          "id": "approved-480244d77b66",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "Mean weight changes -17.6%, -23.7%, -25.0% vs -3.9% placebo, treatment-regimen estimand; knee pain and apnea-hypopnea index improved in prespecified subgroups using distinct estimands",
          "context": "Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Eli Lilly-funded Phase 3 trial; subgroup estimands differ from weight estimand; GI adverse events common; detailed full-text adverse event rates and PK not independently reviewed. PubMed abstract appears to contain a sign inconsistency for one hybrid-estimand apnea value; verify against full text before quoting.",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-480244d77b66"
          ]
        },
        {
          "id": "approved-cd11ee7bb303",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "TRANSCEND-CKD phase 2b randomized trial: measured GFR primary endpoint did not significantly improve at 24 weeks (reported difference -1.4 mL/min/1.73 m², 95% CI -9.2 to 6.3; p=0.714). Secondary albuminuria and other biomarker changes require scoped interpretation.",
          "context": "Owner-published from the Jarvis queue onto Retatrutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "ASN conference abstract, not full peer-reviewed results or poster PDF; 146 adults with CKD and overweight/obesity; UACR analysis restricted to 42 participants with elevated baseline albuminuria. Weekly subcutaneous investigational retatrutide titrated toward 12 mg; studied regimen only. No demonstrated long-term kidney protection; full adverse-event and PK results not independently verified. Compare NCT05936151 and subsequent primary publications.",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-cd11ee7bb303"
          ]
        },
        {
          "id": "literature-retatrutide-39724554",
          "tier": "U",
          "title": "The First Triple Agonist for Antiobesity: Retatrutide.",
          "summary": "Owner accepted PMID 39724554 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 39724554. Reviewed 2026-10-17T12:44:35.822Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-39724554"
          ]
        },
        {
          "id": "literature-retatrutide-42135195",
          "tier": "U",
          "title": "Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.",
          "summary": "Owner accepted PMID 42135195 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42135195. Reviewed 2026-10-17T12:47:22.621Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42135195"
          ]
        },
        {
          "id": "literature-retatrutide-42219269",
          "tier": "U",
          "title": "Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.",
          "summary": "Owner accepted PMID 42219269 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42219269. Reviewed 2026-10-18T01:26:49.270Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42219269"
          ]
        },
        {
          "id": "literature-retatrutide-42250575",
          "tier": "U",
          "title": "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.",
          "summary": "Owner accepted PMID 42250575 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42250575. Reviewed 2026-10-20T03:58:20.004Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42250575"
          ]
        },
        {
          "id": "literature-retatrutide-42385950",
          "tier": "U",
          "title": "Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.",
          "summary": "Owner accepted PMID 42385950 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42385950. Reviewed 2026-10-20T03:58:35.071Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42385950"
          ]
        },
        {
          "id": "literature-retatrutide-42444567",
          "tier": "U",
          "title": "Medical treatments for obesity: what does the future have in store?",
          "summary": "Owner accepted PMID 42444567 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42444567. Reviewed 2026-10-18T07:01:42.362Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42444567"
          ]
        },
        {
          "id": "literature-retatrutide-42603384",
          "tier": "U",
          "title": "Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.",
          "summary": "Owner accepted PMID 42603384 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42603384. Reviewed 2026-10-20T03:58:47.536Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42603384"
          ]
        },
        {
          "id": "literature-retatrutide-42608321",
          "tier": "U",
          "title": "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.",
          "summary": "Owner accepted PMID 42608321 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42608321. Reviewed 2026-10-20T03:58:59.092Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42608321"
          ]
        },
        {
          "id": "literature-retatrutide-42630988",
          "tier": "U",
          "title": "Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.",
          "summary": "Owner accepted PMID 42630988 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42630988. Reviewed 2026-10-20T03:59:32.696Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42630988"
          ]
        },
        {
          "id": "literature-retatrutide-42673585",
          "tier": "U",
          "title": "Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.",
          "summary": "Owner accepted PMID 42673585 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42673585. Reviewed 2026-10-21T07:11:32.217Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42673585"
          ]
        },
        {
          "id": "literature-retatrutide-42734711",
          "tier": "U",
          "title": "Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.",
          "summary": "Owner accepted PMID 42734711 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42734711. Reviewed 2026-10-21T07:11:43.911Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42734711"
          ]
        },
        {
          "id": "literature-retatrutide-42744908",
          "tier": "U",
          "title": "Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.",
          "summary": "Owner accepted PMID 42744908 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42744908. Reviewed 2026-10-21T07:12:03.821Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42744908"
          ]
        },
        {
          "id": "literature-retatrutide-42751099",
          "tier": "U",
          "title": "Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.",
          "summary": "Owner accepted PMID 42751099 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42751099. Reviewed 2026-10-21T07:12:36.734Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42751099"
          ]
        },
        {
          "id": "literature-retatrutide-42768195",
          "tier": "U",
          "title": "Future GLP-1 receptor co-agonists and their cardiac effects.",
          "summary": "Owner accepted PMID 42768195 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42768195. Reviewed 2026-10-21T07:12:52.265Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42768195"
          ]
        },
        {
          "id": "literature-retatrutide-42783450",
          "tier": "U",
          "title": "The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?",
          "summary": "Owner accepted PMID 42783450 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42783450. Reviewed 2026-10-21T07:13:15.899Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42783450"
          ]
        },
        {
          "id": "literature-retatrutide-42808923",
          "tier": "U",
          "title": "Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.",
          "summary": "Owner accepted PMID 42808923 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42808923. Reviewed 2026-10-21T07:13:34.205Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42808923"
          ]
        },
        {
          "id": "literature-retatrutide-42811393",
          "tier": "U",
          "title": "Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.",
          "summary": "Owner accepted PMID 42811393 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42811393. Reviewed 2026-10-21T07:17:01.298Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42811393"
          ]
        },
        {
          "id": "literature-retatrutide-42823062",
          "tier": "U",
          "title": "Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.",
          "summary": "Owner accepted PMID 42823062 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42823062. Reviewed 2026-10-21T07:16:34.683Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42823062"
          ]
        },
        {
          "id": "literature-retatrutide-42843917",
          "tier": "U",
          "title": "Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.",
          "summary": "Owner accepted PMID 42843917 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42843917. Reviewed 2026-10-21T07:16:20.236Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42843917"
          ]
        },
        {
          "id": "literature-retatrutide-42849462",
          "tier": "U",
          "title": "Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?",
          "summary": "Owner accepted PMID 42849462 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42849462. Reviewed 2026-10-21T07:16:05.971Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42849462"
          ]
        },
        {
          "id": "literature-retatrutide-42849689",
          "tier": "U",
          "title": "GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.",
          "summary": "Owner accepted PMID 42849689 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42849689. Reviewed 2026-10-21T07:15:53.310Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42849689"
          ]
        },
        {
          "id": "literature-retatrutide-42871568",
          "tier": "U",
          "title": "The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.",
          "summary": "Owner accepted PMID 42871568 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42871568. Reviewed 2026-10-21T07:14:14.262Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42871568"
          ]
        },
        {
          "id": "literature-retatrutide-42873315",
          "tier": "U",
          "title": "GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?",
          "summary": "Owner accepted PMID 42873315 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42873315. Reviewed 2026-10-21T07:15:29.785Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42873315"
          ]
        },
        {
          "id": "literature-retatrutide-42883986",
          "tier": "U",
          "title": "GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.",
          "summary": "Owner accepted PMID 42883986 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42883986. Reviewed 2026-10-21T07:14:55.745Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42883986"
          ]
        },
        {
          "id": "literature-retatrutide-42889249",
          "tier": "U",
          "title": "Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.",
          "summary": "Owner accepted PMID 42889249 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42889249. Reviewed 2026-10-21T07:15:09.879Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42889249"
          ]
        },
        {
          "id": "literature-retatrutide-42904878",
          "tier": "U",
          "title": "Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.",
          "summary": "Owner accepted PMID 42904878 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42904878. Reviewed 2026-10-23T08:20:25.747Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42904878"
          ]
        },
        {
          "id": "literature-retatrutide-42907720",
          "tier": "U",
          "title": "Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.",
          "summary": "Owner accepted PMID 42907720 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42907720. Reviewed 2026-10-23T08:20:40.574Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42907720"
          ]
        },
        {
          "id": "literature-retatrutide-42942810",
          "tier": "U",
          "title": "Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.",
          "summary": "Owner accepted PMID 42942810 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42942810. Reviewed 2026-10-27T18:45:14.990Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42942810"
          ]
        },
        {
          "id": "literature-retatrutide-42942813",
          "tier": "U",
          "title": "Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.",
          "summary": "Owner accepted PMID 42942813 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42942813. Reviewed 2026-10-27T18:45:30.957Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42942813"
          ]
        },
        {
          "id": "literature-retatrutide-42947668",
          "tier": "U",
          "title": "From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.",
          "summary": "Owner accepted PMID 42947668 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42947668. Reviewed 2026-10-28T15:50:03.293Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42947668"
          ]
        },
        {
          "id": "literature-retatrutide-42978208",
          "tier": "U",
          "title": "Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations.",
          "summary": "Owner accepted PMID 42978208 as a source report. Evidence class stays Unresolved / evidence gap (U).",
          "context": "Retatrutide literature queue. PMID 42978208. Reviewed 2026-11-08T03:42:51.620Z.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Accepted as a source report only. This review does not establish a population, formulation, route, dose, duration, outcome, or a higher evidence class, and it is not a regimen.",
          "strength": "Unresolved / evidence gap; owner-accepted literature source, class not promoted",
          "refs": [
            "pmid-42978208"
          ]
        },
        {
          "id": "retatrutide-osa-pmid-42904878",
          "tier": "U",
          "title": "Retatrutide phase 3 OSA findings — PMID 42904878",
          "summary": "At week 80, placebo-adjusted AHI differences at 9 mg were -24.4 (TRIUMPH-1 OSA) and -14.4 (TRIUMPH-2 OSA) events/hour; at 12 mg, -21.9 and -15.1, respectively, under the hybrid estimand.",
          "context": "Randomized placebo-controlled OSA subgroups: TRIUMPH-1 without diabetes n=243 and TRIUMPH-2 with diabetes n=448. The TRIUMPH-1 subgroup overlaps the earlier NEJM obesity paper and is not independent replication. Investigational once-weekly subcutaneous 4/9/12 mg arms studied over 80 weeks.",
          "route": "Subcutaneous in trial",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Abstract-supported only. Full article, safety tables, attrition, escalation and statistical analysis plan not independently reconciled. Study doses are not recommendations; no approval or evidence-tier promotion implied.",
          "strength": "Owner-authorized abstract publication, unresolved full-text verification",
          "refs": [
            "retatrutide-osa-42904878"
          ]
        }
      ]
    },
    {
      "id": "tesamorelin",
      "name": "Tesamorelin",
      "pathway": "GH / IGF-1",
      "target": "GHRH receptor → GH secretion → IGF-1",
      "aliases": "TESA EGRIFTA SV WR",
      "kind": "Peptide",
      "gap": "Original EGRIFTA absolute SC bioavailability under 4% is an imported older-formulation finding. Do not transfer it to every formulation. Oral, intranasal and IM therapeutic PK are not established here.",
      "records": [
        {
          "id": "tesamorelin-1",
          "tier": "H",
          "title": "Label regimens and formulation-specific PK",
          "summary": "EGRIFTA targets excess abdominal fat in adults with HIV-associated lipodystrophy. WR and SV have different doses.",
          "context": "Approved product labeling, specific indication.",
          "route": "SC",
          "pk": "studied",
          "pktext": "Healthy-subject label half-life: WR ~11 minutes, SV ~8 minutes.",
          "protocol": null,
          "ptype": null,
          "limit": "Formulations are not substitutable. This is not a general weight-loss or research-vial regimen.",
          "strength": "Human labeling; anchors checked",
          "refs": [
            "wr",
            "sv",
            "guide"
          ]
        },
        {
          "id": "tesamorelin-2",
          "tier": "H",
          "title": "Human visceral and liver fat trials",
          "summary": "Trials support visceral-fat reduction and liver-fat improvement in selected populations with HIV.",
          "context": "Original formulation; HIV-associated abdominal fat / fatty liver.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Do not generalize this population or dose to all obesity, longevity, or current formulations.",
          "strength": "Randomized trials; imported",
          "refs": [
            "tvis",
            "tliver",
            "guide"
          ]
        },
        {
          "id": "tesamorelin-3",
          "tier": "A",
          "title": "Creator timing and cycling schedules",
          "summary": "Hunter Williams favors bedtime use after food and five days on / two off; multiple longer cycles are described.",
          "context": "Supplied video transcript, not a comparative dosing trial.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Lower-dose equivalence, bedtime superiority, receptor resets and prevention of allergy are unproven.",
          "strength": "Attributed creator practice",
          "refs": [
            "tvideo",
            "guide"
          ]
        },
        {
          "id": "tesamorelin-4",
          "tier": "T",
          "title": "Stacking and longevity hypotheses",
          "summary": "GH/IGF-1 physiology supplies a rationale, but not proof of added muscle preservation or longevity from stacking.",
          "context": "Proposed uses beyond the studied indication.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Separate pathways and analogies are not controlled human outcome evidence.",
          "strength": "Imported synthesis",
          "refs": [
            "tvideo",
            "stackvideo",
            "guide"
          ]
        },
        {
          "id": "tesamorelin-5",
          "tier": "H",
          "title": "EGRIFTA WR quantified human PK and formulation boundary",
          "summary": "After single 1.28 mg WR SC administration in healthy subjects: median Tmax 0.15 h; mean Cmax 3831 pg/mL (CV 40%); mean AUC0-inf 1172 pg·h/mL (CV 48%); mean elimination half-life 11 min. Systemic exposure resembled older EGRIFTA 2 mg SC.",
          "context": "DailyMed EGRIFTA WR label, sections 12.3 and 2.1; WR 11.6 mg/vial versus original EGRIFTA 1 mg/vial.",
          "route": "SC",
          "pk": "quantified",
          "pktext": "WR: Tmax 0.15 h; Cmax 3831 pg/mL; AUC0-inf 1172 pg·h/mL; half-life 11 min. Older 2 mg EGRIFTA formulation: absolute SC bioavailability less than 4%.",
          "protocol": null,
          "ptype": null,
          "limit": "The less-than-4% absolute SC bioavailability measurement belongs ONLY to older 1 mg/vial EGRIFTA, not WR. WR and SV cannot be substituted; oral/intranasal/IM PK not established.",
          "strength": "Official US product labeling; formulation-specific human PK",
          "refs": [
            "wr"
          ]
        },
        {
          "id": "tesamorelin-6",
          "tier": "H",
          "title": "Pivotal HIV-lipodystrophy visceral-fat outcomes at 26 weeks",
          "summary": "Original EGRIFTA 2 mg SC daily: Study 1 VAT mean change -18% versus +2% placebo; Study 2 -14% versus -2% placebo. Mean weight differences versus placebo were small and not statistically significant in the label tables.",
          "context": "DailyMed EGRIFTA WR label section 14, Table 2 and Table 3; original 1 mg/vial formulation; trials NCT00123253 and NCT00435136.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "These results reflect HIV-infected adults with lipodystrophy, not generalized obesity or WR-specific efficacy trials; VAT reduction does not imply substantial total weight loss.",
          "strength": "Official label reporting two placebo-controlled randomized human studies",
          "refs": [
            "wr"
          ]
        },
        {
          "id": "tesamorelin-7",
          "tier": "H",
          "title": "Original EGRIFTA adverse reactions and immunogenicity",
          "summary": "In original-formulation trials, injection-site reactions occurred in 25% versus 14% placebo, and hypersensitivity reactions in 4% of EGRIFTA recipients. Diabetes defined by HbA1c >=6.5% occurred in 5% versus 1% placebo (HR 3.3, 95% CI 1.4–9.6). Anti-tesamorelin IgG was detected in 50% after 26 weeks, 47% after 52 weeks, and in 85% of the subset with hypersensitivity reactions.",
          "context": "DailyMed EGRIFTA WR label sections 5.4–5.6, 6.1, 12.6; safety extrapolated from original EGRIFTA (1 mg/vial). Antibody positivity is not synonymous with clinical allergy.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Percentages are from the older EGRIFTA clinical studies, not direct WR-specific event rates or estimates for research preparations. Antibody testing depends on assay and observation time. The label also warns of elevated IGF-1, edema, glucose intolerance, neoplasm concerns and severe hypersensitivity.",
          "strength": "Official labeling, original-formulation clinical-trial safety and immunogenicity",
          "refs": [
            "wr"
          ]
        },
        {
          "id": "tesamorelin-8",
          "tier": "H",
          "title": "WR indication, non-interchangeability and evidence gaps",
          "summary": "EGRIFTA WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for weight-loss management. WR 11.6 mg/vial and SV 2 mg/vial differ in dose, reconstitution and storage and are not substitutable. Long-term cardiovascular safety is not established.",
          "context": "DailyMed EGRIFTA WR label sections 1, 2.1, 4, 5 and 12.3; dosing context applies to approved product formulations.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No verified human PK or efficacy here for oral/intranasal formulations, nontrial peptide vials, alternate cycles, or personalized allergy prevention; do not extrapolate original EGRIFTA safety rates to WR as independently measured.",
          "strength": "Regulatory label indication and limits",
          "refs": [
            "wr",
            "sv"
          ]
        },
        {
          "id": "tesamorelin-9",
          "tier": "H",
          "title": "Tesamorelin liver-fat outcome in HIV-associated fatty liver",
          "summary": "In a 12-month randomized study of people with HIV and fatty liver disease, tesamorelin reduced hepatic fat by approximately 37% relative to baseline.",
          "context": "NCT02196831; 61 enrolled; randomized placebo-controlled trial; original studied formulation and HIV-specific population.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Do not generalize to all MASLD populations or current tesamorelin formulations; no general fatty-liver indication is established by this trial.",
          "strength": "Population-specific human trial; original citation already in Atlas",
          "refs": [
            "tliver"
          ]
        },
        {
          "id": "tesamorelin-audit-fat",
          "tier": "H",
          "title": "Corrected pivotal trial numbers",
          "summary": "The 2007 trial randomized 412 adults with HIV and abdominal fat accumulation to original-formulation tesamorelin 2 mg SC daily or placebo for 26 weeks. VAT changed −15.2% versus +5.0%, a 20.2-percentage-point difference.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No established general treatment protocol; retain the population, molecule and route limitations.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "tvis"
          ]
        },
        {
          "id": "tesamorelin-audit-liver",
          "tier": "H",
          "title": "HIV fatty liver trial details",
          "summary": "The 2019 study enrolled 61 participants; 30 per arm received treatment. Tesamorelin 2 mg daily for 12 months produced a liver-fat treatment effect of −4.1 percentage points (approximately −37% relative). Fibrosis progression was 2/19 versus 9/24 evaluable participants.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Small HIV/NAFLD trial; fibrosis progression is a secondary histology result, not proof of fibrosis reversal or non-HIV efficacy.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "tliver"
          ]
        },
        {
          "id": "tesamorelin-audit-cognition",
          "tier": "H",
          "title": "Preliminary executive function signal",
          "summary": "A 2012 trial enrolled 152 adults aged 55–87, including 66 with mild cognitive impairment; 137 completed. Tesamorelin 1 mg SC daily for 20 weeks produced an executive-function signal.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Not established general focus enhancement, dementia prevention or benefit in younger healthy adults.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "tbrain"
          ]
        },
        {
          "id": "tesamorelin-audit-cycling",
          "tier": "T",
          "title": "Cycling and GLP 1 combinations remain unvalidated",
          "summary": "Hexarelin’s reduced GH response during 16-week treatment cannot establish cycling requirements for tesamorelin, CJC or ipamorelin. The article supplies no controlled evidence that its proposed GH-peptide combinations preserve skeletal muscle during GLP-1 treatment.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No validated cycle or GLP-1 muscle-preservation regimen. Current label formulations have distinct daily doses; original trial doses are not interchangeable. IGF-1 elevation alone does not prove benefit or diagnose GH deficiency. Preserve label glucose, IGF-1, fluid-retention, malignancy and hypersensitivity precautions; endogenous GH release is not a safety guarantee.",
          "strength": "Audit qualification",
          "refs": [
            "hex-cycle",
            "gh-report-20261015"
          ]
        },
        {
          "id": "tesamorelin-protocol-label-wr",
          "tier": "H",
          "title": "EGRIFTA WR label",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Adults with HIV-associated excess abdominal fat / lipodystrophy · EGRIFTA WR",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1.28 mg; Frequency: Once daily; Route: SC; Species: Human; Population: Adults with HIV-associated excess abdominal fat / lipodystrophy; Formulation: EGRIFTA WR",
          "ptype": "label",
          "limit": "Formulation-specific label regimen. WR, SV, original EGRIFTA and research-vial products are not interchangeable.",
          "strength": "Label regimen · imported source",
          "refs": [
            "wr",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1.28 mg",
            "frequency": "Once daily",
            "route": "SC",
            "species": "Human",
            "population": "Adults with HIV-associated excess abdominal fat / lipodystrophy",
            "formulation": "EGRIFTA WR"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5,
              20,
              21
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-label-sv",
          "tier": "H",
          "title": "EGRIFTA SV label",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Adults with HIV-associated excess abdominal fat / lipodystrophy · EGRIFTA SV",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1.4 mg; Frequency: Once daily; Route: SC; Species: Human; Population: Adults with HIV-associated excess abdominal fat / lipodystrophy; Formulation: EGRIFTA SV",
          "ptype": "label",
          "limit": "Formulation-specific label regimen. WR, SV, original EGRIFTA and research-vial products are not interchangeable.",
          "strength": "Label regimen · imported source",
          "refs": [
            "sv",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1.4 mg",
            "frequency": "Once daily",
            "route": "SC",
            "species": "Human",
            "population": "Adults with HIV-associated excess abdominal fat / lipodystrophy",
            "formulation": "EGRIFTA SV"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5,
              20,
              21
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-pivotal",
          "tier": "H",
          "title": "Original-formulation visceral-fat trial",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · 412 adults with HIV-associated abdominal fat accumulation · Original formulation",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg; Frequency: Once daily; Duration: 26 weeks; Timing: Between 6 a.m. and noon; Route: SC; Species: Human; Population: 412 adults with HIV-associated abdominal fat accumulation; Formulation: Original formulation",
          "ptype": "studied",
          "limit": "Morning trial dosing does not establish bedtime superiority. This is not general weight-loss dosing.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tvis",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2 mg",
            "frequency": "Once daily",
            "duration": "26 weeks",
            "timing": "Between 6 a.m. and noon",
            "route": "SC",
            "species": "Human",
            "population": "412 adults with HIV-associated abdominal fat accumulation",
            "formulation": "Original formulation"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-liver",
          "tier": "H",
          "title": "HIV-associated fatty-liver trial duration",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · People with HIV and fatty liver · Original formulation",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 12 months; Route: Not documented; Species: Human; Population: People with HIV and fatty liver; Formulation: Original formulation",
          "ptype": "studied",
          "limit": "This saved review passage records duration and outcomes but not the administered amount, frequency or route. Do not infer them from another trial.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tliver",
            "guide"
          ],
          "protocolDetails": {
            "duration": "12 months",
            "route": "Not documented",
            "species": "Human",
            "population": "People with HIV and fatty liver",
            "formulation": "Original formulation"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-cognition",
          "tier": "H",
          "title": "Older-adult cognition trial",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · 152 adults aged 55–87, including mild cognitive impairment",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1 mg; Frequency: Once daily; Duration: 20 weeks; Timing: 30 minutes before bedtime; Route: SC; Species: Human; Population: 152 adults aged 55–87, including mild cognitive impairment",
          "ptype": "studied",
          "limit": "Preliminary executive-function finding; does not establish dementia prevention or general nootropic efficacy.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tbrain",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1 mg",
            "frequency": "Once daily",
            "duration": "20 weeks",
            "timing": "30 minutes before bedtime",
            "route": "SC",
            "species": "Human",
            "population": "152 adults aged 55–87, including mild cognitive impairment"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-women",
          "tier": "A",
          "title": "Williams dose suggestion: 0.5 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Some smaller women",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.5 mg; Frequency: Daily, as described by the speaker; Route: Not documented; Population: Some smaller women",
          "ptype": "anecdotal",
          "limit": "Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "0.5 mg",
            "frequency": "Daily, as described by the speaker",
            "route": "Not documented",
            "population": "Some smaller women"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-optimization",
          "tier": "A",
          "title": "Williams dose suggestion: 1 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "General optimization, as described by the speaker",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1 mg; Route: Not documented; Population: General optimization, as described by the speaker",
          "ptype": "anecdotal",
          "limit": "Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1 mg",
            "route": "Not documented",
            "population": "General optimization, as described by the speaker"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-athletic",
          "tier": "A",
          "title": "Williams dose suggestion: 1–1.5 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Athletic goals, as described by the speaker",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1–1.5 mg; Route: Not documented; Population: Athletic goals, as described by the speaker",
          "ptype": "anecdotal",
          "limit": "Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1–1.5 mg",
            "route": "Not documented",
            "population": "Athletic goals, as described by the speaker"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-visceral",
          "tier": "A",
          "title": "Williams dose suggestion: 2 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Greater visceral-fat goals, as described by the speaker",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg; Route: Not documented; Population: Greater visceral-fat goals, as described by the speaker",
          "ptype": "anecdotal",
          "limit": "Coaching suggestion, not a validated indication-specific regimen. Frequency for each dose category is not independently stated in the saved passage; do not automatically combine with another proposed cycle.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2 mg",
            "route": "Not documented",
            "population": "Greater visceral-fat goals, as described by the speaker"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-timing",
          "tier": "A",
          "title": "Williams timing and split-dose options",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Timing: Bedtime, one to two hours after food; morning if sleep is disturbed; sometimes divides the daily amount; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "No split ratio is provided. Fasting, bedtime and divided administration are not established as clinically superior.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "timing": "Bedtime, one to two hours after food; morning if sleep is disturbed; sometimes divides the daily amount",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-week",
          "tier": "A",
          "title": "Williams weekly cycling pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Five days on / two days off; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "No receptor-reset requirement or equivalent efficacy versus daily labeling has been demonstrated.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "frequency": "Five days on / two days off",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-cycle-8",
          "tier": "A",
          "title": "Williams cycle: 8 weeks on",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 8 weeks on / 4 weeks off; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "8 weeks on / 4 weeks off",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-cycle-12",
          "tier": "A",
          "title": "Williams cycle: 12 weeks on",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 12 weeks on / 4 weeks off; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "12 weeks on / 4 weeks off",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-cycle-16-24",
          "tier": "A",
          "title": "Williams cycle: 16–24 weeks on",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 16–24 weeks on / 8–12 weeks off; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Proposed coaching cycle; dose, route and per-week frequency are not supplied for this specific cycle. Do not automatically assemble separate suggestions into one regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "16–24 weeks on / 8–12 weeks off",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-long",
          "tier": "A",
          "title": "Williams longer liver-fat courses",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: Longer liver-fat courses followed by breaks; exact course and break durations not specified; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Not an established requirement, and not a substitute for the trial’s actual methods.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "Longer liver-fat courses followed by breaks; exact course and break durations not specified",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              19
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-williams-combo",
          "tier": "A",
          "title": "Williams tesamorelin / ipamorelin combination",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Proposed combination; product formulation unspecified",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Approximately 600 mcg tesamorelin + 200 mcg ipamorelin; Route: Not documented; Formulation: Proposed combination; product formulation unspecified",
          "ptype": "anecdotal",
          "limit": "Dose attribution only. Frequency, route and duration are not supplied for this combination passage. Equivalence to HGH, muscle superiority and safety are unproven.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "Approximately 600 mcg tesamorelin + 200 mcg ipamorelin",
            "route": "Not documented",
            "formulation": "Proposed combination; product formulation unspecified"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              20
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-jones-combo",
          "tier": "A",
          "title": "Jones addition after retatrutide",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.5–1 mg; Frequency: Five days on / two days off; Timing: Before bed, away from meals; Route: Not documented; Sequence: After at least two to four weeks or longer on retatrutide",
          "ptype": "anecdotal",
          "limit": "Clinic proposal, not a controlled combination regimen. Route is not explicitly specified in the saved protocol passage.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "stackvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "0.5–1 mg",
            "frequency": "Five days on / two days off",
            "timing": "Before bed, away from meals",
            "route": "Not documented",
            "sequence": "After at least two to four weeks or longer on retatrutide"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              14
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-fatloss-phase",
          "tier": "A",
          "title": "Jones later GH-axis phase / substitution",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns",
          "ptype": "anecdotal",
          "limit": "No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-im-claim",
          "tier": "A",
          "title": "Unsupported IM route-switch suggestion",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "IM",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: IM; Sequence: Speaker suggests changing to IM in response to welts or hives; no dose, schedule or clinical validation supplied",
          "ptype": "anecdotal",
          "limit": "Unsupported route suggestion, not an instruction. Changing route does not remove systemic allergy risk; the saved label review directs discontinuation for hypersensitivity and clinical assessment.",
          "strength": "Unsupported creator proposal · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "IM",
            "sequence": "Speaker suggests changing to IM in response to welts or hives; no dose, schedule or clinical validation supplied"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              20
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-preparation",
          "tier": "T",
          "title": "Proposed mitochondrial preparation period",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: Four months of mitochondrial preparation mentioned as a proposed prerequisite",
          "ptype": "theoretical",
          "limit": "The saved review states that this is not a demonstrated prerequisite. Specific agents, dose, route and frequency for the preparation period are not defined.",
          "strength": "Theoretical prerequisite claim · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "Four months of mitochondrial preparation mentioned as a proposed prerequisite"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              20
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-mars-tesamorelin",
          "tier": "A",
          "title": "Tesamorelin community schedule",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg; Frequency: 5 days on and 2 days off; Duration: 10–12 weeks, then 4–6 weeks off; Timing: Bedtime or fasted morning; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2 mg",
            "frequency": "5 days on and 2 days off",
            "duration": "10–12 weeks, then 4–6 weeks off",
            "timing": "Bedtime or fasted morning",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tesamorelin-protocol-mars-rotation",
          "tier": "A",
          "title": "Author rotation of GHRH peptides",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 12 weeks tesamorelin, 4 weeks off, then 12 weeks CJC no DAC plus ipamorelin; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "duration": "12 weeks tesamorelin, 4 weeks off, then 12 weeks CJC no DAC plus ipamorelin",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "approved-de5ea69b02ec",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "Visible effects usually emerge at weeks 3–8",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Clinical trial outcomes do not validate universal individualized timeline",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-de5ea69b02ec",
            "linked-de5ea69b02ec"
          ]
        },
        {
          "id": "tesamorelin-casey-safety",
          "tier": "H",
          "title": "Fluid retention and IGF-1 monitoring: label-supported findings",
          "summary": "Tesamorelin-induced GH secretion can cause edema, arthralgia and carpal tunnel symptoms. Labeling advises IGF-1 and glucose monitoring; consider discontinuation for persistent IGF-1 elevations, for example >3 age-adjusted SDS, particularly without a robust efficacy response.",
          "context": "Approved EGRIFTA WR label sections 4 and 5; safety observations derive from the original-formulation studies. The video discusses these effects at 0:51–1:22, 1:37–3:24 and 6:10–6:43.",
          "route": "SC approved product",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Active malignancy is contraindicated; prolonged IGF-1 elevation has unknown effects. Glucose intolerance/diabetes and hypersensitivity remain risks. The label does not establish edema resolution at weeks 3–4 or validate a 500 mcg titration scheme. Persistent or progressive symptoms must not be presumed an adjustment period.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "tesa-label-review-20261025"
          ]
        },
        {
          "id": "tesamorelin-casey-withdrawal",
          "tier": "H",
          "title": "Visceral fat benefit can be lost after withdrawal",
          "summary": "In a randomized trial of 404 adults with HIV and central fat accumulation, original-formulation tesamorelin was studied for six months, followed by rerandomization to continuation or placebo for six months. VAT reduction reached approximately 18% at 12 months among continuing patients; initial VAT improvements were rapidly lost after switching to placebo.",
          "context": "Falutz et al. 2010 abstract; original EGRIFTA 2 mg SC daily. Video claim at 8:57–9:34 is supported within this population.",
          "route": "SC in trial",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "HIV-associated abdominal fat accumulation; abstract-only trial review. This does not quantify regain for an individual or validate 12–16-week courses and 30-day breaks. Current approved formulations have different labeled doses.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "tesa-withdrawal-2010",
            "tesa-label-review-20261025"
          ]
        },
        {
          "id": "tesamorelin-casey-muscle",
          "tier": "H",
          "title": "Muscle imaging changes do not establish improved performance",
          "summary": "An exploratory secondary analysis found improvements in selected trunk-muscle CT density and area after 26 weeks. It compared 193 tesamorelin responders with 148 placebo participants with available scans; active participants were selected for at least 8% VAT reduction.",
          "context": "Adults with HIV and abdominal adiposity from two prior trials. DOI 10.14283/jfa.2018.45; full text reviewed. Video 7:26–7:41 generalizes to lean muscle preservation or building.",
          "route": "SC in parent studies",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Responder-selected secondary analysis rather than an unselected randomized comparison. Muscle imaging does not establish strength, function, athletic hypertrophy, or muscle preservation during tirzepatide/retatrutide treatment.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "tesa-muscle-2019"
          ]
        },
        {
          "id": "tesamorelin-casey-sleep-timing",
          "tier": "H",
          "title": "Deep-sleep GH physiology does not prove bedtime superiority",
          "summary": "The major sleep-related GH peak is associated principally with deep, slow-wave sleep, not REM as asserted at 9:41–9:48. A classic physiology study sampled eight young adults over 38 nights; this was not a tesamorelin dosing study. EGRIFTA labeling specifies daily administration without a mandatory bedtime or fasting interval.",
          "context": "General human GH physiology plus selected label administration instructions. Video 9:41–11:02 extrapolates to bedtime, fasting and sleep benefits.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No comparative tesamorelin evidence reviewed establishes bedtime superiority, required 2–3-hour meal separation, better sleep, or extra visceral-fat loss from that window. Human physiology is not clinical validation of a timing protocol.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "gh-sleep-takahashi-1968",
            "tesa-label-review-20261025"
          ]
        },
        {
          "id": "tesamorelin-casey-creator-practice",
          "tier": "A",
          "title": "Casey: attributed low-dose, ratio and cycling observations",
          "summary": "The creator describes starting around 500 mcg tesamorelin for several weeks; approximately 1 mg tesamorelin with 300 mcg ipamorelin, or 200–300 mcg ipamorelin alongside higher tesamorelin; five-on/two-off or six-on/one-off schedules; and 12–16-week courses followed by 30 days off.",
          "context": "Source observations at 2:25–4:26 and 4:34–6:10. No tested population, standardized formulation or validated administration route supplied for these examples. Creator acknowledges these are not FDA schedules.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Anecdotal source record only, not a treatment recommendation or evidence of safe ratios, equivalent efficacy, reduced adverse effects, desensitization prevention or receptor resetting. No steroid-style post-cycle therapy is specified in labeling, but this does not validate arbitrary stop/start cycles.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "tesa-video-casey-20260920"
          ]
        },
        {
          "id": "tesamorelin-casey-stacks",
          "tier": "T",
          "title": "Proposed combinations: different pathways do not establish additive benefit",
          "summary": "At 6:43–8:21 the creator proposes tesamorelin alongside tirzepatide or retatrutide, and discusses MOTS-c/NAD+ or BPC-157/TB-500. These are proposed complementary mechanisms and personal/clinic observations, not controlled combination outcomes.",
          "context": "Video transcript reviewed. Targeted searches did not identify controlled human evidence validating the proposed combinations or tesamorelin/ipamorelin ratios; this is a bounded search, not proof no study exists.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Monotherapy outcomes, GH/IGF-1 biology and distinct targets cannot establish combination efficacy, interactions, muscle preservation or faster recovery. TB-500 product identity must not be conflated with full-length thymosin beta-4. No verified stack regimen is added.",
          "strength": "Claim-specific review completed 25 October 2026; source scope preserved",
          "refs": [
            "tesa-video-casey-20260920",
            "tesa-muscle-2019"
          ]
        }
      ]
    },
    {
      "id": "ipamorelin",
      "name": "Ipamorelin",
      "pathway": "GH / IGF-1",
      "target": "Ghrelin / GHS-R agonism → GH pulse",
      "aliases": "IPA",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "ipamorelin-audit-pk",
          "tier": "H",
          "title": "Human IV PK does not establish SC exposure",
          "summary": "Five 15-minute IV infusion levels, eight healthy male volunteers per level: terminal half-life approximately 2 hours and GH peak around 0.67 hours.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "IV",
          "pk": "studied",
          "pktext": "Approximately 2-hour terminal half-life after IV infusion. SC and oral bioavailability not established by this study.",
          "protocol": null,
          "ptype": null,
          "limit": "No established general treatment protocol; retain the population, molecule and route limitations.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "ipa-pk"
          ]
        },
        {
          "id": "ipamorelin-protocol-williams-combo",
          "tier": "A",
          "title": "Williams tesamorelin / ipamorelin combination",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Proposed combination; product formulation unspecified",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Approximately 600 mcg tesamorelin + 200 mcg ipamorelin; Route: Not documented; Formulation: Proposed combination; product formulation unspecified",
          "ptype": "anecdotal",
          "limit": "Dose attribution only. Frequency, route and duration are not supplied for this combination passage. Equivalence to HGH, muscle superiority and safety are unproven.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "tvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "Approximately 600 mcg tesamorelin + 200 mcg ipamorelin",
            "route": "Not documented",
            "formulation": "Proposed combination; product formulation unspecified"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              20
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ipamorelin-protocol-clinic-combo",
          "tier": "A",
          "title": "CJC no-DAC / ipamorelin clinic-style example",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "CJC no-DAC / Mod GRF(1-29) with ipamorelin",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin; Frequency: Optional five days on / two days off; Timing: Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use; Route: SC; Formulation: CJC no-DAC / Mod GRF(1-29) with ipamorelin",
          "ptype": "anecdotal",
          "limit": "Retained from the field-guide synthesis; original clinic/source identifier is not supplied. Not a validated clinical combination protocol.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "amount": "Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin",
            "frequency": "Optional five days on / two days off",
            "timing": "Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use",
            "route": "SC",
            "formulation": "CJC no-DAC / Mod GRF(1-29) with ipamorelin"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ipamorelin-protocol-fatloss-phase",
          "tier": "A",
          "title": "Jones later GH-axis phase / substitution",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns",
          "ptype": "anecdotal",
          "limit": "No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "cjc-no-dac",
      "name": "CJC-1295 no-DAC",
      "pathway": "GH / IGF-1",
      "target": "Short-acting GHRH receptor agonism",
      "aliases": "Mod GRF 1-29 CJC1295 cjc-1295-no-dac Cjc 1295 No Dac",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "cjc-1295-no-dac"
      ],
      "aliasNames": [
        "Cjc 1295 No Dac"
      ],
      "records": [
        {
          "id": "cjc-no-dac-1",
          "tier": "A",
          "title": "Clinic-style combination proposal",
          "summary": "Guide retains a fasted / bedtime CJC no-DAC plus ipamorelin proposal.",
          "context": "Attributed clinic-style example.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No validated combination outcome protocol. Long-acting CJC-1295 studies do not establish no-DAC PK.",
          "strength": "Anecdotal protocol",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "cjc-no-dac-2",
          "tier": "U",
          "title": "Formulation evidence boundary",
          "summary": "The cited human CJC-1295 study concerned the long-acting compound.",
          "context": "No-DAC / Mod GRF and DAC are not interchangeable.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Do not apply the long-acting study half-life to no-DAC products.",
          "strength": "Imported synthesis",
          "refs": [
            "cjc-dac",
            "guide"
          ]
        },
        {
          "id": "cjc-no-dac-audit-boundary",
          "tier": "U",
          "title": "No DAC timing and clinical evidence gaps",
          "summary": "The article’s approximately 30-minute duration and single bedtime pulse must not be presented as verified human SC PK. Long-acting CJC studies cannot establish the proposed blend’s sleep, recovery or body-composition outcomes. The author’s wearable-estimated deep-sleep increase is an individual anecdote; native IV GHRH sleep studies do not validate predictable sleep improvements with this SC blend. Exact food separation and bedtime superiority remain unvalidated.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No established general treatment protocol; retain the population, molecule and route limitations.",
          "strength": "Audit qualification",
          "refs": [
            "gh-report-20261015",
            "cjc-dac"
          ]
        },
        {
          "id": "cjc-no-dac-protocol-clinic-combo",
          "tier": "A",
          "title": "CJC no-DAC / ipamorelin clinic-style example",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "CJC no-DAC / Mod GRF(1-29) with ipamorelin",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin; Frequency: Optional five days on / two days off; Timing: Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use; Route: SC; Formulation: CJC no-DAC / Mod GRF(1-29) with ipamorelin",
          "ptype": "anecdotal",
          "limit": "Retained from the field-guide synthesis; original clinic/source identifier is not supplied. Not a validated clinical combination protocol.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "amount": "Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin",
            "frequency": "Optional five days on / two days off",
            "timing": "Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use",
            "route": "SC",
            "formulation": "CJC no-DAC / Mod GRF(1-29) with ipamorelin"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "cjc-no-dac-protocol-fatloss-phase",
          "tier": "A",
          "title": "Jones later GH-axis phase / substitution",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns",
          "ptype": "anecdotal",
          "limit": "No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              5,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "cjc-no-dac-protocol-mars-cjc-ipa",
          "tier": "A",
          "title": "CJC no DAC plus ipamorelin",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 250 mcg each; Frequency: 5 days on and 2 days off; Duration: 10–12 weeks, then 4–6 weeks off; Timing: Bedtime or fasted morning; Route: SC",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "250 mcg each",
            "frequency": "5 days on and 2 days off",
            "duration": "10–12 weeks, then 4–6 weeks off",
            "timing": "Bedtime or fasted morning",
            "route": "SC"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "mots-c",
      "name": "MOTS-c",
      "pathway": "Mitochondrial / energy",
      "target": "Mitochondrial-derived stress signaling; AMPK-related biology",
      "aliases": "MOTSC",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "mots-c-1",
          "tier": "P",
          "title": "Mouse performance and metabolic research",
          "summary": "Mouse studies used daily and later intermittent dosing; they did not prove weekly dosing superior.",
          "context": "Exogenous native peptide in mice; human exercise measurements concern endogenous peptide.",
          "route": "Not documented",
          "pk": "preclinical",
          "pktext": "Human injected-native-peptide PK and terminal half-life remain unestablished in the review.",
          "protocol": null,
          "ptype": null,
          "limit": "Animal mg/kg schedules are not human dose conversions. CB4211 is a modified analog, not native MOTS-c.",
          "strength": "Animal experiments; imported",
          "refs": [
            "m2021",
            "m2015",
            "mots-review"
          ]
        },
        {
          "id": "mots-c-2",
          "tier": "A",
          "title": "Intermittent creator protocol",
          "summary": "The MOTS-c deep dive attributes intermittent use to Dr. Jones, based partly on transcript-index sources.",
          "context": "Creator / clinic practice; indirect transcript sourcing.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No native-MOTS-c human dose-ranging or frequency comparison validates either schedule.",
          "strength": "Attributed creator practice",
          "refs": [
            "mjones",
            "mots-review"
          ]
        },
        {
          "id": "mots-c-3",
          "tier": "T",
          "title": "SS-31 sequencing rationale",
          "summary": "Repair → optimize → fuel is a proposed heuristic, not a demonstrated requirement.",
          "context": "Mechanistic explanation and subjective reports.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No controlled sequencing study was identified in these reviews.",
          "strength": "Imported synthesis",
          "refs": [
            "ssvideo",
            "mots-review",
            "guide"
          ]
        },
        {
          "id": "mots-c-4",
          "tier": "P",
          "title": "Experimental NASH: MOTS-c and BCL-2 signaling",
          "summary": "An experimental study reports MOTS-c interaction with BCL-2 and changes in NASH-associated liver injury, inflammatory and fibrosis markers.",
          "context": "Nonclinical NASH disease models and mechanistic experiments; study does not establish therapeutic efficacy of administered MOTS-c in humans.",
          "route": "Not documented",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Do not translate experimental outcomes, dosing or mechanistic AMPK associations into a clinical MASLD protocol.",
          "strength": "Preclinical experimental report; private evidence review",
          "refs": [
            "mots-nash-bcl2"
          ]
        },
        {
          "id": "mots-c-protocol-mouse-daily-5",
          "tier": "P",
          "title": "Mouse daily regimen: 5 mg/kg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mouse · Younger / middle-aged mice",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 5 mg/kg; Frequency: Daily; Route: Not documented; Species: Mouse; Population: Younger / middle-aged mice",
          "ptype": "preclinical",
          "limit": "The imported review does not provide route or phase-specific duration. This is not a human dose conversion.",
          "strength": "Study regimen · imported source",
          "refs": [
            "m2021",
            "mots-review"
          ],
          "protocolDetails": {
            "amount": "5 mg/kg",
            "frequency": "Daily",
            "route": "Not documented",
            "species": "Mouse",
            "population": "Younger / middle-aged mice"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-mouse-daily-15",
          "tier": "P",
          "title": "Mouse daily regimen: 15 mg/kg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mouse · Younger / middle-aged mice",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 15 mg/kg; Frequency: Daily; Route: Not documented; Species: Mouse; Population: Younger / middle-aged mice",
          "ptype": "preclinical",
          "limit": "The imported review does not provide route or phase-specific duration. This is not a human dose conversion.",
          "strength": "Study regimen · imported source",
          "refs": [
            "m2021",
            "mots-review"
          ],
          "protocolDetails": {
            "amount": "15 mg/kg",
            "frequency": "Daily",
            "route": "Not documented",
            "species": "Mouse",
            "population": "Younger / middle-aged mice"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-mouse-intermittent",
          "tier": "P",
          "title": "Old-mouse daily-to-intermittent phase",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mouse · Old mice",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Daily initially; three times weekly after eight weeks; Route: Not documented; Species: Mouse; Population: Old mice",
          "ptype": "preclinical",
          "limit": "Amount, route and total duration for this specific phase are not supplied in the review. It was not a randomized frequency comparison.",
          "strength": "Study regimen · imported source",
          "refs": [
            "m2021",
            "mots-review"
          ],
          "protocolDetails": {
            "frequency": "Daily initially; three times weekly after eight weeks",
            "route": "Not documented",
            "species": "Mouse",
            "population": "Old mice"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-jones-weekly",
          "tier": "A",
          "title": "Jones intermittent option: 10 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed creator / clinic practice",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10 mg; Frequency: Once weekly; Route: Not documented; Population: Attributed creator / clinic practice",
          "ptype": "anecdotal",
          "limit": "Indirect transcript-index attribution. No native-MOTS-c human PK or dose-ranging trial validates this schedule; route and cycle length are not given.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mjones",
            "mots-review"
          ],
          "protocolDetails": {
            "amount": "10 mg",
            "frequency": "Once weekly",
            "route": "Not documented",
            "population": "Attributed creator / clinic practice"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              1,
              2,
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-jones-twice",
          "tier": "A",
          "title": "Jones intermittent option: 5 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed creator / clinic practice",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 5 mg; Frequency: Twice weekly; Route: Not documented; Population: Attributed creator / clinic practice",
          "ptype": "anecdotal",
          "limit": "Indirect transcript-index attribution. No native-MOTS-c human PK or dose-ranging trial validates this schedule; route and cycle length are not given.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mjones",
            "mots-review"
          ],
          "protocolDetails": {
            "amount": "5 mg",
            "frequency": "Twice weekly",
            "route": "Not documented",
            "population": "Attributed creator / clinic practice"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              1,
              2,
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-jones-priming",
          "tier": "A",
          "title": "Jones short higher-frequency initiation",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Brief higher-frequency “priming,” then return to one or two injections weekly; Duration: Short initiation phase; exact length not supplied; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "The source does not define a priming amount or a fixed initiation frequency. Do not turn the warning about indefinite three-times-weekly use into a validated loading schedule.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mjones",
            "mots-review"
          ],
          "protocolDetails": {
            "frequency": "Brief higher-frequency “priming,” then return to one or two injections weekly",
            "duration": "Short initiation phase; exact length not supplied",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              2,
              3
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-between-ss31",
          "tier": "A",
          "title": "Reported MOTS-c interval between SS-31 courses",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: 30 days; Route: Not documented; Sequence: After a reported six-week SS-31 course and before a reported one-month SS-31 course",
          "ptype": "anecdotal",
          "limit": "Amount, frequency, route and washout periods are not stated. Subjective response does not validate sequence superiority.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "ssvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "30 days",
            "route": "Not documented",
            "sequence": "After a reported six-week SS-31 course and before a reported one-month SS-31 course"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-repair-optimize-fuel",
          "tier": "A",
          "title": "Jones “repair → optimize → fuel” sequence",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: SS-31 → MOTS-c → NAD+",
          "ptype": "anecdotal",
          "limit": "A creator heuristic, not a demonstrated prerequisite or controlled sequence. Amounts, routes, phase lengths and washouts are not supplied.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mseq",
            "mots-review"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "SS-31 → MOTS-c → NAD+"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              2,
              3,
              4
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "mots-c-protocol-mars-mots",
          "tier": "A",
          "title": "MOTS c adjunct proposal",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 5 mg; Frequency: Three times weekly; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "5 mg",
            "frequency": "Three times weekly",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "approved-4929293bb614",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "Improves endurance and VO2max",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Preclinical evidence must not be stated as demonstrated human efficacy",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-4929293bb614"
          ]
        },
        {
          "id": "approved-e063d16d706c",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "NAD+ plus MOTS-c improves cellular wellness",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Promotional claim; combination efficacy not established",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-e063d16d706c"
          ]
        },
        {
          "id": "approved-4ca2e571666c",
          "tier": "U",
          "title": "Unverified creator claim",
          "summary": "Human metabolic effectiveness is not yet established",
          "context": "Owner-approved social research lead; not independently substantiated.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Transcript needed to review exact claims",
          "strength": "Unverified; published by owner request",
          "refs": [
            "social-4ca2e571666c"
          ]
        },
        {
          "id": "jarvis-lead-42952740",
          "tier": "U",
          "title": "MOTS-c nominated in silico as a candidate Ms4a6c modulator in radiation proctitis (2026)",
          "summary": "A 2026 computational study linked Ms4a6c+ macrophages to fibrosis in mouse radiation proctitis and, by virtual screening and molecular dynamics, nominated MOTS-c as the top candidate ligand for Ms4a6c. MOTS-c was not tested experimentally.",
          "context": "Mouse transcriptomics and in silico screening only.",
          "route": "Not applicable",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Computational prediction only; docking score moderate-to-weak; no MOTS-c was administered.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-42952740"
          ]
        }
      ]
    },
    {
      "id": "ss31",
      "name": "SS-31 / Elamipretide",
      "pathway": "Mitochondrial / energy",
      "target": "Cardiolipin / inner mitochondrial membrane",
      "aliases": "FORZINITY MTP-131 Bendavia ss-31 Ss 31",
      "kind": "Peptide",
      "gap": "Human SC PK is quantified for the labeled product. Oral and IM bioavailability are not established in the imported material.",
      "aliasIds": [
        "ss-31"
      ],
      "aliasNames": [
        "Ss 31"
      ],
      "records": [
        {
          "id": "ss31-1",
          "tier": "H",
          "title": "Disease-specific label and SC PK",
          "summary": "FORZINITY has accelerated approval for muscle strength in Barth syndrome; confirmation of clinical benefit remains a condition.",
          "context": "Barth syndrome; labeled product.",
          "route": "SC",
          "pk": "quantified",
          "pktext": "Absolute SC bioavailability ~92%; Tmax 0.5–1 hour.",
          "protocol": null,
          "ptype": null,
          "limit": "This does not validate low-dose wellness cycles. The randomized Barth trial missed its primary walking and fatigue endpoints.",
          "strength": "Human labeling; anchors checked",
          "refs": [
            "forz",
            "guide"
          ]
        },
        {
          "id": "ss31-2",
          "tier": "H",
          "title": "Negative trial endpoint matters",
          "summary": "MMPOWER-3 did not meet its primary walking-distance and fatigue endpoints.",
          "context": "Primary mitochondrial myopathy; human trial.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Results should not be generalized as proven fatigue improvement in healthy users.",
          "strength": "Randomized trial; imported",
          "refs": [
            "mm",
            "guide"
          ]
        },
        {
          "id": "ss31-3",
          "tier": "A",
          "title": "Reported repeat-course response",
          "summary": "A presenter reports a better second SS-31 response after intervening MOTS-c, without objective control.",
          "context": "Video self-report; route and frequency not supplied.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Dose, duration and prior exposure changed. This cannot establish sequence superiority or dose-response.",
          "strength": "Individual anecdote",
          "refs": [
            "ssvideo",
            "guide"
          ]
        },
        {
          "id": "ss31-protocol-repair-optimize-fuel",
          "tier": "A",
          "title": "Jones “repair → optimize → fuel” sequence",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: SS-31 → MOTS-c → NAD+",
          "ptype": "anecdotal",
          "limit": "A creator heuristic, not a demonstrated prerequisite or controlled sequence. Amounts, routes, phase lengths and washouts are not supplied.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mseq",
            "mots-review"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "SS-31 → MOTS-c → NAD+"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              2,
              3,
              4
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ss31-protocol-label",
          "tier": "H",
          "title": "FORZINITY disease-specific label",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Barth syndrome; body weight at least 30 kg · Labeled FORZINITY",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 40 mg; Frequency: Once daily; Route: SC; Species: Human; Population: Barth syndrome; body weight at least 30 kg; Formulation: Labeled FORZINITY",
          "ptype": "label",
          "limit": "Renal impairment can change label dosing. Does not validate wellness cycles or research-vial equivalence.",
          "strength": "Label regimen · imported source",
          "refs": [
            "forz",
            "guide"
          ],
          "protocolDetails": {
            "amount": "40 mg",
            "frequency": "Once daily",
            "route": "SC",
            "species": "Human",
            "population": "Barth syndrome; body weight at least 30 kg",
            "formulation": "Labeled FORZINITY"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ss31-protocol-mmpower",
          "tier": "H",
          "title": "MMPOWER-3 study regimen",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Primary mitochondrial myopathy",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 40 mg; Frequency: Once daily; Duration: 24 weeks; Route: SC; Species: Human; Population: Primary mitochondrial myopathy",
          "ptype": "studied",
          "limit": "The trial did not meet its primary walking-distance and fatigue endpoints.",
          "strength": "Study regimen · imported source",
          "refs": [
            "mm",
            "guide"
          ],
          "protocolDetails": {
            "amount": "40 mg",
            "frequency": "Once daily",
            "duration": "24 weeks",
            "route": "SC",
            "species": "Human",
            "population": "Primary mitochondrial myopathy"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "ss31-protocol-first-course",
          "tier": "A",
          "title": "Video: first SS-31 course",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Started at 5 mg; Duration: Six weeks; Route: Not documented; Sequence: Before 30 days of MOTS-c and the second SS-31 course",
          "ptype": "anecdotal",
          "limit": "Frequency, route and any later dose changes are not stated; the presenter’s result is uncontrolled.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "ssvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "Started at 5 mg",
            "duration": "Six weeks",
            "route": "Not documented",
            "sequence": "Before 30 days of MOTS-c and the second SS-31 course"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ss31-protocol-second-course",
          "tier": "A",
          "title": "Video: second SS-31 course",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 4 mg; Duration: One month; Route: Not documented; Sequence: After the reported 30-day MOTS-c phase",
          "ptype": "anecdotal",
          "limit": "Frequency and route are not stated. Dose and duration changed, preventing a clean dose-response comparison.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "ssvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "4 mg",
            "duration": "One month",
            "route": "Not documented",
            "sequence": "After the reported 30-day MOTS-c phase"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ss31-protocol-low-dose",
          "tier": "A",
          "title": "Video: secondhand low-dose reports",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1–2 mg; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Secondhand anecdote. Frequency, route, duration, population and objective outcomes are not supplied.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "ssvideo",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1–2 mg",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              18
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "approved-12d60d041733",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "SS-31 approved for Barth syndrome in 2025",
          "context": "Owner-published from the Jarvis queue onto SS-31 / Elamipretide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Verified for Forzinity (elamipretide), specific indication and patient eligibility only",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-12d60d041733",
            "linked-12d60d041733"
          ]
        }
      ]
    },
    {
      "id": "aod9604",
      "name": "AOD-9604",
      "pathway": "Metabolic / appetite",
      "target": "Modified hGH fragment; lipolysis research",
      "aliases": "aod-9604 Aod 9604",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "aod-9604"
      ],
      "aliasNames": [
        "Aod 9604"
      ],
      "records": [
        {
          "id": "aod9604-1",
          "tier": "H",
          "title": "Human obesity development was unsuccessful",
          "summary": "FDA review describes a 536-person oral study without significant added weight loss.",
          "context": "24 weeks with formal diet and exercise.",
          "route": "Oral",
          "pk": "studied",
          "pktext": "Oral administration does not supply an absolute bioavailability percentage.",
          "protocol": null,
          "ptype": null,
          "limit": "A failed oral efficacy trial is not evidence that a fasting injection strategy works.",
          "strength": "Regulatory review of human trials",
          "refs": [
            "aodfda",
            "guide"
          ]
        },
        {
          "id": "aod9604-protocol-fasting",
          "tier": "A",
          "title": "Jones fasting-window course",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: Three to four months; Timing: During fasting windows; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Video amount and route are not supplied. Fasting timing has not rescued efficacy in the evidence reviewed.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "duration": "Three to four months",
            "timing": "During fasting windows",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              3,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "aod9604-protocol-oral-study",
          "tier": "H",
          "title": "Oral obesity-study duration",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Adults with obesity; 536 enrolled, 502 randomized; diet-and-exercise program",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.25, 0.5 or 1 mg; Frequency: Once daily; Duration: 24 weeks plus a 4-week run-in; Route: Oral; Species: Human; Population: Adults with obesity; 536 enrolled, 502 randomized; diet-and-exercise program",
          "ptype": "studied",
          "limit": "OPTIONS Phase 2B (company announcement, 21 February 2007): oral AOD-9604 tablets at 0.25, 0.5, or 1 mg once daily versus placebo after a four-week diet-and-exercise run-in, followed by 24 weeks of treatment. No dose demonstrated statistically significant additional weight loss versus placebo at 12 or 24 weeks; the developer discontinued its obesity program. Company disclosure, not a peer-reviewed full trial report. Human pharmacokinetic results were not provided in the announcement. Historical study doses are not treatment recommendations. Oral tablet findings do not establish sublingual-troche absorption, efficacy, or fasting-time benefit.",
          "strength": "Study regimen · imported source",
          "refs": [
            "aodfda",
            "jx-asx-aod-2007",
            "guide"
          ],
          "protocolDetails": {
            "amount": "0.25, 0.5 or 1 mg",
            "frequency": "Once daily",
            "duration": "24 weeks plus a 4-week run-in",
            "route": "Oral",
            "species": "Human",
            "population": "Adults with obesity; 536 enrolled, 502 randomized; diet-and-exercise program"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              3,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked guide source not reopened for this update. Dose, once-daily frequency and the 4-week run-in were taken from the Metabolic Pharmaceuticals ASX announcement read 22 October 2026.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "5amino",
      "name": "5-Amino-1MQ",
      "pathway": "Metabolic / appetite",
      "target": "NNMT inhibition",
      "aliases": "5-amino-1mq 5 Amino 1Mq",
      "kind": "Small molecule",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "5-amino-1mq"
      ],
      "aliasNames": [
        "5 Amino 1Mq"
      ],
      "records": [
        {
          "id": "5amino-1",
          "tier": "P",
          "title": "Preclinical metabolic research",
          "summary": "The guide describes predominantly preclinical adipose and metabolic research.",
          "context": "No primary study identifier supplied for this entry.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Human injectable PK, safety and dose-response are not established.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "5amino-3",
          "tier": "P",
          "title": "NNMT inhibition and adipocyte metabolic findings",
          "summary": "5-amino-1MQ lowered NNMT reaction product 1-MNA in cultured adipocytes; the study also reported altered NAD+ and SAM signaling and reduced lipogenesis with NNMT inhibitors.",
          "context": "Neelakantan et al. 2018; cultured cells and diet-induced obese mice, not established human outcomes.",
          "route": "Cell culture / systemic mouse treatment",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Do not infer human efficacy or a validated therapeutic dose. Exact in-vivo salt, route, mass normalization and study endpoints await full-text audit.",
          "strength": "Primary PubMed abstract and figure captions checked 2026-11-01",
          "refs": [
            "amq2018"
          ]
        },
        {
          "id": "5amino-4",
          "tier": "P",
          "title": "Diet-induced obesity findings in mice",
          "summary": "Treatment with a potent NNMT inhibitor reduced weight, white adipose mass, adipocyte size and total cholesterol in diet-induced obese mice; food intake was not altered in the reported model.",
          "context": "Neelakantan et al. 2018; preclinical high-fat-diet mouse model.",
          "route": "Systemic mouse administration",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No established human weight-loss efficacy; the precise treatment schedule should be recorded only after full methods and molecular identity are reconciled.",
          "strength": "Primary abstract checked 2026-11-01; compound identity and protocol detail need full-text confirmation",
          "refs": [
            "amq2018"
          ]
        },
        {
          "id": "5amino-5",
          "tier": "P",
          "title": "Rat oral bioavailability and elimination half-life",
          "summary": "In a rat pharmacokinetic study, 5-amino-1MQ mean oral bioavailability was 38.4%; terminal half-lives were 3.80 ± 1.10 hours IV and 6.90 ± 1.20 hours oral.",
          "context": "Awosemo et al. 2021; rat IV and oral pharmacokinetics, PMID 34304009.",
          "route": "Oral / IV in rats",
          "pk": "quantified",
          "pktext": "Mean oral bioavailability 38.4% in rats; IV t1/2 3.80 ± 1.10 h and oral t1/2 6.90 ± 1.20 h.",
          "protocol": null,
          "ptype": null,
          "limit": "These rat measurements do not establish human absorption, an oral-to-SC conversion, timing, or any human dose.",
          "strength": "Primary PubMed abstract checked 2026-11-01",
          "refs": [
            "amqpk"
          ]
        },
        {
          "id": "5amino-6",
          "tier": "U",
          "title": "Unverified oral dosing claims circulating online",
          "summary": "Public community and vendor descriptions report oral amounts such as 25 mg twice daily, 50 mg once or twice daily, and 50 mg three times daily; some mention 4–12 week cycles.",
          "context": "Unverified community claim summary from 2026-11-01 sweep; individual source URLs/posts were not preserved for this claim.",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "UNVERIFIED: not a validated or recommended human protocol; no firsthand post/transcript attribution, purity, formulation or safety confirmation. Do not enable as calculator default.",
          "strength": "Unverified synthesis; source-post retrieval pending",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "5amino-7",
          "tier": "U",
          "title": "Unverified injectable dosing claims circulating online",
          "summary": "Community discussions describe 150–500 mcg, 1–2 mg, 2.5–5 mg and occasional 5–15 mg SC amounts with varying frequencies.",
          "context": "Unverified community claim summary from 2026-11-01 sweep; no attributable post URLs preserved.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "UNVERIFIED: salt, concentration and administered units are uncertain; do not use as injectable guidance or calculator preset.",
          "strength": "Unverified synthesis; source-post retrieval pending",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "5amino-8",
          "tier": "U",
          "title": "Unverified anecdotal benefits, reactions and combinations",
          "summary": "Some users claim energy, endurance or fat-loss changes; others report no effect or gastrointestinal symptoms, dizziness, insomnia, palpitations, fatigue or local reactions. Online stacks mention retatrutide, MOTS-c and NAD+.",
          "context": "Anecdotal and confounded online reports; platform-wide scrape and individual-post verification not completed.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "UNVERIFIED: no causality, prevalence, interaction safety or combination efficacy established; no human safety profile or validated protocol.",
          "strength": "Unverified secondhand summary; original social posts require retrieval",
          "refs": [
            "guide"
          ]
        }
      ]
    },
    {
      "id": "slu332",
      "name": "SLU-PP-332",
      "pathway": "Metabolic / appetite",
      "target": "ERR agonism / oxidative metabolism",
      "aliases": "",
      "kind": "Small molecule",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "slu332-1",
          "tier": "P",
          "title": "Exercise-mimetic mouse research",
          "summary": "Preclinical experiments support ERR activation and exercise-like metabolic effects.",
          "context": "Mouse studies; no validated human therapeutic regimen.",
          "route": "Oral",
          "pk": "preclinical",
          "pktext": "Researchers describe a lack of oral bioavailability for SLU-PP-332 in preclinical development.",
          "protocol": null,
          "ptype": null,
          "limit": "No human absorption percentage. Distinct SLU-PP-915 is not interchangeable.",
          "strength": "Preclinical primary citations; imported",
          "refs": [
            "slu",
            "slu915",
            "guide"
          ]
        },
        {
          "id": "slu332-protocol-reset",
          "tier": "A",
          "title": "Jones proposed temporary metabolic-reset phase",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: SLU-PP-332 before O304 when calorie intake increases; overlap allowed when no reset is needed",
          "ptype": "anecdotal",
          "limit": "No amount, route, duration or objective reset criterion is supplied. A lasting human metabolic reset is not established.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "SLU-PP-332 before O304 when calorie intake increases; overlap allowed when no reset is needed"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              3,
              4,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "o304",
      "name": "O304 / ATX-304 research",
      "pathway": "Metabolic / appetite",
      "target": "Pan-AMPK activation",
      "aliases": "ATX304 O-304",
      "kind": "Small molecule",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "o304-1",
          "tier": "H",
          "title": "Short oral TELLUS study",
          "summary": "Human oral administration and exposure are documented for the studied O304 formulation.",
          "context": "65 adults with type 2 diabetes taking metformin.",
          "route": "Oral",
          "pk": "studied",
          "pktext": "Absolute human bioavailability percentage is not established here.",
          "protocol": null,
          "ptype": null,
          "limit": "No retail-capsule equivalence, long-term safety, or SLU sequencing benefit is established.",
          "strength": "Small human trial; imported",
          "refs": [
            "ampk",
            "guide"
          ]
        },
        {
          "id": "o304-2",
          "tier": "U",
          "title": "Identity and newer-development limits",
          "summary": "Verify exact identity and formulation before assigning O304 findings to an ATX-304 product.",
          "context": "A 2026 phase 1b abstract was noted but full results were inaccessible.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "The older trial is not the whole development record; unknown is not zero exposure.",
          "strength": "Imported synthesis",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "o304-protocol-tellus",
          "tier": "H",
          "title": "TELLUS study regimen",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · 65 adults with type 2 diabetes on metformin · O304 oral suspension",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1,000 mg; Frequency: Daily; Duration: 28 days; Route: Oral; Species: Human; Population: 65 adults with type 2 diabetes on metformin; Formulation: O304 oral suspension",
          "ptype": "studied",
          "limit": "Do not infer retail ATX-304 capsule equivalence, long-term safety or benefit after SLU-PP-332.",
          "strength": "Study regimen · imported source",
          "refs": [
            "ampk",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1,000 mg",
            "frequency": "Daily",
            "duration": "28 days",
            "route": "Oral",
            "species": "Human",
            "population": "65 adults with type 2 diabetes on metformin",
            "formulation": "O304 oral suspension"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              4,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "o304-protocol-after-slu",
          "tier": "A",
          "title": "Jones O304 introduction / overlap option",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Oral; Sequence: After a proposed SLU-PP-332 reset and increased calorie intake; overlap also permitted by speaker",
          "ptype": "anecdotal",
          "limit": "No dose, frequency, duration or phase interval is given. TELLUS dosing does not supply the video’s missing protocol.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "seqvideo",
            "guide"
          ],
          "protocolDetails": {
            "route": "Oral",
            "sequence": "After a proposed SLU-PP-332 reset and increased calorie intake; overlap also permitted by speaker"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              4,
              22
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "nad",
      "name": "NAD+",
      "pathway": "Mitochondrial / energy",
      "target": "Redox cofactor / sirtuin-PARP biology",
      "aliases": "nad+ Nad+",
      "kind": "Cofactor",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "nad+"
      ],
      "aliasNames": [
        "Nad+"
      ],
      "records": [
        {
          "id": "nad-protocol-repair-optimize-fuel",
          "tier": "A",
          "title": "Jones “repair → optimize → fuel” sequence",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: SS-31 → MOTS-c → NAD+",
          "ptype": "anecdotal",
          "limit": "A creator heuristic, not a demonstrated prerequisite or controlled sequence. Amounts, routes, phase lengths and washouts are not supplied.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "mseq",
            "mots-review"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "SS-31 → MOTS-c → NAD+"
          },
          "sourceLocator": {
            "document": "mots-review",
            "pages": [
              2,
              3,
              4
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "urolithin",
      "name": "Urolithin A",
      "pathway": "Mitochondrial / energy",
      "target": "Mitophagy / mitochondrial quality control",
      "aliases": "",
      "kind": "Metabolite",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "urolithin-1",
          "tier": "H",
          "title": "Human supplement literature reported",
          "summary": "The guide reports human oral supplement data.",
          "context": "Specific trial and primary identifier are not provided in this entry.",
          "route": "Oral",
          "pk": "studied",
          "pktext": "Absolute bioavailability and formulation comparison are not established in this entry.",
          "protocol": null,
          "ptype": null,
          "limit": "This summary is not a primary-source efficacy or PK audit.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "urolithin-protocol-oral-daily",
          "tier": "H",
          "title": "Oral daily pattern in supplement literature",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Human supplement trials described in the field guide",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Daily; Route: Oral; Species: Human; Population: Human supplement trials described in the field guide",
          "ptype": "studied",
          "limit": "No trial identifier, study-specific amount, formulation or duration is supplied. The private supplement-history amount is excluded.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "frequency": "Daily",
            "route": "Oral",
            "species": "Human",
            "population": "Human supplement trials described in the field guide"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              6
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "urolithin-protocol-jarvis-older-adults",
          "tier": "H",
          "title": "Urolithin A in older adults",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "66 older adults",
          "route": "Oral softgels",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1,000 mg; Route: Oral softgels; Frequency: Daily; Duration: 4 months; Species: Human; Population: 66 older adults",
          "ptype": "studied",
          "limit": "No significant between-group difference in six-minute walk distance or maximal ATP production. Muscle endurance was a separate endpoint.",
          "strength": "Primary article, Methods",
          "refs": [
            "urolithin-protocol-jarvis-older-adults-source"
          ],
          "protocolDetails": {
            "amount": "1,000 mg",
            "route": "Oral softgels",
            "frequency": "Daily",
            "duration": "4 months",
            "species": "Human",
            "population": "66 older adults"
          },
          "sourceLocator": {
            "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788244",
            "section": "Primary article, Methods"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "urolithin-protocol-jarvis-middle-aged",
          "tier": "H",
          "title": "Urolithin A in middle-aged adults",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Middle-aged adults",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 500 or 1,000 mg; Route: Oral; Frequency: Daily; Duration: 4 months; Species: Human; Population: Middle-aged adults",
          "ptype": "studied",
          "limit": "Randomized dose arms with a placebo comparator. Muscle strength findings and other exercise endpoints should be interpreted separately.",
          "strength": "Primary abstract and Fig. 1, PMID 35584623",
          "refs": [
            "urolithin-protocol-jarvis-middle-aged-source"
          ],
          "protocolDetails": {
            "amount": "500 or 1,000 mg",
            "route": "Oral",
            "frequency": "Daily",
            "duration": "4 months",
            "species": "Human",
            "population": "Middle-aged adults"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/35584623/",
            "section": "Primary abstract and Fig. 1, PMID 35584623"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "bpc",
      "name": "BPC-157",
      "pathway": "Tissue repair",
      "target": "Preclinical NO / angiogenesis / tendon and GI biology",
      "aliases": "bpc-157 Bpc 157",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "bpc-157"
      ],
      "aliasNames": [
        "Bpc 157"
      ],
      "records": [
        {
          "id": "bpc-1",
          "tier": "P",
          "title": "Rat Achilles transection experiment",
          "summary": "Rat tendon research does not establish human SC tendon treatment.",
          "context": "Rat surgical model; PMID 14554208.",
          "route": "IP",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Route, species and injury model prevent direct transfer to human KLOW dosing.",
          "strength": "Animal experiment; imported",
          "refs": [
            "bpc",
            "guide"
          ]
        },
        {
          "id": "bpc-protocol-rat-micro",
          "tier": "P",
          "title": "Rat Achilles study arm: 10 mcg/kg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Rat · Surgical Achilles transection model",
          "route": "IP",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10 mcg/kg; Frequency: Once daily; Duration: Assessments through day 14; Timing: Beginning 30 minutes after surgery; Route: IP; Species: Rat; Population: Surgical Achilles transection model",
          "ptype": "preclinical",
          "limit": "Animal intraperitoneal treatment cannot establish a human SC tendon or KLOW regimen.",
          "strength": "Study regimen · imported source",
          "refs": [
            "bpc",
            "guide"
          ],
          "protocolDetails": {
            "amount": "10 mcg/kg",
            "frequency": "Once daily",
            "duration": "Assessments through day 14",
            "timing": "Beginning 30 minutes after surgery",
            "route": "IP",
            "species": "Rat",
            "population": "Surgical Achilles transection model"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "bpc-protocol-rat-nano",
          "tier": "P",
          "title": "Rat Achilles study arm: 10 ng/kg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Rat · Surgical Achilles transection model",
          "route": "IP",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10 ng/kg; Frequency: Once daily; Duration: Assessments through day 14; Timing: Beginning 30 minutes after surgery; Route: IP; Species: Rat; Population: Surgical Achilles transection model",
          "ptype": "preclinical",
          "limit": "Animal intraperitoneal treatment cannot establish a human SC tendon or KLOW regimen.",
          "strength": "Study regimen · imported source",
          "refs": [
            "bpc",
            "guide"
          ],
          "protocolDetails": {
            "amount": "10 ng/kg",
            "frequency": "Once daily",
            "duration": "Assessments through day 14",
            "timing": "Beginning 30 minutes after surgery",
            "route": "IP",
            "species": "Rat",
            "population": "Surgical Achilles transection model"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "bpc-protocol-rat-pico",
          "tier": "P",
          "title": "Rat Achilles study arm: 10 pg/kg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Rat · Surgical Achilles transection model",
          "route": "IP",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10 pg/kg; Frequency: Once daily; Duration: Assessments through day 14; Timing: Beginning 30 minutes after surgery; Route: IP; Species: Rat; Population: Surgical Achilles transection model",
          "ptype": "preclinical",
          "limit": "Animal intraperitoneal treatment cannot establish a human SC tendon or KLOW regimen.",
          "strength": "Study regimen · imported source",
          "refs": [
            "bpc",
            "guide"
          ],
          "protocolDetails": {
            "amount": "10 pg/kg",
            "frequency": "Once daily",
            "duration": "Assessments through day 14",
            "timing": "Beginning 30 minutes after surgery",
            "route": "IP",
            "species": "Rat",
            "population": "Surgical Achilles transection model"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "bpc-protocol-mars-bpc",
          "tier": "A",
          "title": "BPC 157 adjunct proposal",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 400 mcg; Frequency: Daily; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "400 mcg",
            "frequency": "Daily",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "tb500",
      "name": "TB-500 / TB-4",
      "pathway": "Tissue repair",
      "target": "Actin / cell migration and repair biology",
      "aliases": "Thymosin beta-4 LKKTETQ tb-500 Tb 500",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "tb-500"
      ],
      "aliasNames": [
        "Tb 500"
      ],
      "records": [
        {
          "id": "tb500-1",
          "tier": "H",
          "title": "Full-length TB-4 phase I is a different molecule",
          "summary": "The guide cites short-term tolerability of full-length thymosin beta-4, not a retail TB-500 fragment.",
          "context": "Healthy volunteers; phase I; full-length molecule.",
          "route": "IV",
          "pk": "studied",
          "pktext": "No absolute bioavailability claim is supplied.",
          "protocol": null,
          "ptype": null,
          "limit": "These doses must not be transferred to TB-500 fragments or KLOW.",
          "strength": "Phase I tolerability; imported",
          "refs": [
            "tb4",
            "guide"
          ]
        },
        {
          "id": "tb500-2",
          "tier": "U",
          "title": "Fragment naming and PK gap",
          "summary": "FDA identifies TB-500 as LKKTETQ; naming is inconsistent in commerce.",
          "context": "Human fragment exposure and musculoskeletal self-treatment remain unresolved in the guide.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Verify sequence before borrowing full-length thymosin beta-4 evidence.",
          "strength": "Imported synthesis",
          "refs": [
            "fda-risk",
            "guide"
          ]
        },
        {
          "id": "tb500-protocol-tb4-42",
          "tier": "H",
          "title": "Full-length TB-4 phase I arm: 42 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment",
          "route": "IV",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 42 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment",
          "ptype": "studied",
          "limit": "Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tb4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "42 mg",
            "frequency": "Initially once, then daily",
            "duration": "14 days in repeated-dose phase",
            "route": "IV",
            "species": "Human",
            "population": "Healthy volunteers",
            "formulation": "Full-length thymosin beta-4; NOT a TB-500 fragment"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tb500-protocol-tb4-140",
          "tier": "H",
          "title": "Full-length TB-4 phase I arm: 140 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment",
          "route": "IV",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 140 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment",
          "ptype": "studied",
          "limit": "Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tb4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "140 mg",
            "frequency": "Initially once, then daily",
            "duration": "14 days in repeated-dose phase",
            "route": "IV",
            "species": "Human",
            "population": "Healthy volunteers",
            "formulation": "Full-length thymosin beta-4; NOT a TB-500 fragment"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tb500-protocol-tb4-420",
          "tier": "H",
          "title": "Full-length TB-4 phase I arm: 420 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment",
          "route": "IV",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 420 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment",
          "ptype": "studied",
          "limit": "Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tb4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "420 mg",
            "frequency": "Initially once, then daily",
            "duration": "14 days in repeated-dose phase",
            "route": "IV",
            "species": "Human",
            "population": "Healthy volunteers",
            "formulation": "Full-length thymosin beta-4; NOT a TB-500 fragment"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tb500-protocol-tb4-1260",
          "tier": "H",
          "title": "Full-length TB-4 phase I arm: 1260 mg",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment",
          "route": "IV",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1260 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment",
          "ptype": "studied",
          "limit": "Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.",
          "strength": "Study regimen · imported source",
          "refs": [
            "tb4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1260 mg",
            "frequency": "Initially once, then daily",
            "duration": "14 days in repeated-dose phase",
            "route": "IV",
            "species": "Human",
            "population": "Healthy volunteers",
            "formulation": "Full-length thymosin beta-4; NOT a TB-500 fragment"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "tb500-protocol-loading-concept",
          "tier": "A",
          "title": "Unspecified loading / maintenance concepts",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Not documented; Sequence: Loading followed by maintenance, as mentioned in the saved synthesis",
          "ptype": "anecdotal",
          "limit": "No dose, route, interval or duration is preserved. This is an incomplete anecdotal concept, not a defined regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "route": "Not documented",
            "sequence": "Loading followed by maintenance, as mentioned in the saved synthesis"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              7
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "tb500-protocol-mars-tb500",
          "tier": "A",
          "title": "TB 500 adjunct proposal",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 5 mg; Frequency: Twice weekly; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "5 mg",
            "frequency": "Twice weekly",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "klow",
      "name": "KLOW blend",
      "pathway": "Tissue repair",
      "target": "GHK-Cu + KPV + BPC-157 + TB-500",
      "aliases": "",
      "kind": "Blend",
      "gap": "No established human blend-specific SC, oral or IM PK or absolute bioavailability. Component data do not resolve the combination.",
      "records": [
        {
          "id": "klow-1",
          "tier": "A",
          "title": "Online dosing proposals",
          "summary": "Assumed composition: 50 mg GHK-Cu + 10 mg each KPV, BPC-157 and TB-500 (80 mg total).",
          "context": "Online proposals; no controlled blend trial identified in the source audit.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Total blend mass differs from GHK-Cu mass. Audit found an inconsistent PeptaBase volume calculation.",
          "strength": "Online proposals",
          "refs": [
            "klow1",
            "klow2",
            "guide"
          ]
        },
        {
          "id": "klow-2",
          "tier": "A",
          "title": "Escalation proposal",
          "summary": "Research Stacks proposes escalating the total blend.",
          "context": "Commercial educational schedule, not a dose-response study.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Audit found first-eight-week supply math exceeds three 80 mg vials; phases are unvalidated.",
          "strength": "Online proposal",
          "refs": [
            "klow3",
            "guide"
          ]
        },
        {
          "id": "klow-3",
          "tier": "A",
          "title": "Forum reports and adverse symptoms",
          "summary": "Forums contain variable proposals and reports of nausea, anxiety and stinging.",
          "context": "Unverified anecdotes; no causal or incidence estimate.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Syringe units alone are not a mass dose. These reports cannot establish safety or efficacy.",
          "strength": "Forum anecdotes",
          "refs": [
            "klow4",
            "klow5",
            "klow6",
            "guide"
          ]
        },
        {
          "id": "klow-protocol-peptabase",
          "tier": "A",
          "title": "PeptaBase fixed daily proposal",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Assumed 80 mg blend; 50:10:10:10 mg ingredients",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 3.2 mg total blend: 2 mg GHK-Cu + 400 mcg each BPC-157, TB-500 and KPV; Frequency: Daily; Duration: Two to three months on / one month off; Route: SC; Formulation: Assumed 80 mg blend; 50:10:10:10 mg ingredients",
          "ptype": "anecdotal",
          "limit": "No controlled blend trial. The audited page’s stated volume did not match its component amounts; retain mass rather than treating syringe units as universal.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow1",
            "guide"
          ],
          "protocolDetails": {
            "amount": "3.2 mg total blend: 2 mg GHK-Cu + 400 mcg each BPC-157, TB-500 and KPV",
            "frequency": "Daily",
            "duration": "Two to three months on / one month off",
            "route": "SC",
            "formulation": "Assumed 80 mg blend; 50:10:10:10 mg ingredients"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              7,
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-peptidefox",
          "tier": "A",
          "title": "PeptideFox range and 12-week taper",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Assumed 80 mg 5:1:1:1 blend",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1.6–4.8 mg total per injection; 3.2 mg described as standard; Frequency: Daily weeks 1–4; five times weekly weeks 5–8; two or three times weekly weeks 9–12; Duration: 12 weeks; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend",
          "ptype": "anecdotal",
          "limit": "Unvalidated proposed activation/remodeling/maintenance phases; no dose-response trial.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow2",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1.6–4.8 mg total per injection; 3.2 mg described as standard",
            "frequency": "Daily weeks 1–4; five times weekly weeks 5–8; two or three times weekly weeks 9–12",
            "duration": "12 weeks",
            "route": "SC",
            "formulation": "Assumed 80 mg 5:1:1:1 blend"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              7
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-researchstacks",
          "tier": "A",
          "title": "Research Stacks four-phase escalation",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Assumed 80 mg 5:1:1:1 blend",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg weeks 1–2; 4 mg weeks 3–4; 6 mg weeks 5–8; 4 mg weeks 9–12; all total-blend mass; Frequency: Daily; Duration: 12 weeks; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend",
          "ptype": "anecdotal",
          "limit": "Proposed escalation, not a trial. The audited first eight weeks total 252 mg, exceeding three 80 mg vials.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow3",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2 mg weeks 1–2; 4 mg weeks 3–4; 6 mg weeks 5–8; 4 mg weeks 9–12; all total-blend mass",
            "frequency": "Daily",
            "duration": "12 weeks",
            "route": "SC",
            "formulation": "Assumed 80 mg 5:1:1:1 blend"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              7,
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-forum4-poster",
          "tier": "A",
          "title": "PeptideForum: Poster’s 10-unit suggestion",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2.67 mg total; 1.67 mg GHK-Cu + approximately 333 mcg each other ingredient; Frequency: Daily; Route: SC; Formulation: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation",
          "ptype": "anecdotal",
          "limit": "Amounts are the prior audit’s concentration-dependent calculations, not outcome evidence or a universal syringe-volume recommendation.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2.67 mg total; 1.67 mg GHK-Cu + approximately 333 mcg each other ingredient",
            "frequency": "Daily",
            "route": "SC",
            "formulation": "Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-forum4-commenter",
          "tier": "A",
          "title": "PeptideForum: Commenter’s 12-unit suggestion",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 3.2 mg total; 2 mg GHK-Cu + 400 mcg each other ingredient; Frequency: Daily; Route: SC; Formulation: Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation",
          "ptype": "anecdotal",
          "limit": "Amounts are the prior audit’s concentration-dependent calculations, not outcome evidence or a universal syringe-volume recommendation.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow4",
            "guide"
          ],
          "protocolDetails": {
            "amount": "3.2 mg total; 2 mg GHK-Cu + 400 mcg each other ingredient",
            "frequency": "Daily",
            "route": "SC",
            "formulation": "Mass calculations assume 80 mg vial with 3 mL diluent and U-100 notation"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-forum5",
          "tier": "A",
          "title": "PeptideGuide proposed five-times-weekly escalation",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Assumed 80 mg 5:1:1:1 blend",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg total, potentially rising to 4 mg after several weeks; Frequency: Five times weekly; Route: SC; Formulation: Assumed 80 mg 5:1:1:1 blend",
          "ptype": "anecdotal",
          "limit": "Unverified proposed self-experiment. Exact escalation week and total duration are not given; no established successful outcome.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow5",
            "guide"
          ],
          "protocolDetails": {
            "amount": "2 mg total, potentially rising to 4 mg after several weeks",
            "frequency": "Five times weekly",
            "route": "SC",
            "formulation": "Assumed 80 mg 5:1:1:1 blend"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "klow-protocol-forum6",
          "tier": "A",
          "title": "PeptidePathways reported five-night pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Prior audit calculated mass from 80 mg vial / 3 mL diluent",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.8 mg total; 500 mcg GHK-Cu + 100 mcg each other ingredient; Frequency: Five nights weekly; Route: SC; Formulation: Prior audit calculated mass from 80 mg vial / 3 mL diluent",
          "ptype": "anecdotal",
          "limit": "Unverified report includes nausea and initial anxiety; other account reports stinging. Cannot establish causation or event frequency.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "klow6",
            "guide"
          ],
          "protocolDetails": {
            "amount": "0.8 mg total; 500 mcg GHK-Cu + 100 mcg each other ingredient",
            "frequency": "Five nights weekly",
            "route": "SC",
            "formulation": "Prior audit calculated mass from 80 mg vial / 3 mL diluent"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "ghk",
      "name": "GHK-Cu",
      "pathway": "Tissue repair",
      "target": "Copper binding / extracellular matrix remodeling",
      "aliases": "ghk-cu Ghk Cu",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "ghk-cu"
      ],
      "aliasNames": [
        "Ghk Cu"
      ],
      "records": [
        {
          "id": "ghk-1",
          "tier": "P",
          "title": "Local rat wound research",
          "summary": "Repeated local injections were studied in rat wound chambers.",
          "context": "Rat local connective-tissue model.",
          "route": "Local",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Topical human precedent does not validate systemic injection or KLOW.",
          "strength": "Animal experiment; imported",
          "refs": [
            "ghk",
            "guide"
          ]
        },
        {
          "id": "ghk-protocol-rat-local",
          "tier": "P",
          "title": "Rat wound-chamber local injections",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Rat · Wound-chamber connective-tissue model",
          "route": "Local",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Varying concentrations; numeric concentrations not supplied; Frequency: Repeated local injections; Route: Local; Species: Rat; Population: Wound-chamber connective-tissue model",
          "ptype": "preclinical",
          "limit": "No human systemic regimen or blend equivalence can be inferred.",
          "strength": "Study regimen · imported source",
          "refs": [
            "ghk",
            "guide"
          ],
          "protocolDetails": {
            "amount": "Varying concentrations; numeric concentrations not supplied",
            "frequency": "Repeated local injections",
            "route": "Local",
            "species": "Rat",
            "population": "Wound-chamber connective-tissue model"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "kpv",
      "name": "KPV",
      "pathway": "Immune / inflammation",
      "target": "Alpha-MSH-derived anti-inflammatory tripeptide",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "kpv-1",
          "tier": "P",
          "title": "Oral mouse colitis experiment",
          "summary": "Mouse colitis research used KPV in drinking water.",
          "context": "Mouse model; PMID 18061177.",
          "route": "Oral",
          "pk": "preclinical",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "A drinking-water concentration is not a human injection dose or a bioavailability percentage.",
          "strength": "Animal experiment; imported",
          "refs": [
            "kpv",
            "guide"
          ]
        },
        {
          "id": "kpv-protocol-mouse-water",
          "tier": "P",
          "title": "Mouse colitis drinking-water concentration",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Mouse · Colitis model",
          "route": "Oral",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 100 micromolar in drinking water; Route: Oral; Species: Mouse; Population: Colitis model",
          "ptype": "preclinical",
          "limit": "A concentration is not a delivered mg/kg dose. Water intake, duration and frequency are not supplied in the saved passage.",
          "strength": "Study regimen · imported source",
          "refs": [
            "kpv",
            "guide"
          ],
          "protocolDetails": {
            "amount": "100 micromolar in drinking water",
            "route": "Oral",
            "species": "Mouse",
            "population": "Colitis model"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              8
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "cagrilintide",
      "name": "Cagrilintide",
      "pathway": "Metabolic / appetite",
      "target": "Long-acting amylin analogue / satiety",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "cagrilintide-1",
          "tier": "H",
          "title": "Human clinical development",
          "summary": "The guide reports once-weekly dosing in human development.",
          "context": "Trial-specific indication and formulation; primary identifier not supplied. Route is not specified in this imported entry.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Combination use with retatrutide is not an established regimen.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "cagrilintide-2",
          "tier": "H",
          "title": "Human SC PK in renal and hepatic impairment",
          "summary": "Two single-dose studies found no consistent AUC or Cmax differences across renal or hepatic impairment groups.",
          "context": "Adults with renal impairment (0.6 mg SC; n=33) or hepatic impairment (0.9 mg SC; n=32) versus normal-function groups; DOI 10.1007/s40262-026-01654-0; NCT04209049 and NCT05564104.",
          "route": "SC",
          "pk": "studied",
          "pktext": "AUC0-infinity ratios vs normal: renal mild 1.23, moderate 1.18, severe 1.21; hepatic mild 0.99, moderate 1.01, severe 1.11. Cmax and Tmax assessed; route-specific absolute bioavailability not established.",
          "protocol": null,
          "ptype": null,
          "limit": "Small severe-impairment groups (n=5 renal; n=4 hepatic); within-route comparisons do not estimate absolute or oral bioavailability or support extrapolation to other analogues or combinations.",
          "strength": "Peer-reviewed human PK; primary abstract checked 16 October 2026",
          "refs": [
            "cagrilintide-pk"
          ]
        },
        {
          "id": "cagrilintide-protocol-weekly",
          "tier": "H",
          "title": "Clinical-development weekly pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Once weekly; Route: Not documented; Species: Human",
          "ptype": "studied",
          "limit": "Trial identifier, route, amount and duration are not supplied. Does not establish a retatrutide combination regimen.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "frequency": "Once weekly",
            "route": "Not documented",
            "species": "Human"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              4
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "eloralintide",
      "name": "Eloralintide",
      "pathway": "Metabolic / appetite",
      "target": "Amylin-receptor pathway / satiety",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "eloralintide-1",
          "tier": "H",
          "title": "Investigational human development",
          "summary": "The guide reports investigational human obesity / metabolic development.",
          "context": "Primary trial identifier, route and numeric dose not supplied in this entry.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No self-directed protocol assigned; trial-specific data are needed.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "eloralintide-protocol-jarvis-phase2",
          "tier": "H",
          "title": "Eloralintide phase 2 obesity trial",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults with obesity or qualifying overweight without type 2 diabetes",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Fixed 1, 3, 6 or 9 mg; separate 6 to 9 mg and 3 to 9 mg escalation arms; Route: Subcutaneous; Frequency: Once weekly; Duration: 48 weeks; Species: Human; Population: Adults with obesity or qualifying overweight without type 2 diabetes",
          "ptype": "studied",
          "limit": "Randomized dose-finding trial. Escalation intervals were not extracted.",
          "strength": "Primary abstract, NCT06230523",
          "refs": [
            "eloralintide-protocol-jarvis-phase2-source"
          ],
          "protocolDetails": {
            "amount": "Fixed 1, 3, 6 or 9 mg; separate 6 to 9 mg and 3 to 9 mg escalation arms",
            "route": "Subcutaneous",
            "frequency": "Once weekly",
            "duration": "48 weeks",
            "species": "Human",
            "population": "Adults with obesity or qualifying overweight without type 2 diabetes"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/41207310/",
            "section": "Primary abstract, NCT06230523"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "cartalax",
      "name": "Cartalax",
      "pathway": "Tissue repair",
      "target": "Cartilage / chondrocyte claims",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "cartalax-1",
          "tier": "U",
          "title": "Limited evidence",
          "summary": "Marketed or researched around cartilage biology; no validated human therapeutic injection protocol in the guide.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No primary study supplied; vendor protocols are not established clinical evidence.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        }
      ]
    },
    {
      "id": "peg-mgf",
      "name": "PEG-MGF",
      "pathway": "Tissue repair",
      "target": "PEGylated mechano-growth-factor / IGF-related signaling",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "peg-mgf-1",
          "tier": "T",
          "title": "Proposed repair signaling",
          "summary": "Intended anabolic / repair rationale; no validated human dose or tendon-repair cycle.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No human protocol or route-specific PK established in this entry.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        }
      ]
    },
    {
      "id": "tp508",
      "name": "TP-508 / Chrysalin",
      "pathway": "Tissue repair",
      "target": "Thrombin-derived angiogenesis / wound repair",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "tp508-1",
          "tier": "H",
          "title": "Clinical-development history",
          "summary": "Human clinical research is reported in the guide, but no general tendon self-injection protocol is established.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Specific primary trial is not supplied; human development history is not proof of tendon efficacy.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "tp508-protocol-jarvis-chrysalin",
          "tier": "H",
          "title": "TP-508 in diabetic foot ulcers",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "60 participants with diabetic foot ulcers",
          "route": "Topical wound bed",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1 or 10 µg; Route: Topical wound bed; Frequency: Twice weekly; Species: Human; Population: 60 participants with diabetic foot ulcers",
          "ptype": "studied",
          "limit": "Phase I/II randomized study with standardized wound care and offloading. Healing signal reported in the per-protocol analysis.",
          "strength": "Primary abstract, PMID 17244316",
          "refs": [
            "tp508-protocol-jarvis-chrysalin-source"
          ],
          "protocolDetails": {
            "amount": "1 or 10 µg",
            "route": "Topical wound bed",
            "frequency": "Twice weekly",
            "duration": null,
            "species": "Human",
            "population": "60 participants with diabetic foot ulcers"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/17244316/",
            "section": "Primary abstract, PMID 17244316"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "ta1",
      "name": "Thymosin alpha-1",
      "pathway": "Immune / inflammation",
      "target": "T-cell, dendritic and NK-cell modulation",
      "aliases": "thymosin-alpha-1 Thymosin Alpha 1",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "thymosin-alpha-1"
      ],
      "aliasNames": [
        "Thymosin Alpha 1"
      ],
      "records": [
        {
          "id": "ta1-1",
          "tier": "H",
          "title": "Indication-specific human literature",
          "summary": "Guide reports substantial human clinical literature; status varies by indication and country.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No specific primary study link supplied for this entry.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "ta1-protocol-twice-weekly",
          "tier": "H",
          "title": "Indication-specific thymalfasin literature pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Specific infectious-disease / chronic hepatitis literature",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1.6 mg; Frequency: Twice weekly; Route: SC; Species: Human; Population: Specific infectious-disease / chronic hepatitis literature",
          "ptype": "studied",
          "limit": "Primary study identifier and course length are missing. Not a general immune-boosting regimen.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "amount": "1.6 mg",
            "frequency": "Twice weekly",
            "route": "SC",
            "species": "Human",
            "population": "Specific infectious-disease / chronic hepatitis literature"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              10,
              13
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "ta1-protocol-loading",
          "tier": "H",
          "title": "Daily loading then twice-weekly pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human · Some indication-specific studies summarized in the guide",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Frequency: Daily for one week, then twice weekly; Duration: One-week loading phase; total course not supplied; Route: SC; Species: Human; Population: Some indication-specific studies summarized in the guide",
          "ptype": "studied",
          "limit": "The passage does not supply the loading amount or a primary study identifier. Do not assume it matches the separate 1.6 mg example.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "frequency": "Daily for one week, then twice weekly",
            "duration": "One-week loading phase; total course not supplied",
            "route": "SC",
            "species": "Human",
            "population": "Some indication-specific studies summarized in the guide"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              10
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "ara290",
      "name": "ARA-290 / Cibinetide",
      "pathway": "Immune / inflammation",
      "target": "EPOR/CD131 innate repair receptor",
      "aliases": "ara-290 Ara 290",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "ara-290"
      ],
      "aliasNames": [
        "Ara 290"
      ],
      "records": [
        {
          "id": "ara290-1",
          "tier": "H",
          "title": "Cibinetide: early human neuropathy evidence and route-specific PK",
          "summary": "A 64-person randomized phase 2b sarcoidosis trial compared 1, 4 and 8 mg/day with placebo for 28 days; 4 mg/day improved corneal nerve fiber area. This is a surrogate endpoint, not proof of general nerve restoration or tendon repair.",
          "context": "Sarcoidosis-associated small nerve fiber loss and neuropathic pain; 2017 trial abstract reviewed. Separate 2015 diabetes paper reports prior healthy-volunteer SC PK.",
          "route": "SC",
          "pk": "studied",
          "pktext": "The 2015 paper reports prior normal-volunteer data after 4 mg SC: peak plasma concentration approximately 3 ng/mL and terminal half-life approximately 20 minutes. Absolute SC bioavailability was not established by this report.",
          "protocol": null,
          "ptype": null,
          "limit": "Small, short, indication-specific studies. The 2017 full text was not independently reviewed. No established repeat-cycle interval, general anti-aging benefit, combination efficacy or optimal longer course. Half-life is not absolute bioavailability; a blanket two-minute half-life omits route context.",
          "strength": "Limited human clinical research; selected primary findings reviewed 24 October 2026",
          "refs": [
            "ara290-sarcoidosis-2017",
            "ara290-diabetes-2015"
          ]
        },
        {
          "id": "ara290-protocol-neuropathy",
          "tier": "H",
          "title": "Type 2 diabetes and neuropathic symptoms: 28-day study",
          "summary": "49 enrolled, 48 analyzed; serial HbA1c available in 42. Mean HbA1c change at day 28 was -0.16 percentage points with ARA 290 versus -0.01 placebo; at day 56, -0.21 versus +0.21. HbA1c was a primary endpoint. PainDetect improved; corneal nerve findings were restricted to a low-baseline-density subgroup.",
          "context": "Randomized double-blind placebo-controlled trial in adults with type 2 diabetes and painful distal neuropathic symptoms; 28 days of treatment and 28 days of follow-up.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Studied regimen: 4 mg SC once daily for 28 days, followed by 28 days without study drug. Research exposure, not a recommended regimen.",
          "ptype": "studied",
          "limit": "Small, short trial; modest glycemic change, multiple outcomes and subgroup limits. Four serious adverse events occurred in the active arm; two were judged possibly related. Causality is uncertain; the safety committee judged the reported fatal myocardial infarction unrelated. Does not establish long-term safety or a treatment recommendation.",
          "strength": "Limited human clinical research; selected primary findings reviewed 24 October 2026",
          "refs": [
            "ara290-diabetes-2015"
          ],
          "protocolDetails": {
            "amount": "4 mg",
            "frequency": "Daily",
            "duration": "28 days",
            "route": "SC",
            "species": "Human",
            "population": "Diabetic neuropathy"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              10,
              13
            ]
          },
          "protocolVerification": "Primary publication full text independently reopened 24 October 2026; study exposure and outcomes checked. Saved guide locator retained as import provenance.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "ara290-protocol-macular",
          "tier": "H",
          "title": "Diabetic macular edema: exploratory 12-week study",
          "summary": "Nine enrolled and eight completed an uncontrolled open-label study. Mean visual acuity, central retinal thickness, retinal sensitivity and tear production did not improve at week 12. Some individual exploratory measures and vision-related questionnaire scores improved. No serious adverse events/reactions or anti-cibinetide antibodies were observed.",
          "context": "2020 phase 2 pilot in patients with diabetic macular edema; eight completers cannot establish uncommon risks or comparative efficacy.",
          "route": "SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Studied regimen: 4 mg SC once daily for 12 weeks. Research exposure, not a recommended regimen.",
          "ptype": "studied",
          "limit": "No placebo control; very small sample. Tolerability during 12 weeks does not establish benefit from longer use for glucose control, an optimal duration, or long-term safety.",
          "strength": "Limited human clinical research; selected primary findings reviewed 24 October 2026",
          "refs": [
            "ara290-macular-2020"
          ],
          "protocolDetails": {
            "amount": "4 mg",
            "frequency": "Daily",
            "duration": "12 weeks",
            "route": "SC",
            "species": "Human",
            "population": "Diabetic macular edema"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              10,
              13
            ]
          },
          "protocolVerification": "Primary publication full text independently reopened 24 October 2026; study exposure and outcomes checked. Saved guide locator retained as import provenance.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "ll37",
      "name": "LL-37",
      "pathway": "Immune / inflammation",
      "target": "Cathelicidin / innate immunity and microbial membranes",
      "aliases": "ll-37 Ll 37",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "ll-37"
      ],
      "aliasNames": [
        "Ll 37"
      ],
      "records": [
        {
          "id": "ll37-1",
          "tier": "U",
          "title": "Systemic treatment gap",
          "summary": "Innate immune and wound biology is described; systemic self-injection protocol is not validated here.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No primary study or systemic PK anchor supplied.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "ll37-protocol-jarvis-venous-ulcer",
          "tier": "H",
          "title": "LL-37 topical venous leg ulcer phase IIb trial",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults with hard-to-heal venous leg ulcers",
          "route": "Topical wound bed",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.5 or 1.6 mg/mL, applied at 25 µL/cm²; Route: Topical wound bed; Frequency: Every third day ±1 day, at most twice weekly; Species: Human; Population: Adults with hard-to-heal venous leg ulcers",
          "ptype": "studied",
          "limit": "The concentrations delivered 12.5 or 40 µg/cm² with standard care. Overall healing superiority was not demonstrated.",
          "strength": "Trial registry, arms and endpoints",
          "refs": [
            "ll37-protocol-jarvis-venous-ulcer-source"
          ],
          "protocolDetails": {
            "amount": "0.5 or 1.6 mg/mL, applied at 25 µL/cm²",
            "route": "Topical wound bed",
            "frequency": "Every third day ±1 day, at most twice weekly",
            "duration": null,
            "species": "Human",
            "population": "Adults with hard-to-heal venous leg ulcers"
          },
          "sourceLocator": {
            "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000536-10/results",
            "section": "Trial registry, arms and endpoints"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "foxo4",
      "name": "FOXO4-DRI",
      "pathway": "Senescence / longevity",
      "target": "FOXO4–p53 interaction / senescent-cell apoptosis",
      "aliases": "foxo4-dri Foxo4 Dri",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "foxo4-dri"
      ],
      "aliasNames": [
        "Foxo4 Dri"
      ],
      "records": [
        {
          "id": "foxo4-1",
          "tier": "P",
          "title": "Preclinical senolytic concept",
          "summary": "Designed to disrupt FOXO4–p53 interaction in senescent cells.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No validated human dose, cycle, selectivity or safety framework. Primary study identifier not supplied in the guide entry.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        }
      ]
    },
    {
      "id": "epithalon",
      "name": "Epithalon / Epitalon",
      "pathway": "Senescence / longevity",
      "target": "Pineal / circadian and telomere claims",
      "aliases": "epitalon Epitalon",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "aliasIds": [
        "epitalon"
      ],
      "aliasNames": [
        "Epitalon"
      ],
      "records": [
        {
          "id": "epithalon-1",
          "tier": "U",
          "title": "Limited older literature",
          "summary": "The guide describes limited older human literature and unconfirmed longevity claims.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No modern validated sleep or longevity protocol; no primary identifier supplied.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "epithalon-protocol-courses",
          "tier": "A",
          "title": "Unspecified circulating short-course proposals",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Duration: Short courses; numeric duration not supplied; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Source mentions circulating anecdotes but gives no amount, route, frequency, product identity or primary source. Not a complete regimen.",
          "strength": "Unvalidated proposal / report · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "duration": "Short courses; numeric duration not supplied",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              11
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "epithalon-protocol-mars-epithalon",
          "tier": "A",
          "title": "Epithalon adjunct proposal",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 1–2 mg; Frequency: Daily during cycle; Duration: Short cycle once or twice yearly; exact length unspecified; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "1–2 mg",
            "frequency": "Daily during cycle",
            "duration": "Short cycle once or twice yearly; exact length unspecified",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "klotho",
      "name": "Klotho",
      "pathway": "Senescence / longevity",
      "target": "FGF23 / mineral metabolism and longevity-associated biology",
      "aliases": "",
      "kind": "Protein",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "klotho-1",
          "tier": "P",
          "title": "Early translational research",
          "summary": "The guide describes preclinical and early translational protein research.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No validated human injectable product regimen. Online product mass is not a clinical dose.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "klotho-protocol-jarvis-rhesus",
          "tier": "P",
          "title": "Soluble rhesus α-klotho in aged macaques",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Aged rhesus macaques",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10 µg/kg; Route: Subcutaneous; Frequency: Single administration; Species: Rhesus macaque; Population: Aged rhesus macaques",
          "ptype": "preclinical",
          "limit": "Spatial-memory task performance improved at 10 µg/kg. The higher tested doses did not show a significant benefit on the same task.",
          "strength": "Primary article, Fig. 2",
          "refs": [
            "klotho-protocol-jarvis-rhesus-source"
          ],
          "protocolDetails": {
            "amount": "10 µg/kg",
            "route": "Subcutaneous",
            "frequency": "Single administration",
            "duration": null,
            "species": "Rhesus macaque",
            "population": "Aged rhesus macaques"
          },
          "sourceLocator": {
            "url": "https://www.nature.com/articles/s43587-023-00441-x.pdf",
            "section": "Primary article, Fig. 2"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "flgr",
      "name": "FLGR-242",
      "pathway": "Senescence / longevity",
      "target": "Unresolved regenerative / longevity claims",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "flgr-1",
          "tier": "U",
          "title": "Identity and evidence unresolved",
          "summary": "Experimental compound naming in prior research is too uncertain for a defensible protocol.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Identity and mechanism need primary-source resolution; no protocol is supplied in the imported record.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "flgr-2",
          "tier": "U",
          "title": "FLGR242 / FLGR-242: proposed identity and human evidence gaps",
          "summary": "FLGR242 is marketed as a modified follistatin construct designed to inhibit myostatin (GDF-8), with claimed albumin binding and prolonged exposure. Full product sequence, formulation, independent identity testing, ligand selectivity and human target engagement were not verified.",
          "context": "Owner-supplied article and promotional interview description compared with the patent and primary literature. The Atlas registry snapshot returned no matching studies for FLGR-242. Direct registry retrieval was unavailable during this audit.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": "Human SC, oral and IM pharmacokinetics and absolute bioavailability are not established. No verified human terminal half-life or duration of effect.",
          "protocol": null,
          "ptype": null,
          "limit": "No compound-specific human dose-response, dosing protocol, safety, hypertrophy, strength, functional benefit, sarcopenia outcome or post-discontinuation effect was established by sources reviewed.",
          "strength": "Unverified product claims and scoped evidence search",
          "refs": [
            "flgr-farber-interview",
            "flgr-farber-patent",
            "flgr-registry-audit"
          ]
        },
        {
          "id": "flgr-3",
          "tier": "U",
          "title": "Albumin-binding patent and claimed half-life",
          "summary": "US12377158B1 discloses an SA21-based binder, describes a Klotho fusion and states a seven-day half-life for a canine follistatin construct. It also asserts approximately 19 days for human binder-linked proteins, a figure it gives for human albumin itself.",
          "context": "Patent specification and Dennis et al. albumin-binding experiments. The Dennis study measured binding in vitro and extended exposure of a different fusion construct in animals.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No primary human concentration-time data for FLGR-242 or demonstrated equivalence between the commercial vial and the patent example. The patent figures do not establish dosing frequency.",
          "strength": "Patent claim with independent platform precedent",
          "refs": [
            "flgr-farber-patent",
            "flgr-dennis"
          ]
        },
        {
          "id": "flgr-4",
          "tier": "P",
          "title": "Follistatin, FLRG and FST-344 nomenclature",
          "summary": "Structural work shows direct binding of FST288 to myostatin. Hill et al. found binding and inhibitory activity for FLRG (FSTL3), a distinct protein. FST-344 refers to a precursor of mature FST315 in the primary sequence literature.",
          "context": "Structural, serum binding, reporter assay and precursor sequence studies of named molecules.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "These findings establish pathway biology and nomenclature. They do not determine the sequence, composition or ligand selectivity of FLGR-242.",
          "strength": "Primary mechanistic research on related proteins",
          "refs": [
            "flgr-thompson",
            "flgr-hill",
            "flgr-precursor"
          ]
        },
        {
          "id": "flgr-5",
          "tier": "P",
          "title": "FS I-I and DF-3: distinct preclinical constructs",
          "summary": "Transgenic skeletal-muscle expression of FS I-I increased muscle mass and strength in mice and improved selected outcomes in mdx mice. FS I-I bound myostatin at 46.8 nM and activin at 64.3 micromolar. In separate work, the synthetic DF-3 14-mer increased mouse muscle mass after intramuscular injection and inhibited myostatin without inhibiting activin A or TGF-beta1 in the reported reporter assay.",
          "context": "FS I-I was expressed from a muscle-specific transgene. DF-3 was an injected peptide and a separate sequence.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Neither study tested a vial identified as FLGR-242. Transgene expression and IM DF-3 cannot establish FLGR-242 administration, potency or PK.",
          "strength": "Primary mouse and laboratory studies of other constructs",
          "refs": [
            "flgr-nakatani",
            "flgr-saitoh"
          ]
        },
        {
          "id": "flgr-6",
          "tier": "H",
          "title": "Human pathway context: MSTN genetics and sarcopenia",
          "summary": "A child with an MSTN splice-site mutation showed marked muscle hypertrophy. In a separate 24-week sarcopenia trial, the activin-receptor antibody bimagrumab increased lean mass but did not significantly improve the primary physical-performance endpoint versus placebo.",
          "context": "Single human genetic case and randomized trial in community-dwelling older adults with sarcopenia. Neither study administered FLGR-242.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Human pathway evidence cannot establish FLGR-242 efficacy, safety or dosing. Lean mass and functional performance are separate outcomes.",
          "strength": "Human genetics and clinical comparator evidence only",
          "refs": [
            "flgr-schuelke",
            "flgr-rooks"
          ]
        },
        {
          "id": "flgr-7",
          "tier": "P",
          "title": "Tendon findings in myostatin-deficient mice",
          "summary": "Mendias et al. found smaller, more brittle and less cellular tendons in mice with constitutive myostatin deficiency.",
          "context": "Genetic knockout mouse model comparing tendon morphology and mechanical properties.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "This is a pathway-level safety question. The model does not quantify tendon risk from adult exposure to FLGR-242.",
          "strength": "Primary knockout mouse study",
          "refs": [
            "flgr-mendias"
          ]
        }
      ]
    },
    {
      "id": "p21",
      "name": "P21",
      "pathway": "Neuro / reproductive",
      "target": "Neurotrophic / BDNF and synaptic-plasticity claims",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "p21-1",
          "tier": "P",
          "title": "Preclinical neuro research",
          "summary": "The guide describes experimental neurotrophic research.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No validated human dose; no primary study or route-specific PK supplied.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "p21-protocol-jarvis-maternal-chow",
          "tier": "P",
          "title": "P021 maternal chow experiment",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Pregnant 3xTg-AD and wild-type mice",
          "route": "Oral, formulated chow",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 60 nmol/g diet; Route: Oral, formulated chow; Frequency: Access to formulated chow; Duration: Embryonic day 8 to offspring postnatal day 21; Species: Mouse; Population: Pregnant 3xTg-AD and wild-type mice",
          "ptype": "preclinical",
          "limit": "The amount is a concentration in maternal chow. The experiment measured Alzheimer-like behaviors and pathology in offspring.",
          "strength": "Primary article, Treatment of animals with P021",
          "refs": [
            "p21-protocol-jarvis-maternal-chow-source"
          ],
          "protocolDetails": {
            "amount": "60 nmol/g diet",
            "route": "Oral, formulated chow",
            "frequency": "Access to formulated chow",
            "duration": "Embryonic day 8 to offspring postnatal day 21",
            "species": "Mouse",
            "population": "Pregnant 3xTg-AD and wild-type mice"
          },
          "sourceLocator": {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7450938/",
            "section": "Primary article, Treatment of animals with P021"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "pnc27",
      "name": "PNC-27",
      "pathway": "Experimental oncology",
      "target": "Membrane-associated HDM2/MDM2; membrane disruption",
      "aliases": "PNC27 PNC-27 OM-301",
      "kind": "Peptide",
      "gap": "No established human benefit, safety profile, dosing regimen, response timeline or route-specific bioavailability. ClinicalTrials.gov direct retrieval was unavailable in this review; registry coverage remains incomplete.",
      "records": [
        {
          "id": "pnc27-1",
          "tier": "P",
          "title": "PNC-27 identity and membrane-HDM2 targeting",
          "summary": "PNC-27 is a synthetic 32-amino-acid chimeric peptide containing p53 residues 12–26 and a membrane-interacting leader. In the 2010 study, membrane-localized full-length HDM2 made otherwise resistant untransformed cells susceptible to PNC-27.",
          "context": "Preclinical cell models; p53-derived sequence does not mean restoration of TP53 function.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Target accessibility supports the mechanism in tested models; it does not establish that every tumor expresses the target or that all healthy tissues are spared.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-pnas-2010",
            "pnc27-aml-2020"
          ]
        },
        {
          "id": "pnc27-pores-2022",
          "tier": "P",
          "title": "Membrane pores: observed structures and proposed molecular organization",
          "summary": "Immuno-electron microscopy identified PNC-27 and HDM2 labels around pore-associated ring structures. Structural calculations support a proposed peptide–protein pore assembly.",
          "context": "Cancer-cell cultures and untransformed fibroblast comparisons; exact pore architecture remains a mechanistic interpretation.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Laboratory selectivity is not comprehensive safety. Patent inventorship is disclosed by several authors. Independently replicated tissue-wide selectivity remains unresolved.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-pores-2022"
          ]
        },
        {
          "id": "pnc27-pancreas-2008",
          "tier": "P",
          "title": "Pancreatic cells: lytic injury in a conference abstract",
          "summary": "PNC-27-treated MiaPaCa-2 cells showed concentration-dependent death, rapid LDH release and membrane pores without elevation of caspases 3 and 7.",
          "context": "2008 conference abstract/section snippets; daily direct cell exposure described, concentration not specified in retrieved text.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Conference abstract only. No patient tumor response or survival endpoint; distinguish PNC-27 from the related PNC-28 molecule.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-pancreas-2008"
          ]
        },
        {
          "id": "pnc27-k562-2014",
          "tier": "P",
          "title": "p53-independent killing in K562 leukemia cells",
          "summary": "PNC-27 colocalized with membrane HDM2 and induced LDH-associated cytotoxicity in p53-null K562 cells; murine leukocyte controls were spared under tested conditions.",
          "context": "Human leukemia cell line with deleted p53; abstract reviewed.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Supports a p53-independent pathway in this model; does not repair TP53 or establish activity in every p53-deficient cancer.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-k562-2014"
          ]
        },
        {
          "id": "pnc27-aml-2020",
          "tier": "P",
          "title": "AML: E-cadherin degradation and transplantation experiments",
          "summary": "PNC-27 enhanced membrane HDM2–E-cadherin interaction and E-cadherin ubiquitination/degradation. In murine and human-AML xenograft models it reduced leukemia burden and leukemia-initiating activity; normal hematopoietic function was comparatively preserved in tested mice.",
          "context": "Wang et al., online 2019/issue 2020; main text reviewed. Human AML xenograft primary recipients had median survival 136.5 days with PNC-27 versus 115 with PNC-29 and 111 with vehicle (n=8/8/7).",
          "route": "Intraperitoneal administration in mice",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Small animal cohorts; patient-derived cells do not make this a clinical trial. Hematopoietic preservation does not establish safety in other organs or human relapse prevention.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-aml-2020"
          ],
          "protocolDetails": {
            "amount": "40 mg/kg",
            "frequency": "Daily",
            "duration": "3 weeks in survival cohorts; separate 2-week transplantation cohorts",
            "route": "Intraperitoneal",
            "species": "Mouse",
            "population": "Murine AML and human AML xenograft models"
          },
          "protocolVerification": "Main-text methods and Figure 3 reviewed 2 November 2026. Animal study exposure only; no human dose conversion.",
          "protocolCompleteness": "Animal amount, route, frequency and cohort duration reported",
          "audience": "nonpersonal"
        },
        {
          "id": "pnc27-mito-2024",
          "tier": "P",
          "title": "Cancer-cell mitochondrial disruption",
          "summary": "PNC-27-treated MIA-PaCa-2 cells lost mitochondrial dye retention while lysosomal dye retention persisted. Immuno-electron microscopy localized peptide-associated labels to mitochondrial membranes.",
          "context": "2024 primary abstract; mitochondrial injury studied in pancreatic cancer cells.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Does not establish mitochondrial enhancement, increased energy, exercise benefit or general metabolic health.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-mito-2024"
          ]
        },
        {
          "id": "pnc27-ovarian-2015",
          "tier": "P",
          "title": "Patient-derived ovarian cancer: ex vivo findings",
          "summary": "Primary cultures from two epithelial ovarian cancers showed concentration-dependent growth inhibition and cytotoxicity. Established and chemotherapy-resistant ovarian cancer lines also showed activity.",
          "context": "Mucinous and high-grade papillary serous primary cultures; MTT and LDH assays, abstract reviewed.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Patients provided tumor cells; they were not treated in this experiment. Two primary cultures cannot establish clinical response or broad tumor coverage.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-ovarian-2015"
          ]
        },
        {
          "id": "pnc27-cervical-2025",
          "tier": "P",
          "title": "Cervical cancer cell comparison",
          "summary": "PNC-27 was cytotoxic to HTB-35/SiHa cervical cancer cells (reported IC50 12.4 micromolar), while the PCS-480 nonmalignant comparison was spared. Membrane HDM2 was detected in malignant cells.",
          "context": "2025 primary abstract; one malignant/nonmalignant cell-line comparison.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "IC50 is a culture concentration, not an injectable dose or human exposure target. Cannot establish efficacy across cervical cancer subtypes.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-cervical-2025"
          ]
        },
        {
          "id": "pnc27-leukemia-timing-2020",
          "tier": "P",
          "title": "Experimental onset: hours in directly exposed cells",
          "summary": "U937, OCI-AML3 and HL-60 leukemia cells expressed membrane HDM2; PNC-27 induced necrosis and LDH release within four hours.",
          "context": "2020 cell-culture study; primary abstract reviewed.",
          "route": "Direct exposure in cell culture",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "LDH release measures membrane injury in culture. It is not a validated patient response test; culture timing does not establish clinical onset, cycle length or time to maximum benefit.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-leukemia-2020"
          ]
        },
        {
          "id": "pnc27-paclitaxel-2017",
          "tier": "P",
          "title": "Paclitaxel combination: preclinical synergy",
          "summary": "Paclitaxel-surviving ID8 ovarian cancer cells showed increased surface MDM2 and susceptibility to PNC-27. Isobologram analysis indicated synergy, and combination treatment reduced tumor growth in a mouse model.",
          "context": "Abstract: 12-hour paclitaxel exposure followed by 24-hour PNC-27 exposure in vitro; separate intraperitoneal ID8 ovarian cancer mouse model.",
          "route": "Cell culture and mouse model; peptide administration route not reported in retrieved abstract",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Tumor implantation site is not proof of peptide administration route. No safe or effective clinical combination regimen established; animal dose/route not extracted from abstract.",
          "strength": "Preclinical findings; source-review scope stated in citations",
          "refs": [
            "pnc27-paclitaxel-2017"
          ]
        },
        {
          "id": "pnc27-gi-case-2017",
          "tier": "A",
          "title": "Human exposure: severe bleeding report, causation unresolved",
          "summary": "A conference case report described massive gastrointestinal bleeding after experimental PNC-27 exposure in a heavily pretreated woman with metastatic cervical cancer. She subsequently died; the authors could not establish causation.",
          "context": "Single 46-year-old patient; bleeding reportedly began two days after infusion. Prior chemotherapy and major pelvic surgery confound attribution.",
          "route": "Infusion reported; dose and formulation not reported",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Temporal association does not establish causality, adverse-event frequency or treatment efficacy. Human exposure cannot be assumed harmless.",
          "strength": "Single human case report; causation uncertain",
          "refs": [
            "pnc27-gi-case-2017"
          ]
        },
        {
          "id": "pnc27-regulatory-context",
          "tier": "U",
          "title": "Unapproved-product history and product-quality risk",
          "summary": "The DOJ Bishop case describes unapproved products purportedly containing PNC-27, marketed for cancer and manufactured in nonsterile facilities.",
          "context": "Official enforcement history concerning products distributed in 2015–2016, not a controlled pharmacology study.",
          "route": "Not applicable",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Product-quality risk is distinct from intrinsic biological toxicity. This historical account does not establish a current clinical-trial inventory.",
          "strength": "Attributed regulatory/development context; no clinical efficacy evidence",
          "refs": [
            "pnc27-doj-bishop"
          ]
        },
        {
          "id": "pnc27-om301-context",
          "tier": "U",
          "title": "OM-301 identity and unresolved clinical translation",
          "summary": "Oncolyze identifies OM-301 as previously PNC-27. No published prospective human treatment trial was identified in this review; human efficacy, dosing, safety profile and response timeline remain unestablished.",
          "context": "Sponsor identity statement checked. Searches included PNC-27 and OM-301; direct ClinicalTrials.gov retrieval failed, so registry coverage is incomplete.",
          "route": "Human administration not established",
          "pk": "unknown",
          "pktext": "Human route-specific absolute bioavailability, half-life and tumor exposure are not established in the sources reviewed.",
          "protocol": null,
          "ptype": null,
          "limit": "Sponsor development statements are not independent efficacy evidence. Do not claim that no trial exists worldwide, or equate a development designation with approval.",
          "strength": "Attributed regulatory/development context; no clinical efficacy evidence",
          "refs": [
            "pnc27-oncolyze",
            "pnc27-aml-2020"
          ]
        }
      ]
    },
    {
      "id": "kisspeptin",
      "name": "Kisspeptin",
      "pathway": "Neuro / reproductive",
      "target": "KISS1 receptor → GnRH → LH / FSH",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "kisspeptin-1",
          "tier": "H",
          "title": "Human reproductive-axis research",
          "summary": "Human studies use indication-specific IV or SC administration.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "IV / SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No universal testosterone-support protocol; specific primary trial not supplied.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "kisspeptin-protocol-study-routes",
          "tier": "H",
          "title": "Indication-specific IV / SC research pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human",
          "route": "IV / SC",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: IV / SC; Species: Human",
          "ptype": "studied",
          "limit": "No trial-specific amount, schedule, formulation or duration is supplied. No universal testosterone-support protocol is established.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "route": "IV / SC",
            "species": "Human"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              12
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        },
        {
          "id": "jarvis-lead-38866494",
          "tier": "U",
          "title": "Kisspeptin in human reproduction: KNDy neuron review (Endocr J 2024)",
          "summary": "A 2024 review reports that peripheral kisspeptin raises gonadotropins in humans; twice-daily subcutaneous kisspeptin-54 in hypothalamic amenorrhoea increased LH pulses but lost effect within 14 days through receptor desensitization; and an intravenous kisspeptin-10 test helped predict progression in delayed puberty.",
          "context": "Narrative review of human studies.",
          "route": "SC (kisspeptin-54), IV (kisspeptin-10)",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Review; doses and study sizes not given; summarizes cited human studies.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-38866494"
          ]
        }
      ]
    },
    {
      "id": "selank",
      "name": "Selank",
      "pathway": "Neuro / reproductive",
      "target": "Tuftsin analogue / neuroimmune and anxiolytic research",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "selank-1",
          "tier": "H",
          "title": "Limited regional human literature",
          "summary": "Guide describes limited regional / experimental human literature and intranasal regimens.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Intranasal",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No FDA-approved regimen; quality and applicability cannot be judged from the summary alone.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        },
        {
          "id": "selank-protocol-intranasal",
          "tier": "H",
          "title": "Product-specific intranasal research pattern",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Human",
          "route": "Intranasal",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Route: Intranasal; Species: Human",
          "ptype": "studied",
          "limit": "The imported synthesis supplies no product-specific dose, frequency, duration or primary identifier; do not invent one.",
          "strength": "Study regimen · imported source",
          "refs": [
            "guide"
          ],
          "protocolDetails": {
            "route": "Intranasal",
            "species": "Human"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              12
            ]
          },
          "protocolVerification": "Extracted from the saved review on 15 October 2026; original linked source not reopened for this update.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "adamax",
      "name": "Adamax / Adamax-1032",
      "pathway": "Neuro / reproductive",
      "target": "Unresolved neuroactive research-product naming",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Route-specific human PK and absolute bioavailability are not established in the imported material.",
      "records": [
        {
          "id": "adamax-1",
          "tier": "U",
          "title": "Insufficient evidence",
          "summary": "High-quality human evidence and a validated protocol are not established in the guide.",
          "context": "Imported field-guide summary; primary citation incomplete.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Product naming is not evidence of a defined clinical molecule or effective dose.",
          "strength": "Imported summary; citation incomplete",
          "refs": [
            "guide"
          ]
        }
      ]
    },
    {
      "id": "sermorelin",
      "name": "Sermorelin",
      "pathway": "GH / IGF-1",
      "target": "GHRH receptor agonism",
      "aliases": "Geref GHRH 1-29",
      "kind": "Peptide",
      "gap": "Human route-specific absolute bioavailability is not established here. Modified GHRH analogues must retain their exact identities.",
      "records": [
        {
          "id": "sermorelin-audit-molecule",
          "tier": "H",
          "title": "Older adult studies require exact molecule identity",
          "summary": "The likely 1997 mixed-sex reference used modified [Nle27]GHRH(1–29)-NH2 at 10 mcg/kg SC nightly for 16 weeks after four placebo weeks in 19 adults aged 55–71. Sleep quality was unchanged. A separate study in 11 older men used GHRH(1–29) 2 mg SC nightly for six weeks. Neither validates ordinary sermorelin 200–300 mcg community cycles.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Related-analogue evidence is explicitly identified; it must not be assigned directly to ordinary sermorelin or interpreted as comparative potency evidence.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "serm-1997",
            "serm-men"
          ]
        },
        {
          "id": "sermorelin-protocol-mars-sermorelin",
          "tier": "A",
          "title": "Sermorelin community schedule",
          "summary": "Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.",
          "context": "Attributed research context; population or formulation not fully specified.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 200–300 mcg; Frequency: Once nightly; Duration: 12 weeks, then 4–6 weeks off; Timing: Bedtime; fasted morning also mentioned; Route: Not documented",
          "ptype": "anecdotal",
          "limit": "Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.",
          "strength": "Attributed community protocol · imported source",
          "refs": [
            "gh-report-20261015",
            "guide"
          ],
          "protocolDetails": {
            "amount": "200–300 mcg",
            "frequency": "Once nightly",
            "duration": "12 weeks, then 4–6 weeks off",
            "timing": "Bedtime; fasted morning also mentioned",
            "route": "Not documented"
          },
          "sourceLocator": {
            "document": "guide",
            "pages": [
              25
            ]
          },
          "protocolVerification": "Extracted from owner-supplied article text and master guide version 7 on 15 October 2026; direct article page inaccessible; underlying schedule not clinically validated. Original page not reopened successfully.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "cjc-dac",
      "name": "CJC-1295 with DAC",
      "pathway": "GH / IGF-1",
      "target": "Long-acting albumin-binding GHRH receptor agonism",
      "aliases": "CJC1295 DAC cjc-1295-w-dac Cjc 1295 W Dac",
      "kind": "Peptide",
      "gap": "Human SC PK exists for the DAC molecule; absolute SC bioavailability and oral or IM therapeutic PK are not established here.",
      "aliasIds": [
        "cjc-1295-w-dac"
      ],
      "aliasNames": [
        "Cjc 1295 W Dac"
      ],
      "records": [
        {
          "id": "cjc-dac-audit-pk",
          "tier": "H",
          "title": "Long acting CJC 1295 human PK",
          "summary": "Healthy-adult SC trials found a 5.8–8.1-day half-life and prolonged GH and IGF-1 elevation. These are DAC-containing molecule findings.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": "Human SC half-life 5.8–8.1 days; absolute SC bioavailability not established here.",
          "protocol": null,
          "ptype": null,
          "limit": "No established general treatment protocol; retain the population, molecule and route limitations.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "cjc-dac"
          ]
        },
        {
          "id": "cjc-dac-audit-pulses",
          "tier": "H",
          "title": "Pulses persist despite higher trough GH",
          "summary": "Healthy men aged 20–40 received 60 or 90 mcg/kg; overnight sampling one week afterward showed 7.5-fold higher trough GH with unchanged pulse frequency and magnitude. This does not establish no-DAC superiority.",
          "context": "October 15 2026 article audit; primary evidence and author claims distinguished.",
          "route": "SC",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "No established general treatment protocol; retain the population, molecule and route limitations.",
          "strength": "Selected primary findings checked 15 October 2026",
          "refs": [
            "cjc-pulses"
          ]
        },
        {
          "id": "cjc-dac-protocol-jarvis-single-dose",
          "tier": "H",
          "title": "CJC-1295 with DAC single-dose trial",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Healthy adults",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 30, 60, 125 or 250 µg/kg; Route: Subcutaneous; Frequency: Single administration; Duration: 28-day study; Species: Human; Population: Healthy adults",
          "ptype": "studied",
          "limit": "The trial measured GH and IGF-I and studied the long-acting DAC construct.",
          "strength": "Primary paper, Study 1",
          "refs": [
            "cjc-dac-protocol-jarvis-single-dose-source"
          ],
          "protocolDetails": {
            "amount": "30, 60, 125 or 250 µg/kg",
            "route": "Subcutaneous",
            "frequency": "Single administration",
            "duration": "28-day study",
            "species": "Human",
            "population": "Healthy adults"
          },
          "sourceLocator": {
            "url": "https://academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.pdf",
            "section": "Primary paper, Study 1"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "adipotide",
      "name": "Adipotide",
      "pathway": "Metabolic / appetite",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "adipotide-protocol-jarvis-macaque",
          "tier": "P",
          "title": "Adipotide in obese rhesus macaques",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "15 obese rhesus macaques including controls",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.43 mg/kg; Route: Subcutaneous; Frequency: Daily; Duration: 28 days of dosing, 28 days of recovery; Species: Rhesus macaque; Population: 15 obese rhesus macaques including controls",
          "ptype": "preclinical",
          "limit": "The study tracked anthropometric outcomes and reported renal proximal tubule effects.",
          "strength": "Primary article, fixed-dose study",
          "refs": [
            "adipotide-protocol-jarvis-macaque-source"
          ],
          "protocolDetails": {
            "amount": "0.43 mg/kg",
            "route": "Subcutaneous",
            "frequency": "Daily",
            "duration": "28 days of dosing, 28 days of recovery",
            "species": "Rhesus macaque",
            "population": "15 obese rhesus macaques including controls"
          },
          "sourceLocator": {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3666164/",
            "section": "Primary article, fixed-dose study"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "vip",
      "name": "VIP",
      "pathway": "Immune / inflammation",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "jarvis-lead-42953880",
          "tier": "U",
          "title": "VIP excess from tumours: secretory diarrhoea in two case reports (2026)",
          "summary": "A 2026 case report describes two VIP-secreting neuroendocrine tumours that caused severe secretory diarrhoea and electrolyte abnormalities; one patient improved after adrenalectomy, the other had persistent symptoms despite debulking and somatostatin analogues.",
          "context": "Two patients; endogenous VIP hypersecretion.",
          "route": "Not applicable (endogenous)",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Case report of endogenous VIP excess; says nothing about administered VIP or any dose.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-42953880"
          ]
        },
        {
          "id": "vip-protocol-jarvis-inhaled-pph",
          "tier": "H",
          "title": "Inhaled VIP in primary pulmonary hypertension",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Patients with primary pulmonary hypertension",
          "route": "Inhaled",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 200 µg/day; Route: Inhaled; Frequency: Daily; Species: Human; Population: Patients with primary pulmonary hypertension",
          "ptype": "studied",
          "limit": "Small exploratory pulmonary hemodynamics study using inhaled VIP.",
          "strength": "Primary article, Methods and Results",
          "refs": [
            "vip-protocol-jarvis-inhaled-pph-source"
          ],
          "protocolDetails": {
            "amount": "200 µg/day",
            "route": "Inhaled",
            "frequency": "Daily",
            "duration": null,
            "species": "Human",
            "population": "Patients with primary pulmonary hypertension"
          },
          "sourceLocator": {
            "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC154449/",
            "section": "Primary article, Methods and Results"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "survodutide",
      "name": "Survodutide",
      "pathway": "Metabolic / appetite",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "gap": "Image does not establish human pharmacokinetics or clinical effectiveness.",
      "records": [
        {
          "id": "approved-33956f741338",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "Treatment-regimen estimand mean weight change -12.2% and -13.0% versus -5.4% placebo; gastrointestinal adverse events frequent",
          "context": "Owner-published from the Jarvis queue onto Survodutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Sponsor-funded, 76-week follow-up, no active comparator; do not infer validation of unverified twice-weekly protocol graphics",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-33956f741338"
          ]
        },
        {
          "id": "approved-6415cae3ca10",
          "tier": "U",
          "title": "Unresolved / evidence gap finding",
          "summary": "Treatment-regimen estimand mean weight change -8.2% and -9.8% versus -3.9% placebo; HbA1c change -0.9 and -0.8 percentage points versus -0.2 placebo; GI events common",
          "context": "Owner-published from the Jarvis queue onto Survodutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Sponsor-funded; T2D-specific population; no active comparator; efficacy estimand results must not be conflated with treatment-regimen results; not validation of unverified twice-weekly protocol graphics",
          "strength": "Unresolved / evidence gap; owner-published Jarvis finding, not an evidence promotion",
          "refs": [
            "social-6415cae3ca10"
          ]
        },
        {
          "id": "survodutide-protocol-jarvis-phase2",
          "tier": "H",
          "title": "Survodutide phase 2 obesity trial",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults with BMI ≥27 kg/m² without diabetes",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.6, 2.4, 3.6 or 4.8 mg target arms; Route: Subcutaneous; Frequency: Once weekly; Duration: 46 weeks, including 20 weeks of escalation; Species: Human; Population: Adults with BMI ≥27 kg/m² without diabetes",
          "ptype": "studied",
          "limit": "Randomized dose-finding trial. The target amounts identify study arms.",
          "strength": "Trial subgroup publication, NCT04667377",
          "refs": [
            "survodutide-protocol-jarvis-phase2-source"
          ],
          "protocolDetails": {
            "amount": "0.6, 2.4, 3.6 or 4.8 mg target arms",
            "route": "Subcutaneous",
            "frequency": "Once weekly",
            "duration": "46 weeks, including 20 weeks of escalation",
            "species": "Human",
            "population": "Adults with BMI ≥27 kg/m² without diabetes"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/39821928/",
            "section": "Trial subgroup publication, NCT04667377"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "semaglutide",
      "name": "Semaglutide",
      "pathway": "Metabolic / appetite",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "semaglutide-protocol-jarvis-ozempic",
          "tier": "H",
          "title": "Ozempic prescribing information",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Patients meeting Ozempic labeling",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.25 mg initiation for four weeks, then 0.5 mg; additional increases depend on indication; Route: Subcutaneous; Frequency: Once weekly; Species: Human; Population: Patients meeting Ozempic labeling",
          "ptype": "label",
          "limit": "The source concerns the Ozempic injectable formulation and its approved indications.",
          "strength": "DailyMed, Dosage and Administration",
          "refs": [
            "semaglutide-protocol-jarvis-ozempic-source"
          ],
          "protocolDetails": {
            "amount": "0.25 mg initiation for four weeks, then 0.5 mg; additional increases depend on indication",
            "route": "Subcutaneous",
            "frequency": "Once weekly",
            "duration": null,
            "species": "Human",
            "population": "Patients meeting Ozempic labeling"
          },
          "sourceLocator": {
            "url": "https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79",
            "section": "DailyMed, Dosage and Administration"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "pe-22-28",
      "name": "PE-22-28",
      "pathway": "Neuro / reproductive",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "pe-22-28-protocol-jarvis-mouse-ip",
          "tier": "P",
          "title": "PE 22-28 mouse corticosterone experiment",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Mice in a corticosterone model",
          "route": "Intraperitoneal",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 3.0 µg/kg; Route: Intraperitoneal; Frequency: Acute and repeated cohorts; Duration: Acute or four-day experiment; Species: Mouse; Population: Mice in a corticosterone model",
          "ptype": "preclinical",
          "limit": "Behavioral endpoints in mice. Modified spadin analogs were separate experiments.",
          "strength": "Primary article, Fig. 5",
          "refs": [
            "pe-22-28-protocol-jarvis-mouse-ip-source"
          ],
          "protocolDetails": {
            "amount": "3.0 µg/kg",
            "route": "Intraperitoneal",
            "frequency": "Acute and repeated cohorts",
            "duration": "Acute or four-day experiment",
            "species": "Mouse",
            "population": "Mice in a corticosterone model"
          },
          "sourceLocator": {
            "url": "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00643/full",
            "section": "Primary article, Fig. 5"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "oxytocin",
      "name": "Oxytocin",
      "pathway": "Neuroendocrine / sexual health",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "oxytocin-protocol-jarvis-labor",
          "tier": "H",
          "title": "Oxytocin label for induction or stimulation of labor",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Patients receiving monitored obstetric care",
          "route": "Intravenous infusion",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Initial rate no more than 1–2 mU/min in this product label; Route: Intravenous infusion; Frequency: Continuous titrated infusion; Species: Human; Population: Patients receiving monitored obstetric care",
          "ptype": "label",
          "limit": "The infusion rate is titrated to uterine response under monitoring.",
          "strength": "DailyMed, Dosage and Administration",
          "refs": [
            "oxytocin-protocol-jarvis-labor-source"
          ],
          "protocolDetails": {
            "amount": "Initial rate no more than 1–2 mU/min in this product label",
            "route": "Intravenous infusion",
            "frequency": "Continuous titrated infusion",
            "duration": null,
            "species": "Human",
            "population": "Patients receiving monitored obstetric care"
          },
          "sourceLocator": {
            "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fe8365-86e3-414e-84dc-c98e097a2f36",
            "section": "DailyMed, Dosage and Administration"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "melanotan-ii",
      "name": "Melanotan II",
      "pathway": "Neuroendocrine / sexual health",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "melanotan-ii-protocol-jarvis-phase1",
          "tier": "H",
          "title": "Melanotan II pilot phase I study",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Three healthy male volunteers",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.01 mg/kg starting dose; Route: Subcutaneous; Frequency: Alternating treatment days; Species: Human; Population: Three healthy male volunteers",
          "ptype": "studied",
          "limit": "Single-blind exploratory tanning study. The starting dose is the observed study parameter.",
          "strength": "Primary abstract, PMID 8637402",
          "refs": [
            "melanotan-ii-protocol-jarvis-phase1-source"
          ],
          "protocolDetails": {
            "amount": "0.01 mg/kg starting dose",
            "route": "Subcutaneous",
            "frequency": "Alternating treatment days",
            "duration": null,
            "species": "Human",
            "population": "Three healthy male volunteers"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/8637402/",
            "section": "Primary abstract, PMID 8637402"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "melanotan-i",
      "name": "Melanotan I",
      "pathway": "Skin / pigmentation",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "melanotan-i-protocol-jarvis-scenesse",
          "tier": "H",
          "title": "Afamelanotide SCENESSE implant label",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults with erythropoietic protoporphyria and a history of phototoxic reactions",
          "route": "Subcutaneous implant",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 16 mg; Route: Subcutaneous implant; Frequency: Every two months; Species: Human; Population: Adults with erythropoietic protoporphyria and a history of phototoxic reactions",
          "ptype": "label",
          "limit": "The pharmaceutical implant increases pain-free light exposure under its labeled indication.",
          "strength": "DailyMed, Dosage and Administration",
          "refs": [
            "melanotan-i-protocol-jarvis-scenesse-source"
          ],
          "protocolDetails": {
            "amount": "16 mg",
            "route": "Subcutaneous implant",
            "frequency": "Every two months",
            "duration": null,
            "species": "Human",
            "population": "Adults with erythropoietic protoporphyria and a history of phototoxic reactions"
          },
          "sourceLocator": {
            "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48&version=11",
            "section": "DailyMed, Dosage and Administration"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "mazdutide",
      "name": "Mazdutide",
      "pathway": "Metabolic / appetite",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "mazdutide-protocol-jarvis-glory1",
          "tier": "H",
          "title": "Mazdutide GLORY-1 trial",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Chinese adults with obesity or qualifying overweight",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 4 or 6 mg target arms; Route: Subcutaneous; Frequency: Once weekly; Duration: 48 weeks; Species: Human; Population: Chinese adults with obesity or qualifying overweight",
          "ptype": "studied",
          "limit": "Randomized trial with a placebo comparator and China-specific BMI eligibility.",
          "strength": "Primary abstract, PMID 40421736",
          "refs": [
            "mazdutide-protocol-jarvis-glory1-source"
          ],
          "protocolDetails": {
            "amount": "4 or 6 mg target arms",
            "route": "Subcutaneous",
            "frequency": "Once weekly",
            "duration": "48 weeks",
            "species": "Human",
            "population": "Chinese adults with obesity or qualifying overweight"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/40421736/",
            "section": "Primary abstract, PMID 40421736"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "l-carnitine",
      "name": "L-carnitine",
      "pathway": "Mitochondrial / energy",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Metabolite",
      "records": [
        {
          "id": "l-carnitine-protocol-jarvis-carnitor-dialysis",
          "tier": "H",
          "title": "CARNITOR dialysis-associated deficiency label",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Patients with ESRD on dialysis and carnitine deficiency",
          "route": "Intravenous, venous return line",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 10–20 mg/kg dry body weight initial dose; Route: Intravenous, venous return line; Frequency: After each dialysis session; Species: Human; Population: Patients with ESRD on dialysis and carnitine deficiency",
          "ptype": "label",
          "limit": "Product-specific starting dose with monitoring and subsequent adjustment per the label.",
          "strength": "DailyMed, Dosage and Administration",
          "refs": [
            "l-carnitine-protocol-jarvis-carnitor-dialysis-source"
          ],
          "protocolDetails": {
            "amount": "10–20 mg/kg dry body weight initial dose",
            "route": "Intravenous, venous return line",
            "frequency": "After each dialysis session",
            "duration": null,
            "species": "Human",
            "population": "Patients with ESRD on dialysis and carnitine deficiency"
          },
          "sourceLocator": {
            "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3",
            "section": "DailyMed, Dosage and Administration"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "hgh",
      "name": "HGH / somatropin",
      "pathway": "GH / IGF-1",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "hgh-protocol-jarvis-genotropin-adult",
          "tier": "H",
          "title": "Genotropin adult GH deficiency label",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults with growth hormone deficiency",
          "route": "Subcutaneous",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: Approximately 0.2 mg/day for the non-weight-based starting approach; Route: Subcutaneous; Frequency: Daily; Species: Human; Population: Adults with growth hormone deficiency",
          "ptype": "label",
          "limit": "The label also describes a weight-based approach. The non-weight-based dose is individualized over time.",
          "strength": "DailyMed, section 2.2",
          "refs": [
            "hgh-protocol-jarvis-genotropin-adult-source"
          ],
          "protocolDetails": {
            "amount": "Approximately 0.2 mg/day for the non-weight-based starting approach",
            "route": "Subcutaneous",
            "frequency": "Daily",
            "duration": null,
            "species": "Human",
            "population": "Adults with growth hormone deficiency"
          },
          "sourceLocator": {
            "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765&version=36",
            "section": "DailyMed, section 2.2"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "glutathione",
      "name": "Glutathione",
      "pathway": "Mitochondrial / energy",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "jarvis-lead-27499402",
          "tier": "U",
          "title": "Glutathione review: no published study of IV glutathione for skin lightening (SAMJ 2016)",
          "summary": "A 2016 South African Medical Journal review found no published study of intravenous glutathione for skin lightening and no study of long-term IV glutathione for any indication. Studies of oral, lozenge and topical glutathione for lightening were small and lasted 4-12 weeks.",
          "context": "Narrative MEDLINE review to September 2015; human studies only.",
          "route": "IV (no study found); oral, lozenge, topical in the studies reviewed",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Review, not a trial. It documents an evidence gap for IV skin-lightening use; it does not establish safety or efficacy of any dose.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-27499402"
          ]
        },
        {
          "id": "jarvis-lead-41897500",
          "tier": "U",
          "title": "Oral glutathione PK: micellar 300 mg vs standard 500 mg in healthy adults (n = 14)",
          "summary": "In a randomized double-blind crossover study of 14 healthy adults, a single 300 mg dose of a micellar glutathione formulation raised baseline-adjusted whole-blood glutathione about 2.5-fold more (iAUC0-24) than 500 mg of standard glutathione. 600 mg/day for 30 days produced no significant change in routine blood safety markers.",
          "context": "Healthy adults; single-dose crossover PK, then 30-day single-arm safety phase; NCT06345950.",
          "route": "Oral",
          "pk": "studied",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Pilot study of a branded formulation (manufacturer supplied samples); n = 14; unequal doses; no clinical endpoints; not a regimen.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-41897500"
          ]
        }
      ]
    },
    {
      "id": "dsip",
      "name": "DSIP",
      "pathway": "Neuro / reproductive",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Peptide",
      "records": [
        {
          "id": "dsip-protocol-jarvis-crossover",
          "tier": "H",
          "title": "DSIP in a human sleep crossover study",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Six healthy volunteers",
          "route": "Slow intravenous infusion",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 25 nmol/kg; Route: Slow intravenous infusion; Frequency: Morning administration; Species: Human; Population: Six healthy volunteers",
          "ptype": "studied",
          "limit": "Small double-blind crossover experiment measuring acute and later sleep outcomes.",
          "strength": "Primary abstract, PMID 6895513",
          "refs": [
            "dsip-protocol-jarvis-crossover-source"
          ],
          "protocolDetails": {
            "amount": "25 nmol/kg",
            "route": "Slow intravenous infusion",
            "frequency": "Morning administration",
            "duration": null,
            "species": "Human",
            "population": "Six healthy volunteers"
          },
          "sourceLocator": {
            "url": "https://pubmed.ncbi.nlm.nih.gov/6895513/",
            "section": "Primary abstract, PMID 6895513"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Partial details",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "aicar",
      "name": "AICAR",
      "pathway": "Mitochondrial / energy",
      "target": "Mechanism not verified by source image",
      "aliases": "",
      "kind": "Small molecule",
      "records": [
        {
          "id": "aicar-protocol-jarvis-red-cabg",
          "tier": "H",
          "title": "Acadesine in RED-CABG",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "Adults undergoing coronary artery bypass grafting",
          "route": "Intravenous infusion plus cardioplegia",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 0.1 mg/kg/min IV; 5 µg/mL in cardioplegia; Route: Intravenous infusion plus cardioplegia; Frequency: Perioperative; Duration: Approximately 7 hours for the IV infusion; Species: Human; Population: Adults undergoing coronary artery bypass grafting",
          "ptype": "studied",
          "limit": "The randomized trial did not demonstrate a significant benefit on its primary composite endpoint.",
          "strength": "Primary article, Methods",
          "refs": [
            "aicar-protocol-jarvis-red-cabg-source"
          ],
          "protocolDetails": {
            "amount": "0.1 mg/kg/min IV; 5 µg/mL in cardioplegia",
            "route": "Intravenous infusion plus cardioplegia",
            "frequency": "Perioperative",
            "duration": "Approximately 7 hours for the IV infusion",
            "species": "Human",
            "population": "Adults undergoing coronary artery bypass grafting"
          },
          "sourceLocator": {
            "url": "https://jamanetwork.com/journals/jama/fullarticle/1216478",
            "section": "Primary article, Methods"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    },
    {
      "id": "leap2",
      "name": "LEAP2",
      "pathway": "Appetite / ghrelin",
      "target": "Ghrelin receptor (GHSR) endogenous antagonist and inverse agonist",
      "aliases": "LEAP-2, Liver-expressed antimicrobial peptide 2",
      "kind": "Peptide",
      "records": [
        {
          "id": "jarvis-lead-34512549",
          "tier": "U",
          "title": "LEAP2 review: endogenous ghrelin-receptor antagonist in obesity (2021)",
          "summary": "A 2021 review describes LEAP2 as an endogenous competitive antagonist and inverse agonist of the ghrelin receptor (GHS-R1a). Plasma LEAP2 rises with feeding and obesity and falls with fasting and weight loss, the opposite of ghrelin.",
          "context": "Narrative review of human and animal studies.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Review with no new data.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-34512549"
          ]
        }
      ]
    },
    {
      "id": "dihexa",
      "name": "Dihexa",
      "pathway": "Cognition / brain angiotensin IV (AT4) system",
      "target": "Proposed HGF/c-Met potentiation (the main mechanism paper, PMID 25187433, was retracted in 2025); a 2020 review states its effect is not via IRAP inhibition",
      "aliases": "PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide",
      "kind": "Peptide",
      "gap": "No human data and no approved product. Evidence is from rodent studies, mostly from one research group. The principal mechanism paper (Benoist et al. 2014, PMID 25187433) received an expression of concern in 2021 and was retracted in April 2025.",
      "records": [
        {
          "id": "jarvis-lead-29733881",
          "tier": "U",
          "title": "Dihexa in rats: systematic review of angiotensin IV analogues and cognition (2018)",
          "summary": "A 2018 systematic review of 32 animal studies reported that dihexa reversed scopolamine-induced memory impairment in rats when given intracerebroventricularly (1.0 nmol), intraperitoneally (0.50 mg/kg/day) or orally (2.0 mg/kg/day).",
          "context": "Animal studies only (rats, mice); no human data.",
          "route": "ICV, IP, oral (rats)",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Animal data from one research group; the review's mechanism discussion relies partly on a paper retracted in 2025 (PMID 25187433).",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-29733881"
          ]
        },
        {
          "id": "jarvis-lead-33178027",
          "tier": "U",
          "title": "Dihexa (PNB-0408): review says its cognitive effect is not via IRAP inhibition (2020)",
          "summary": "A 2020 review of angiotensin IV-derived IRAP inhibitors describes dihexa (PNB-0408) as a brain-penetrant Ang IV derivative with pro-cognitive effects in animal models, notes there are no data on IRAP inhibition by dihexa, and concludes its cognitive effects are not attributable to IRAP inhibition.",
          "context": "Narrative review; preclinical sources.",
          "route": "Not documented",
          "pk": "unknown",
          "pktext": null,
          "protocol": null,
          "ptype": null,
          "limit": "Review with no new data; its c-Met mechanism citation (PMID 25187433) was retracted in 2025.",
          "strength": "Unresolved / evidence gap; owner-approved Jarvis primary-source verification, class not promoted",
          "refs": [
            "jarvis-lead-src-33178027"
          ]
        },
        {
          "id": "dihexa-protocol-jarvis-aged-rat",
          "tier": "P",
          "title": "Dihexa in aged rats",
          "summary": "Administration reported for this specific study or labeled indication.",
          "context": "24-month-old Sprague-Dawley rats",
          "route": "Oral gavage",
          "pk": "unknown",
          "pktext": null,
          "protocol": "Amount: 2 mg/kg; Route: Oral gavage; Frequency: Daily before maze testing; Duration: 8 test days; Species: Rat; Population: 24-month-old Sprague-Dawley rats",
          "ptype": "preclinical",
          "limit": "Small groups in a water-maze spatial-learning experiment.",
          "strength": "Primary article, Fig. 5",
          "refs": [
            "dihexa-protocol-jarvis-aged-rat-source"
          ],
          "protocolDetails": {
            "amount": "2 mg/kg",
            "route": "Oral gavage",
            "frequency": "Daily before maze testing",
            "duration": "8 test days",
            "species": "Rat",
            "population": "24-month-old Sprague-Dawley rats"
          },
          "sourceLocator": {
            "url": "https://jpet.aspetjournals.org/content/jpet/344/1/141.full.pdf",
            "section": "Primary article, Fig. 5"
          },
          "protocolVerification": "Source checked 3 November 2026 within the cited retrieval scope.",
          "protocolCompleteness": "Amount, route, frequency and duration reported",
          "audience": "nonpersonal"
        }
      ]
    }
  ]
}